<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19 - Reis, S - 2023 | Cochrane Library</title> <meta content="Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19 - Reis, S - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015395.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19 - Reis, S - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015395.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015395.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19" name="citation_title"/> <meta content="Stefanie Reis" name="citation_author"/> <meta content="University Hospital Würzburg" name="citation_author_institution"/> <meta content="Maria-Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich-Heine University Düsseldorf" name="citation_author_institution"/> <meta content="Rebecca Kuehn" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Maria Popp" name="citation_author"/> <meta content="University Hospital Würzburg" name="citation_author_institution"/> <meta content="Ildiko Gagyor" name="citation_author"/> <meta content="University Hospital Würzburg" name="citation_author_institution"/> <meta content="Peter Kranke" name="citation_author"/> <meta content="University Hospital Würzburg" name="citation_author_institution"/> <meta content="Patrick Meybohm" name="citation_author"/> <meta content="University Hospital Würzburg" name="citation_author_institution"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="Center for Integrated Oncology, University of Cologne" name="citation_author_institution"/> <meta content="Stephanie Weibel" name="citation_author"/> <meta content="University Hospital Würzburg" name="citation_author_institution"/> <meta content="weibel_s@ukw.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD015395.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/11/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015395.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015395.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015395.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*COVID-19 [prevention &amp; control]; COVID-19 Drug Treatment; Ritonavir [therapeutic use]; SARS-CoV-2" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&amp;doi=10.1002/14651858.CD015395.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015395\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015395\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ms","ja","fa","pl","fr","hu"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD015395.pub3",title:"Nirmatrelvir combined with ritonavir for preventing and treating COVID\\u201019",firstPublishedDate:"Nov 30, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015395.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015395.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015395.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015395.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015395.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015395.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015395.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015395.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015395.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015395.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7212 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015395.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-sec-0122"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/appendices#CD015395-sec-0130"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/supinfo/CD015395-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/supinfo/CD015395-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0004">Stefanie Reis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0005">Maria-Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0006">Rebecca Kuehn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0007">Maria Popp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0008">Ildiko Gagyor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0009">Peter Kranke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0010">Patrick Meybohm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0011">Nicole Skoetz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information#CD015395-cr-0012"><i class="icon corresponding-author fa fa-envelope"></i>Stephanie Weibel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information/en#CD015395-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 November 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015395.pub3">https://doi.org/10.1002/14651858.CD015395.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015395-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015395-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015395-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015395-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015395-abs-0010">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015395-abs-0001" lang="en"> <section id="CD015395-sec-0001"> <h3 class="title" id="CD015395-sec-0001">Background</h3> <p>Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and death. It remains to be evaluated for which indications and patient populations the drug is suitable. </p> </section> <section id="CD015395-sec-0002"> <h3 class="title" id="CD015395-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of nirmatrelvir/ritonavir plus standard of care (SoC) compared to SoC with or without placebo, or any other intervention for treating COVID‐19 or preventing SARS‐CoV‐2 infection. </p> <p>To explore equity aspects in subgroup analyses.</p> <p>To keep up to date with the evolving evidence base using a living systematic review (LSR) approach and make new relevant studies available to readers in‐between publication of review updates. </p> </section> <section id="CD015395-sec-0003"> <h3 class="title" id="CD015395-sec-0003">Search methods</h3> <p>We searched the Cochrane COVID‐19 Study Register, Scopus, and World Health Organization COVID‐19 Research Database, identifying completed and ongoing studies without language restrictions and incorporating studies up to 15 May 2023. </p> <p>This is a LSR. We conduct update searches every two months and make them publicly available on the open science framework (OSF) platform. </p> </section> <section id="CD015395-sec-0004"> <h3 class="title" id="CD015395-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) comparing nirmatrelvir/ritonavir plus SoC to SoC with or without placebo, or any other intervention for treatment of people with confirmed COVID‐19 diagnosis, irrespective of disease severity or treatment setting, and for prevention of SARS‐CoV‐2 infection. </p> <p>We screened all studies for research integrity. Studies were ineligible if they had been retracted, or if they were not prospectively registered including appropriate ethics approval. </p> </section> <section id="CD015395-sec-0005"> <h3 class="title" id="CD015395-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology and used the Cochrane RoB 2 tool. We rated the certainty of evidence using the GRADE approach for the following outcomes: 1. to treat outpatients with mild COVID‐19; 2. to treat inpatients with moderate to severe COVID‐19: mortality, clinical worsening or improvement, quality of life, (serious) adverse events, and viral clearance; 3. to prevent SARS‐CoV‐2 infection in postexposure prophylaxis (PEP); and 4. pre‐exposure prophylaxis (PrEP) scenarios: SARS‐CoV‐2 infection, development of COVID‐19 symptoms, mortality, admission to hospital, quality of life, and (serious) adverse events. </p> <p>We explored inequity by subgroup analysis for elderly people, socially‐disadvantaged people with comorbidities, populations from low‐income countries and low‐ to middle‐income countries, and people from different ethnic and racial backgrounds. </p> </section> <section id="CD015395-sec-0006"> <h3 class="title" id="CD015395-sec-0006">Main results</h3> <p>As of 15 May 2023, we included two RCTs with 2510 participants with mild and mild to moderate symptomatic COVID‐19 in outpatient and inpatient settings comparing nirmatrelvir/ritonavir plus SoC to SoC with or without placebo. All trial participants were without previous confirmed SARS‐CoV‐2 infection and at high risk for progression to severe disease. Randomization coincided with the Delta wave for outpatients and Omicron wave for inpatients. Outpatient trial participants and 73% of inpatients were unvaccinated. Symptom onset in outpatients was no more than five days before randomisation and prior or concomitant therapies including medications highly dependent on CYP3A4 were not allowed. </p> <p>We excluded two studies due to concerns with research integrity. We identified 13 ongoing studies. Three studies are currently awaiting classification. </p> <p><b>Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings</b> </p> <p>Nirmatrelvir/ritonavir plus SoC compared to SoC plus placebo may reduce all‐cause mortality at 28 days (risk ratio (RR) 0.04, 95% confidence interval (CI) 0.00 to 0.68; 1 study, 2224 participants; low‐certainty evidence) and admission to hospital or death within 28 days (RR 0.13, 95% CI 0.07 to 0.27; 1 study, 2224 participants; low‐certainty evidence). </p> <p>Nirmatrelvir/ritonavir plus SoC may reduce serious adverse events during the study period compared to SoC plus placebo (RR 0.24, 95% CI 0.15 to 0.41; 1 study, 2224 participants; low‐certainty evidence). Nirmatrelvir/ritonavir plus SoC probably has little or no effect on treatment‐emergent adverse events (RR 0.95, 95% CI 0.82 to 1.10; 1 study, 2224 participants; moderate‐certainty evidence), and probably increases treatment‐related adverse events such as dysgeusia and diarrhoea during the study period compared to SoC plus placebo (RR 2.06, 95% CI 1.44 to 2.95; 1 study, 2224 participants; moderate‐certainty evidence). Nirmatrelvir/ritonavir plus SoC probably decreases discontinuation of study drug due to adverse events compared to SoC plus placebo (RR 0.49, 95% CI 0.30 to 0.80; 1 study, 2224 participants; moderate‐certainty evidence). </p> <p>No studies reported improvement of clinical status, quality of life, or viral clearance.</p> <p><b>Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings</b> </p> <p>We are uncertain whether nirmatrelvir/ritonavir plus SoC compared to SoC reduces all‐cause mortality at 28 days (RR 0.63, 95% CI 0.21 to 1.86; 1 study, 264 participants; very low‐certainty evidence), or increases viral clearance at seven days (RR 1.06, 95% CI 0.71 to 1.58; 1 study, 264 participants; very low‐certainty evidence) and 14 days (RR 1.05, 95% CI 0.92 to 1.20; 1 study, 264 participants; very low‐certainty evidence). </p> <p>No studies reported improvement or worsening of clinical status and quality of life. We did not include data for safety outcomes due to insufficient and inconsistent information. </p> <p><b>Subgroup analyses for equity</b> </p> <p>For outpatients, the outcome 'admission to hospital or death' was investigated for equity regarding age (less than 65 years versus 65 years or greater) and ethnicity. There were no subgroup differences for age or ethnicity. </p> <p>For inpatients, the outcome 'all‐cause mortality' was investigated for equity regarding age (65 years or less versus greater than 65 years). There was no difference between subgroups of age. </p> <p>No further equity‐related subgroups were reported, and no subgroups were reported for other outcomes. </p> <p><b>Nirmatrelvir/ritonavir for preventing SARS‐CoV‐2 infection (PrEP and PEP)</b> </p> <p>No studies available.</p> </section> <section id="CD015395-sec-0007"> <h3 class="title" id="CD015395-sec-0007">Authors' conclusions</h3> <p>Low‐certainty evidence suggests nirmatrelvir/ritonavir reduces the risk of all‐cause mortality and hospital admission or death in high‐risk, unvaccinated COVID‐19 outpatients infected with the Delta variant of SARS‐CoV‐2. There is low‐ to moderate‐certainty evidence of the safety of nirmatrelvir/ritonavir. </p> <p>Very low‐certainty evidence exists regarding the effects of nirmatrelvir/ritonavir on all‐cause mortality and viral clearance in mildly to moderately affected, mostly unvaccinated COVID‐19 inpatients infected with the Omicron variant of SARS‐CoV‐2. Insufficient and inconsistent information prevents the assessment of safety outcomes. </p> <p>No reliable differences in effect size and direction were found regarding equity aspects.</p> <p>There is no available evidence supporting the use of nirmatrelvir/ritonavir for preventing SARS‐CoV‐2 infection. </p> <p>We are continually updating our search and making search results available on the OSF platform. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015395-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015395-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015395-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015395-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015395-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015395-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD015395-abs-0012">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD015395-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015395-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD015395-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015395-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015395-abs-0002" lang="en"> <h3>Is the combination of nirmatrelvir plus ritonavir effective for treating or preventing COVID‐19? </h3> <p><b>Key messages</b> </p> <p>Nirmatrelvir/ritonavir (Paxlovid) is evaluated for the treatment of coronavirus disease 2019 (COVID‐19). </p> <p>Nirmatrelvir/ritonavir may lead to fewer deaths and improve patient condition, as assessed by need for hospitalization or death within 28 days for unvaccinated outpatients at increased risk for disease progression receiving treatment within five days of symptom onset. </p> <p>We are very uncertain about the effectiveness of nirmatrelvir/ritonavir in inpatients.</p> <p>We excluded two studies due to concerns with research integrity. We found 13 ongoing studies. </p> <p><b>What is nirmatrelvir/ritonavir?</b> </p> <p>The combination of nirmatrelvir with ritonavir is a new medicine developed to treat infection with the SARS‐CoV‐2 virus and aims to avoid severe COVID‐19 in people without symptoms, or those with mild symptoms. Ritonavir increases the effectiveness of nirmatrelvir but it can interact with many other medicines, which can increase side effects. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know if nirmatrelvir/ritonavir reduces death, illness, and length of infection in people with COVID‐19, or if it is useful in prevention of the disease. We included studies comparing the medicine with placebo (dummy treatment), no treatment, usual care, or any other treatments for COVID‐19. We addressed equity and wanted to know whether there are certain groups of people for which nirmatrelvir/ritonavir works best or is less effective. We looked at elderly people, socially disadvantaged people with other illnesses (comorbidities), people from low‐income and low‐ to middle‐income countries, and people from different ethnic and racial backgrounds. </p> <p>We evaluated the effects of nirmatrelvir/ritonavir in people with COVID‐19 regarding:</p> <p>– people dying;</p> <p>– whether COVID‐19 symptoms got better or worse;</p> <p>– quality of life;</p> <p>– unwanted effects of the medicine;</p> <p>– virus elimination.</p> <p>For prevention, we sought the effect on preventing COVID‐19 and SARS‐CoV‐2 infection.</p> <p><b>What did we do?</b> </p> <p>We searched for randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) that investigated nirmatrelvir/ritonavir to prevent or treat COVID‐19. People receiving nirmatrelvir/ritonavir as treatment had to have laboratory‐confirmed COVID‐19 and be treated in hospital or as outpatients. People receiving nirmatrelvir/ritonavir to prevent an infection had to have a high risk of contracting the disease or had to have had a high‐risk contact with a person with confirmed COVID‐19. </p> <p>We summarized the results of the studies and rated our confidence in the evidence, based on common criteria as to how reliable the evidence was. </p> <p>We examined differences with respect to age, level of comorbidity, country according to the World Bank country classification by income level, and ethnicity. </p> <p><b>What did we find?</b> </p> <p>We found two studies with 2510 participants that investigated nirmatrelvir/ritonavir compared to placebo or standard of care for the treatment of COVID‐19 in people without previous confirmed SARS‐CoV‐2 infection and at increased risk for progression to severe disease due to a comorbidity or risk factor such as current smoking. Included outpatients were enrolled during the Delta wave, unvaccinated, and had a symptom onset of up to five days before starting treatment. Included inpatients were enrolled during the Omicron wave, mostly unvaccinated, and mildly to moderately affected. </p> <p>We found 13 ongoing studies that have not yet been completed, and three studies are currently awaiting classification. </p> <p><b>Main results</b> </p> <p><b><i>Treating outpatients with COVID‐19</i> </b> </p> <p>For the specific population of unvaccinated, high‐risk patients, nirmatrelvir/ritonavir may: </p> <p>– lead to fewer deaths;</p> <p>– improve patients' condition assessed by need for admission to hospital or death within 28 days; </p> <p>– reduce serious unwanted events.</p> <p>For the specific population of unvaccinated, high‐risk patients, nirmatrelvir/ritonavir probably: </p> <p>– has little effect on any unwanted events;</p> <p>– increases any treatment‐related unwanted events (mostly taste disturbance and diarrhoea);</p> <p>– decreases discontinuation of study medicine due to unwanted events.</p> <p><i>Equity aspects</i> </p> <p>Most study participants were younger than 65 years and of white ethnicity. There was no difference in effectiveness between younger and older participants and participants from different ethnic groups. No subgroups were reported for different levels of comorbidity and World Bank country classification by income level. </p> <p><b><i>Treating inpatients with COVID‐19</i> </b> </p> <p>We are uncertain whether, for the specific population of mildly to moderately affected, high‐risk patients, nirmatrelvir/ritonavir: </p> <p>– leads to fewer deaths; and</p> <p>– increases virus elimination</p> <p><i>Equity aspects</i> </p> <p>Most study participants were older than 65 years. There was no difference in effectiveness between younger and older participants. No subgroups were reported for different levels of comorbidity, ethnicity, and World Bank country classification by income level. </p> <p>No subgroups were reported for other outcomes.</p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is low to moderate for outpatients and very low for inpatients. The studies did not report everything we were interested in, such as quality of life and symptom resolution, and had a highly specific population of people at high risk of progression to severe COVID‐19. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to 15 May 2023.</p> <p>According to this review's living approach, we will update our search every two months. We are making search results and new relevant studies publicly available. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015395-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015395-sec-0122"></div> <h3 class="title" id="CD015395-sec-0123">Implications for practice</h3> <section id="CD015395-sec-0123"> <p>With ritonavir being a CYP3A4 inhibitor, nirmatrelvir/ritonavir bears the potential for significant drug–drug interactions with many medications commonly used, especially in people with comorbidities. If there are known or anticipated drug interactions with concomitant medications that cannot be discontinued or reduced, the manufacturer, Pfizer, advises against the use of nirmatrelvir/ritonavir, thereby limiting the transferability of results to a broader high‐risk population. </p> <section id="CD015395-sec-0124"> <h5 class="title">Outpatients</h5> <p>Based on the current low‐certainty evidence (one trial), in outpatients nirmatrelvir/ritonavir may reduce all‐cause mortality and hospital admission or death within 28 days. Subgroup analyses regarding equity for admission to hospital or death suggested that there are no differences in efficacy regarding participants' age, but we only have data in a mostly White ethnic population and cannot, therefore, assess benefit in other ethnicities. </p> <p>There is low‐ to moderate‐certainty evidence that nirmatrelvir/ritonavir is safe in people without prior or concomitant therapies, including medications highly dependent on CYP3A4 for clearance and CYP3A4 inducers. </p> <p>This review only included one trial for the outpatient setting investigating people who were unvaccinated without previous infection who were at high risk of disease progression due to coexisting conditions or other characteristics associated with an increased risk of developing severe illness from COVID‐19. There is currently no evidence for the use of nirmatrelvir/ritonavir in a broader population of vaccinated people, those with previous SARS‐CoV‐2 infection, or those without increased risk for progression to severe disease. Therefore, external validity of the results is limited. All participants were enrolled until December 2021, which coincided with the Delta wave before the start of the Omicron wave; therefore, the findings of this review might not be directly applicable to the treatment situation of people who are infected with later (sub‐)variants of SARS‐CoV‐2. </p> </section> <section id="CD015395-sec-0125"> <h5 class="title">Inpatients</h5> <p>Based on the current low‐certainty evidence (one trial), we are uncertain whether nirmatrelvir/ritonavir reduces all‐cause mortality at 28 days or increases viral clearance at seven or 14 days. Subgroup analyses regarding equity for all‐cause mortality suggested that there are no differences in efficacy regarding patients' age. </p> <p>The safety of nirmatrelvir/ritonavir could not be assessed for the inpatient setting, due to insufficient and inconsistent information on the time of the outcome assessment, the handling of missing outcome data, and the outcome assessment itself. Upon enquiry, the authors provided no further information regarding the outcomes. </p> <p>The study only included mildly to moderately affected participants, which might not resemble the typical hospitalized people with COVID‐19. It only included participants without previous infection and most were unvaccinated who were at high risk of disease progression due to severe comorbidities or a SOFA/Charlson score of 2 or greater. There is currently no evidence for the use of nirmatrelvir/ritonavir in more severely affected people as well as a broader population of participants with previous SARS‐CoV‐2 infection, or those without increased risk for progression to severe disease. Therefore, external validity of the results was limited. All participants were enrolled during the Omicron wave. </p> <p>Currently, there is no evidence to explore the benefits and harms of nirmatrelvir/ritonavir as treatment as pre‐exposure or postexposure prophylaxis. </p> </section> </section> <h3 class="title" id="CD015395-sec-0126">Implications for research</h3> <section id="CD015395-sec-0126"> <p>There is a need for evidence for the use of nirmatrelvir/ritonavir as a treatment for in‐ and outpatients with previous SARS‐CoV‐2 infection or vaccination and those without increased risk for progression to severe disease. There is also a need for studies investigating the use of nirmatrelvir/ritonavir to prevent SARS‐CoV‐2 infection. For these scenarios and populations, we need high‐quality randomized controlled trials (RCTs). </p> <p>To address equity, we need further trials investigating:</p> <p> <ul id="CD015395-list-0043"> <li> <p>populations from low‐income countries and low‐ to middle‐income countries;</p> </li> <li> <p>people from different ethnic and racial backgrounds, including minorities.</p> </li> </ul> </p> <p>We identified 13 ongoing studies investigating nirmatrelvir/ritonavir for treatment of COVID‐19, which may change the findings of the review or the certainty of evidence, and broaden the applicability of results. </p> <p>In accordance with the living approach of this review, we are continually updating our search and evaluating new potentially relevant trials for inclusion (<a href="https://osf.io/7g49c/" target="_blank">osf.io/7g49c/</a>; <a href="./references#CD015395-bbs2-0130" title='ReisS , MetzendorfM , KuehnR , PoppM , GagyorI , KrankeP , et al. Living evidence base for Cochrane Review "Nirmatrelvir combined with ritonavir for preventing and treating COVID-19". osf.io/7g49c/ (created 30 May 2022). [DOI: 10.17605/OSF.IO/7G49C]'>Reis 2022a</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015395-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015395-sec-0008"></div> <div class="table" id="CD015395-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> nirmatrelvir/ritonavir (plus standard of care) </p> <p><b>Comparison:</b> placebo (plus standard of care) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with nirmatrelvir/ritonavir</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality at day 28</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.04</b> (0.00 to 0.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir may reduce all‐cause mortality<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>11 fewer per 1000</b> </p> <p>(11 fewer to 4 fewer)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Worsening of clinical status within 28 days</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Admission to hospital or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.13</b> (0.07 to 0.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir may reduce (COVID‐19‐related) hospitalization or death<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>53 fewer per 1000</b> </p> <p>(57 fewer to 45 fewer)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admission to ICU or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported admission to ICU or death</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Improvement of clinical status</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All initial symptoms resolved at 28 days, and up to the longest follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported all initial symptoms resolved</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to symptom resolution</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported time to symptom resolution</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life up to 28 days and longest follow‐up available</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>SAEs during the study period</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.24</b> (0.15 to 0.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir may reduce SAEs<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>50 fewer per 1000</b> </p> <p>(56 fewer to 39 fewer)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adverse events during the study period</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any grade TEAE</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.95</b> (0.82 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir probably has little or no effect on any TEAE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>12 fewer per 1000</b> </p> <p>(43 fewer to 24 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any grade TRAE</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.06</b> (1.44 to 2.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir probably increases any TRAE (mostly attributed to dysgeusia and diarrhoea)<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>40 more per 1000</b> </p> <p>(17 more to 74 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Discontinuation of study drug due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.49</b> (0.30 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir probably decreases discontinuation of study drug due to adverse events<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>21 fewer per 1000</b> </p> <p>(29 fewer to 8 fewer)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral clearance at 14 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported viral clearance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event; <b>TEAE:</b> treatment‐emergent adverse event; <b>TRAE:</b> treatment‐related adverse event; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations on certainty in the evidence (GRADE)</b> </p> <p><sup>a</sup>Downgraded one level for serious risk of bias (inappropriate analysis) and one level for serious imprecision (few events).<br/><sup>b</sup>Downgraded one level for serious risk of bias (inappropriate analysis) and one level for serious indirectness (COVID‐19‐related hospitalization).<br/><sup>c</sup>Downgraded one level for serious risk of bias (inappropriate analysis) and one level for serious imprecision (due to few SAEs other than hospitalization or death).<br/><sup>d</sup>Downgraded one level for serious risk of bias (inappropriate analysis). </p> <p><b>Explanations on 'equity considerations'</b> </p> <p>Most study participants were younger than 65 years, of white ethnicity, and from upper middle‐ or high‐income countries. No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated a high‐risk population.<br/><sup>1</sup>No subgroup analyses were reported for age, ethnicity, and World Bank country classification by income level. We are uncertain whether results are applicable to all prespecified subgroups.<br/><sup>2</sup>Subgroup analyses were reported for age and ethnicity only. There was no difference between subgroups of age. The effects favoured a treatment with nirmatrelvir/ritonavir for the white ethnic group. Estimated effects of the other ethnic groups included the line of no effect (RR = 1). Numbers of participants in the other ethnic groups were low. No subgroups were reported for World Bank country classification by income level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015395-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> nirmatrelvir/ritonavir (plus standard of care) </p> <p><b>Comparison:</b> standard of care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard of care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with nirmatrelvir/ritonavir</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality at day 28</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.63</b> (0.21 to 1.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>264 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain whether nirmatrelvir/ritonavir reduces all‐cause mortality<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>23 fewer per 1000</b> </p> <p>(48 fewer to 52 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Worsening of clinical status within 28 days</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with new need for invasive mechanical ventilation or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>—</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported worsening of clinical status</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Improvement of clinical status within 28 days</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants discharged alive. Participants should be discharged without clinical deterioration or death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported improvement of clinical status</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life up to 28 days and longest follow‐up available</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs during the study period</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed due to insufficient and inconsistent information</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adverse events during the study period</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade TEAE</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed due to insufficient and inconsistent information</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade TRAE</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed due to insufficient and inconsistent information</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation of study drug due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed due to insufficient and inconsistent information</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Viral clearance</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Viral clearance at 7 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>258</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.06</b> (0.71 to 1.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>264 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain whether nirmatrelvir/ritonavir increases viral clearance at 7 days<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>15 more per 1000</b> </p> <p>(75 fewer to 150 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Viral clearance at 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>742</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>779</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> (0.92 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>264 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain whether nirmatrelvir/ritonavir increases viral clearance at 7 days<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Difference <b>37 more per 1000</b><br/>(59 fewer to 148 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event; <b>TEAE:</b> treatment‐emergent adverse event; <b>TRAE:</b> treatment‐related adverse event; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations on certainty in the evidence (GRADE)</b> </p> <p><sup>a</sup>Downgraded two levels for imprecision (minimally contextualized approach), and one level for indirectness (atypical hospital population: WHO 2 to 4). </p> <p><b>Explanations on 'equity considerations'</b> </p> <p>Most study participants were older than 65 years. The study was conducted in China, which in general classifies as upper middle‐income country; however, no further information was given about World Bank country classification by income level and race/ethnicity of study participants. No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated a high‐risk population.<br/><sup>1</sup>Subgroup analyses were reported for age only. There was no difference between subgroups of age. Estimated effects included the line of no effect (RR = 1).<br/><sup>2</sup>No subgroup analyses were reported for age, comorbidity, ethnicity, and World Bank country classification by income level. We are uncertain whether results are applicable to all prespecified subgroups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015395-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015395-sec-0009"></div> <section id="CD015395-sec-0010"> <h3 class="title" id="CD015395-sec-0010">Description of the condition</h3> <p>Coronavirus disease 2019 (COVID‐19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was declared a public health emergency of international concern by the World Health Organization (WHO) between January 2020 and May 2023 (<a href="./references#CD015395-bbs2-0148" title="World Health Organization (WHO). Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 24 November 2021).">WHO 2020a</a>). The COVID‐19 pandemic led to severe global health system disruption, and economic and social upheaval. As of 18 June 2023, over 768 million confirmed cases and over 6.9 million deaths globally have been reported to the WHO; however, due to global reductions in testing and reporting, this is considered an underestimate of the true numbers (<a href="./references#CD015395-bbs2-0153" title="World Health Organization (WHO). COVID-19 weekly epidemiological update. Edition 148. Published 22 June 2023. who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2023 (accessed 26 June 2023).">WHO 2023a</a>). The risk of new virus variants that may lead to a surge in new cases remains an ongoing threat. The variant XBB.1.5 (an Omicron subvariant) is currently the most reported lineage worldwide (<a href="./references#CD015395-bbs2-0153" title="World Health Organization (WHO). COVID-19 weekly epidemiological update. Edition 148. Published 22 June 2023. who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2023 (accessed 26 June 2023).">WHO 2023a</a>). The WHO is currently tracking two variants of interest (XBB.1.5, XBB.1.16), and monitoring a further six variants and their descendant lineages. </p> <p>SARS‐CoV‐2 is a positive‐sense, double‐stranded ribonucleic acid (RNA) virus that belongs to the <i>Coronaviridae</i> family (<a href="./references#CD015395-bbs2-0110" title="KumarM , Al KhodorS . Pathophysiology and treatment strategies for COVID-19. Journal of Translational Medicine2020;18(1):353. [DOI: 10.1186/s12967-020-02520-8]">Kumar 2020</a>). </p> <p>SARS‐CoV‐2 uses its spike glycoprotein‐S to bind to an angiotensin‐converting enzyme 2 (ACE2) receptor on a host cell surface to initiate the infection process. ACE2 receptors are expressed in lung, heart, kidney, intestine, and endothelium in the human body. The main expression site that is central to the pathophysiology of COVID‐19 is the respiratory epithelium of the nasopharynx. SARS‐CoV‐2 genes can then enter the human cell to begin viral replication and shedding. The process of viral replication is mediated by, and depends on, viral proteolytic enzymes (proteases), including main protease (M<sup>pro</sup>, also known as 3C‐like protease, 3CL<sup>pro</sup>) (<a href="./references#CD015395-bbs2-0074" title="AminSA , BanerjeeS , GhoshK , GayenS , JhaT . Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorganic &amp; Medicinal Chemistry2021;29:115860. [PMID: 33191083]">Amin 2021</a>; <a href="./references#CD015395-bbs2-0075" title="AnandK , ZiebuhrJ , WadhwaniP , MestersJR , HilgenfeldR . Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science2003;300(5626):1763-7. [PMID: 12746549]">Anand 2003</a>). Viral variants mainly present mutational changes in the spike glycoprotein (<a href="./references#CD015395-bbs2-0099" title="HarveyWT , CarabelliAM , JacksonB , GuptaRK , ThomsonEC , HarrisonEM , et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology2021;19(7):409-24. [PMID: 34075212]">Harvey 2021</a>). The spike glycoprotein is recognized by the immune system, and is the main target of vaccines against SARS‐CoV‐2 (<a href="./references#CD015395-bbs2-0133" title="SalvatoriG , LubertoL , MaffeiM , AurisicchioL , RoscilliG , PalomboF , et al. SARS-CoV-2 spike protein: an optimal immunological target for vaccines. Journal of Translational Medicine2020;18(1):222. [PMID: 32493510]">Salvatori 2020</a>; <a href="./references#CD015395-bbs2-0142" title="WallsAC , ParkYJ , TortoriciMA , WallA , McGuireAT , VeeslerD . Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell2020;183(6):1735. [PMID: 32155444]">Walls 2020</a>). In contrast, the M<sup>pro</sup> active binding site is highly conserved between different virus variants and less affected by mutations. </p> <p>Most individuals with COVID‐19 are either asymptomatic or develop mild symptoms not requiring hospitalization (approximately 80% to 90%), depending on the time of the investigation, the cohort investigated, and the virus variant (<a href="./references#CD015395-bbs2-0081" title="ChenS , JonasF , ShenC , HilgenfeldR . Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. Protein Cell2010;1(1):59-74. [PMID: 21203998]">Chen 2010</a>; <a href="./references#CD015395-bbs2-0093" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveillance2021;26(16):2100348. [PMID: 33890566]">Funk 2021</a>; <a href="./references#CD015395-bbs2-0158" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [PMID: 32091533]">Wu 2020</a>). A smaller proportion is affected by severe (approximately 11% to 20%) or critical (approximately 1% to 5%) disease with hospitalization and intensive care unit (ICU) admittance due to respiratory failure, septic shock, or multiple organ dysfunction syndrome (<a href="./references#CD015395-bbs2-0093" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveillance2021;26(16):2100348. [PMID: 33890566]">Funk 2021</a>; <a href="./references#CD015395-bbs2-0158" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [PMID: 32091533]">Wu 2020</a>). Risk for severe disease, hospitalization, and mortality is higher for individuals aged 65 years or older, males, smokers, and individuals with certain underlying medical conditions (such as cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), moderate‐to‐severe asthma, immunocompromised state, obesity, sickle cell disease, or type 2 diabetes mellitus) (<a href="./references#CD015395-bbs2-0077" title="BoothA , ReedAB , PonzoS , YassaeeA , AralM , PlansD , et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLOS One2021;16(3):e0247461. [PMID: 33661992]">Booth 2021</a>; <a href="./references#CD015395-bbs2-0103" title="HuangC , WangY , LiX , RenL , ZhaoJ , HuY , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395(10223):497-506. [PMID: 31986264]">Huang 2020</a>; <a href="./references#CD015395-bbs2-0107" title="KaragiannidisC , MostertC , HentschkerC , VoshaarT , MalzahnJ , SchillingerG , et al. Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respiratory Medicine2020;8(9):853-62. [PMID: 32735842]">Karagiannidis 2020</a>; <a href="./references#CD015395-bbs2-0125" title="PetrilliCM , JonesSA , YangJ , RajagopalanH , O'DonnellL , ChernyakY , et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ2020;369:m1966. [PMID: 32444366]">Petrilli 2020</a>; <a href="./references#CD015395-bbs2-0156" title="WilliamsonEJ , WalkerAJ , BhaskaranK , BaconS , BatesC , MortonCE , et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature2020;584(7821):430-6. [PMID: 32640463]">Williamson 2020</a>). Most common symptoms and signs of acute infection include fever, cough, fatigue, and shortness of breath (<a href="./references#CD015395-bbs2-0096" title="GrantMC , GeogheganL , ArbynM , MohammedZ , McGuinnessL , ClarkeEL , et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLOS One2020;15(6):e0234765. [PMID: 32574165]">Grant 2020</a>). Infection with SARS‐CoV‐2 may also lead to long‐term health conditions including persistent fatigue, cognitive dysfunction, and postexertional malaise (<a href="./references#CD015395-bbs2-0104" title="HuangC , HuangL , WangY , LiX , RenL , GuX , et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet2021;397(10270):220-32. [PMID: 33428867]">Huang 2021</a>). </p> <p>The gold standard for confirming a SARS‐CoV‐2 infection is the reverse transcription polymerase chain reaction (RT‐PCR)‐based detection of viral RNA from a nasopharyngeal swab test, anterior nares swab test (nasal swab), sputum, or tracheal secretion, with a sensitivity ranging from 70% to 98%, depending on pretest probability (<a href="./references#CD015395-bbs2-0144" title="WatsonJ , WhitingPF , BrushJE . Interpreting a COVID-19 test result. BMJ2020;369:m1808. [DOI: 10.1136/bmj.m1808]">Watson 2020</a>). Offering lower sensitivity but greater practicality and accessibility, antigen tests can play a role in diagnosis or diagnostic triage, especially in point‐of‐care diagnostics of COVID‐19 (<a href="./references#CD015395-bbs2-0088" title="DinnesJ , SharmaP , BerhaneS , vanWykSS , NyaabaN , DomenJ , et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic Reviews2022, Issue 7. Art. No: CD013705. [DOI: 10.1002/14651858.CD013705.pub3]">Dinnes 2022</a>; <a href="./references#CD015395-bbs2-0149" title="World Health Organization (WHO). Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. apps.who.int/iris/handle/10665/331713 (accessed 8 April 2020).">WHO 2020b</a>). Antibody tests could be a useful diagnostic tool for those in whom molecular‐ or antigen‐based tests have failed to detect the SARS‐CoV‐2 virus (<a href="./references#CD015395-bbs2-0092" title="FoxT , GeppertJ , DinnesJ , ScandrettK , BigioJ , SulisG , et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database of Systematic Reviews2022, Issue 11. Art. No: CD013652. [DOI: 10.1002/14651858.CD013652.pub2]">Fox 2022</a>). </p> <p>Viral transmission is typically inferred from population‐level information. Inherent properties of virus variants of concern, and individual differences in infectiousness among individuals or groups, and differences in local herd immunity make it difficult to contain its spread in the community (<a href="./references#CD015395-bbs2-0150" title="World Health Organization (WHO). WHO coronavirus disease (COVID-19) dashboard. covid19.who.int/table (accessed 23 May 2022).">WHO 2021a</a>). Currently, the most effective strategy to combat the pandemic is vaccination. COVID‐19 vaccines are effective, reduce the risk of getting SARS‐CoV‐2, reduce the risk of severe COVID‐19, and decrease hospitalization rates (<a href="./references#CD015395-bbs2-0079" title="Centers for Disease Control and Prevention (CDC). Benefits of getting a COVID-19 vaccine. cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html (accessed 14 December 2021).">CDC 2021</a>; <a href="./references#CD015395-bbs2-0097" title="GrañaC , GhosnL , EvrenoglouT , JardeA , MinozziS , BergmanH , et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database of Systematic Reviews2022, Issue 12. Art. No: CD015477. [DOI: 10.1002/14651858.CD015477]">Graña 2022</a>; <a href="./references#CD015395-bbs2-0106" title="JuthaniPV , GuptaA , BorgesKA , PriceCC , LeeAI , WonCH , et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infectious Diseases2021;21(11):1485-6. [DOI: 10.1016/S1473-3099(21)00558-2]">Juthani 2021</a>). However, vaccination can fail to produce a sufficiently robust immune response, and the response it does elicit can wane over time and be less effective against new variants (<a href="./references#CD015395-bbs2-0113" title="LinDY , GuY , WheelerB , YoungH , HollowayS , SunnySK , et al. Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina. New England Journal of Medicine2022;386(10):933-41. [PMID: 35020982]">Lin 2022</a>). Furthermore, some people cannot receive a COVID‐19 vaccine for medical reasons, such as anaphylaxis, or may not develop sufficient immunogenicity following vaccination (<a href="./references#CD015395-bbs2-0122" title="National Health Service (NHS) UK. Who cannot have vaccines. nhs.uk/conditions/vaccinations/why-vaccination-is-safe-and-important/ (accessed 14 December 2021).">NHS 2021</a>). Others are hesitant to get vaccinated due to concerns about vaccine side effects and safety (<a href="./references#CD015395-bbs2-0073" title="AltulahiN , AlNujaimS , AlabdulqaderA , AlkharashiA , AlMalkiA , AlSiariF , et al. Willingness, beliefs, and barriers regarding the COVID-19 vaccine in Saudi Arabia: a multiregional cross-sectional study. BMC Family Practice2021;22(1):247. [DOI: 10.1186/s12875-021-01606-6]">Altulahi 2021</a>; <a href="./references#CD015395-bbs2-0143" title="WangC , HanB , ZhaoT , LiuH , LiuB , ChenL , et al. Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: a national cross-sectional study. Vaccine2021;39(21):2833-42. [PMID: 33896661]">Wang 2021</a>). The major obstacle in overcoming this pandemic, however, is vaccine inequity in different regions of the world (<a href="./references#CD015395-bbs2-0151" title="World Health Organization (WHO). Vaccine equity. who.int/campaigns/vaccine-equity (accessed 14 December 2021).">WHO 2021b</a>). Additionally, emerging new virus variants can increase the risk of infection in all countries, including the vaccinated population if vaccines become less effective due to viral immune escape mutations as could be seen with Omicron variants (<a href="./references#CD015395-bbs2-0131" title="RenSY , WangWB , GaoRD , ZhouAM . Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World Journal of Clinical Cases2022;10(1):1-11. [PMID: 35071500]">Ren 2022</a>). Therefore, research on pre‐exposure prophylaxis (PrEP) or postexposure prophylaxis (PEP) of SARS‐CoV‐2 infection and treatment of COVID‐19 is still of high relevance and is being carried out under great pressure worldwide. </p> </section> <section id="CD015395-sec-0011"> <h3 class="title" id="CD015395-sec-0011">Description of the intervention</h3> <p>Pfizer's drug combination nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and death. Nirmatrelvir/ritonavir is a combination of the SARS‐CoV‐2 protease inhibitor nirmatrelvir, and ritonavir, a CYP3A4 inhibitor used in the treatment of HIV to enhance HIV protease inhibitors. Nirmatrelvir blocks the activity of the SARS‐CoV‐2‐3CL<sup>pro</sup> protease, an enzyme needed for viral replication. In humans, nirmatrelvir is metabolized by the P450 cytochrome enzyme CYP3A4. In order to remain active in the body for longer periods of time, nirmatrelvir is co‐administered with low‐dose ritonavir, to slow down the breakdown of nirmatrelvir (<a href="./references#CD015395-bbs2-0126" title="Pfizer Inc. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (accessed 23 November 2021).">Pfizer 2021</a>). Nirmatrelvir/ritonavir is to be administered orally within five days of symptom onset and taken twice daily for five days. Given the inactivation of CYP3A4 by ritonavir, a common enzyme in drug metabolism, ritonavir interferes with the metabolism of many drugs, can alter their plasma concentrations, and increase drug‐related adverse effects. The applicability of nirmatrelvir/ritonavir may thus be limited in some populations at high risk of severe COVID‐19, such as those with comorbidities requiring medications metabolized using the CYP3A4 enzyme. As 3CL<sup>pro</sup>, the substrate‐binding site is highly conserved among all coronaviruses and shares no homology with human proteases, a SARS‐CoV‐2‐3CL<sup>pro</sup> antagonist will be highly specific to SARS‐CoV‐2 and less affected by virus mutations (<a href="./references#CD015395-bbs2-0084" title="DaiW , ZhangB , Jiang X-M, SuH , LiJ , ZhaoY , et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science2020;368(6497):1331-5. [PMID: 32321856]">Dai 2020</a>) compared to antivirals binding to other sites, more prone to mutation. </p> <p>There are several therapeutic options for people with COVID‐19. Choice of therapy depends on severity of illness; drug availability; route of administration; time of onset of symptoms to starting treatment; co‐administered medication; and patient‐specific factors such as age, pregnancy, or current lactation. In people who are at the highest risk of hospitalization or progression to severe illness, including consideration in women who are pregnant or lactating, the WHO Living Guideline for Therapeutics and COVID‐19 includes a strong recommendation for use of nirmatrelvir/ritonavir, in addition to symptomatic management (<a href="./references#CD015395-bbs2-0154" title="Therapeutics and COVID-19: living guideline. www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1 (accessed 1 November 2023). [LICENCE: CC BY-NC-SA 3.0 IGO]">WHO 2023b</a>). Alternative therapeutics for people in this group include remdesivir, which requires intravenous administration, and in some countries, the oral antiviral molnupiravir. Molnupiravir has a conditional recommendation for use by the WHO in people with non‐severe COVID‐19 at highest risk of hospitalization, excluding pregnant or breastfeeding women, and children. It is noted at the current time that the European Medicines Agency (EMA) has recommended the refusal of the marketing authorization of molnupiravir; however, this drug is available outside the EU. </p> <p>Nirmatrelvir/ritonavir is not recommended by the WHO for people with severe COVID‐19; recommended therapeutics in these patients include corticosteroids, interleukin‐6 receptor blockers (tocilizumab, sarilumab), remdesivir (an antiviral), and the janus kinase inhibitor baricitinib in addition to cardiorespiratory support measures as indicated (<a href="./references#CD015395-bbs2-0154" title="Therapeutics and COVID-19: living guideline. www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1 (accessed 1 November 2023). [LICENCE: CC BY-NC-SA 3.0 IGO]">WHO 2023b</a>). </p> <p>The WHO also has a conditional recommendation against the use of nirmatrelvir/ritonavir in people with non‐severe illness at the lowest risk of hospitalization (<a href="./references#CD015395-bbs2-0154" title="Therapeutics and COVID-19: living guideline. www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1 (accessed 1 November 2023). [LICENCE: CC BY-NC-SA 3.0 IGO]">WHO 2023b</a>). </p> <p>The WHO currently does not recommend any therapeutic to prevent COVID‐19 in close contacts of infected patients or in other high‐risk groups (<a href="./references#CD015395-bbs2-0155" title="Drugs to prevent COVID-19: living guideline. www.who.int/publications/i/item/WHO-2019-nCoV-prophylaxes-2023.1 (accessed 1 November 2023).">WHO 2023c</a>). </p> </section> <section id="CD015395-sec-0012"> <h3 class="title" id="CD015395-sec-0012">How the intervention might work</h3> <p>Viral non‐structural proteins are important for replication and transcription of SARS‐CoV‐2. The SARS‐CoV‐2‐3CL<sup>pro</sup> plays a key role in the production of 16 non‐structural proteins of SARS‐CoV‐2. Inhibition of 3CL<sup>pro</sup> by nirmatrelvir blocks the release of these non‐structural proteins, thereby suppressing further maturation and replication of SARS‐CoV‐2 (<a href="./references#CD015395-bbs2-0161" title="ZhangY , TangLV . Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication. Journal of Proteome Research2021;20(1):49-59. [PMID: 33347311]">Zhang 2021</a>). Boosting with ritonavir, a CYP3A4 inhibitor, is required to increase nirmatrelvir to a concentration that is effective against SARS‐CoV‐2 (<a href="./references#CD015395-bbs2-0126" title="Pfizer Inc. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (accessed 23 November 2021).">Pfizer 2021</a>). There is reason to presume that viral load, infectivity, and disease severity are positively correlated (<a href="./references#CD015395-bbs2-0091" title="FajnzylberJ , ReganJ , CoxenK , CorryH , WongC , RosenthalA , et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nature Communications2020;11(1):5493. [PMID: 33127906]">Fajnzylber 2020</a>; <a href="./references#CD015395-bbs2-0108" title="KawasujiH , TakegoshiY , KanedaM , UenoA , MiyajimaY , KawagoK , et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLOS One2020;15(12):e0243597. [PMID: 33296437]">Kawasuji 2020</a>; <a href="./references#CD015395-bbs2-0114" title="LiuY , YanL , WanL , XiangT , LeA , LiuJ , et al. Viral dynamics in mild and severe cases of COVID-19. Lancet2020;20(6):656-7. [PMID: 32199493]">Liu 2020</a>). Decreasing the viral load by blocking viral replication could thereby prevent disease progression and limit the infectivity of COVID‐19 patients. </p> <p>Nirmatrelvir (PF‐07321332), the protease inhibitor agent in nirmatrelvir/ritonavir, was developed by modification of an earlier clinical candidate PF‐00835231, originally developed as a potent inhibitor of recombinant SARS‐CoV‐1‐3CL<sup>pro</sup> during the SARS‐CoV‐1 pandemic in 2002/2003. SARS‐CoV‐1‐3CL<sup>pro</sup> and SARS‐CoV‐2‐3CL<sup>pro</sup> share 96% sequence homology (<a href="./references#CD015395-bbs2-0160" title="ZhangL , LinD , SunX , CurthU , DrostenC , SauerheringL , et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science2020;368(6489):409-12. [PMID: 32198291]">Zhang 2020</a>). However, PF‐00835231 needs to be administered intravenously, limiting its application mainly to hospital settings. Stepwise modification led to the new substance nirmatrelvir, with increased oral bioavailability. To date, nirmatrelvir has shown potent inhibition of 3CL<sup>pro</sup> from all coronavirus types known to infect humans, as well as favourable selectivity profiles against mammalian proteases (<a href="./references#CD015395-bbs2-0123" title="OwenDR , AllertonCM , AndersonAS , AschenbrennerL , AveryM , BerrittS , et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science2021;374(6575):1586-93. [PMID: 34726479]">Owen 2021</a>). </p> <p>Lufotrelvir, the phosphate prodrug of PF‐00835231, with a similar mechanism of action to nirmatrelvir but with intravenous administration, is currently studied for safety and efficacy in the treatment of hospitalized people with COVID‐19, including trials in conjunction with remdesivir, as in vitro data showed synergistic effects (<a href="./references#CD015395-bbs2-0086" title="deVriesM , MohamedAS , PrescottRA , Valero-JimenezAM , DesvignesL , O'ConnorR , et al. Comparative study of a 3CL pro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models. bioRxiv2020;95(10):1819-20. [DOI: 10.1101/2020.08.28.272880]">de Vries 2020</a>; <a href="./references#CD015395-bbs2-0120" title="NCT04501978. ACTIV-3: Therapeutics for Inpatients with COVID-19 (TICO) [A multicenter, adaptive, randomized, blinded controlled trial of the safety and efficacy of investigational therapeutics for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/NCT04501978 (first received 6 August 2020).">NCT04501978</a>; <a href="./references#CD015395-bbs2-0121" title="NCT04535167. First-in-human study to evaluate safety, tolerability, and pharmacokinetics following single ascending and multiple ascending doses of PF-07304814 in hospitalized participants with COVID-19 [A phase 1B, 2-part, double-blind, placebo-controlled, sponsor-open study, to evaluate the safety, tolerability and pharmacokinetics of single ascending (24-hour, part 1) and multiple ascending (120-hour, part 2) intravenous infusions of PF-07304814 in hospitalized participants with COVID-19]. clinicaltrials.gov/ct2/show/NCT04535167 (first received 1 September 2020).">NCT04535167</a>). </p> </section> <section id="CD015395-sec-0013"> <h3 class="title" id="CD015395-sec-0013">Why it is important to do this review</h3> <p>Current treatment for hospitalized people with COVID‐19 includes supportive care with oxygen in moderate cases, systemic corticosteroids, remdesivir, baricitinib, interleukin‐6 blockers, and non‐invasive ventilation or invasive mechanical ventilation and extracorporeal membrane oxygenation (ECMO) in severe or critical cases (<a href="./references#CD015395-bbs2-0072" title="AgarwalA , RochwergB , LamontagneF , SiemieniukRA , AgoritsasT , AskieL , et al. A living WHO guideline on drugs for COVID-19. BMJ2020;370:m3379. [DOI: 10.1136/bmj.m3379]">Agarwal 2020</a>). Overall, data from randomized controlled trials (RCTs) with exception to the aforementioned treatments do not demonstrate a clear, major clinical benefit with most drugs evaluated so far. Therapeutic options for treatment of COVID‐19 in the outpatient setting or for prevention of a SARS‐CoV‐2 infection in close contacts of infected people or in people at risk are still limited. In light of the ongoing potential for evolving virus variants, scarcity of effective treatments, and global vaccination coverage issues, the role of effective oral therapies for people at high risk of severe disease is of utmost interest for reducing morbidity and mortality secondary to COVID‐19. </p> <p>The COVID‐19 pandemic has brought social and racial injustice and health inequity in the spotlight of public health. The impact of COVID‐19 disproportionally affects elderly, poor, racial and ethnic minorities, as well as a broad range of vulnerable populations, putting them at increased risk of illness and death (<a href="./references#CD015395-bbs2-0109" title="KillerbyME , Link-GellesR , HaightSC , SchrodtCA , EnglandL , GomesDJ , et al. Characteristics associated with hospitalization among patients with COVID-19 – Metropolitan Atlanta, Georgia, March–April 2020. Morbidity and Mortality Weekly Report2020;69:790-4. [DOI: 10.15585/mmwr.mm6925e1]">Killerby 2020</a>). Reasons include, but are not limited to, inequitable viral spread in areas of dense population, and limited mitigation capacity due to a higher prevalence of chronic conditions or poor access to high‐quality medical care (<a href="./references#CD015395-bbs2-0135" title="ShadmiE , ChenY , DouradoI , Faran-PerachI , FurlerJ , HangomaP , et al. Health equity and COVID-19: global perspectives. International Journal for Equity in Health2020;19(1):104. [PMID: 32586388]">Shadmi 2020</a>). Studies of the average effects of interventions, which control for confounding across individual and population‐level characteristics, hide their impact on health equity (<a href="./references#CD015395-bbs2-0146" title="WelchV , PetticrewM , TugwellP , MoherD , O'NeillJ , WatersE , et al. PRISMA-Equity 2012 Extension: reporting guidelines for systematic reviews with a focus on health equity. PLOS Medicine2012;9(10):e1001333. [DOI: 10.1371/journal.pmed.1001333]">Welch 2012</a>). Therefore, special consideration of health equity in studies and meta‐analyses is needed, which can be obtained by reporting and analysis of population characteristics per outcome on the study‐level. </p> <p>Prevention of COVID‐19 in people at high risk for developing severe disease requiring hospital‐level treatment is critical, especially from a global perspective considering limited hospital capacity in low‐income countries (LICs) and low‐ to middle‐income countries (LMICs). Antiviral drugs such as nirmatrelvir/ritonavir might therefore be of vital importance in the global fight against SARS‐CoV‐2. However, it is yet to be determined whether the fact that nirmatrelvir/ritonavir has to be administered within five days of symptom onset may decrease its applicability due to inadequate healthcare infrastructures and lack of access to public health and medical care in LMICs, in older people, and in racial and ethnic minority populations. </p> <p>To allow equity of access across countries, Pfizer has signed a voluntary licence agreement for nirmatrelvir/ritonavir with the Medicines Patent Pool (MPP), a United Nations‐backed public health organization working to increase access to life‐saving medicines for LMICs (<a href="./references#CD015395-bbs2-0118" title="Medicines Patent Pool (MPP). Medicines Patent Pool. medicinespatentpool.org/who-we-are/about-us (accessed 1 December 2021).">MPP 2021a</a>; <a href="./references#CD015395-bbs2-0126" title="Pfizer Inc. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (accessed 23 November 2021).">Pfizer 2021</a>). With the MPP having a licence on ritonavir for many years, the agreement will enable MPP to facilitate additional production and distribution of both ritonavir and nirmatrelvir by granting sublicenses to qualified generic medicine manufacturers (<a href="./references#CD015395-bbs2-0119" title="Medicines Patent Pool (MPP). Nirmatrelvir – license agreement; November 2021. Available at medicinespatentpool.org/licence-post/pf-07321332 (accessed prior to 1 November 2023).">MPP 2021b</a>). Pfizer further aims to offer a tiered pricing approach based on the income level of a country, with high‐income countries (HICs) and upper‐middle income countries (UMICs) paying more than LICs, which will pay a not‐for‐profit price (<a href="./references#CD015395-bbs2-0126" title="Pfizer Inc. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (accessed 23 November 2021).">Pfizer 2021</a>). </p> <p>To date, several trials for nirmatrelvir/ritonavir on clinical outcomes for people with COVID‐19 at high and standard risk are ongoing or terminated, but results have not been posted. A trial for PEP by Pfizer has been completed but not yet been published (<a href="./references#CD015395-bbs2-0126" title="Pfizer Inc. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (accessed 23 November 2021).">Pfizer 2021</a>). This review is designed as a living systematic review (LSR) with continuous monitoring of new and ongoing studies. We aim to keep the evidence base on clinical studies investigating nirmatrelvir/ritonavir for COVID‐19 up to date. </p> <p>This Cochrane Review will provide a complete evidence profile, based on current Cochrane standards, for nirmatrelvir/ritonavir with regard to efficacy and safety for PrEP and PEP and treatment of COVID‐19 in out‐ and inpatient settings. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015395-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015395-sec-0014"></div> <p>To assess the efficacy and safety of nirmatrelvir/ritonavir plus standard of care (SoC) compared to SoC with or without placebo, or any other intervention for treating COVID‐19 or preventing SARS‐CoV‐2 infection. </p> <p>To explore equity aspects in subgroup analyses.</p> <p>To keep up to date with the evolving evidence base using a living systematic review (LSR) approach and make new relevant studies available to readers in‐between publication of review updates. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015395-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015395-sec-0015"></div> <section id="CD015395-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015395-sec-0017"> <h4 class="title">Types of studies</h4> <p>Studies were eligible if they were RCTs.</p> <p>We searched for full‐text journal articles published in PubMed‐indexed and non‐indexed journals, preprint articles, results published in trials registers, clinical study reports (CSRs), and abstract publications. We applied no restrictions on the language of published articles. </p> <p>We screened all identified studies for research integrity using a tool developed by our group to deal with problematic studies (see <a href="#CD015395-sec-0033">Selection of studies</a>). </p> </section> <section id="CD015395-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD015395-sec-0019"> <h5 class="title">Treating COVID‐19</h5> <p>Studies were eligible if they included participants with confirmed SARS‐CoV‐2 infection (RT‐PCR or antigen testing), regardless of age, gender, ethnicity, serology status, vaccination status, previous SARS‐CoV‐2 infection, and risk factors for developing severe COVID‐19. If studies included participants with a confirmed or suspected COVID‐19 diagnosis, we used only the data for the population with confirmed COVID‐19 diagnosis. </p> <p>COVID‐19 severity was classified according to the WHO clinical progression scale (<a href="./references#CD015395-bbs2-0115" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: 32539990]">Marshall 2020</a>) into mild (WHO 1 to 3), moderate (WHO 4 to 5), and severe (WHO 6 to 9). </p> <p>In cases where data were not reported separately for people with confirmed or suspected COVID‐19 diagnosis, we excluded the study. </p> </section> <section id="CD015395-sec-0020"> <h5 class="title">Preventing SARS‐CoV‐2 infection</h5> <p>We synthesized evidence for both PEP and PrEP scenarios. For PEP, we included studies investigating participants who were not infected with SARS‐CoV‐2 at enrollment (negative RT‐PCR), but were at high risk of developing the infection following exposure to infected people or infectious viral particles. For PrEP, we included studies investigating participants who were not infected with SARS‐CoV‐2 at enrollment (negative RT‐PCR) and were not yet exposed to infected people or infectious viral particles, but were at increased risk of contracting the disease (e.g. healthcare workers). </p> <p>Participants in both settings were eligible regardless of age, gender, ethnicity, serology status, vaccination status, previous SARS‐CoV‐2 infection, and risk factors for developing severe COVID‐19. Eligible trials must have reported the history of previous SARS‐CoV‐2 infection or serological evidence and the vaccination status of included participants. A history of SARS‐CoV‐2 infection or vaccination was not an exclusion criterion. </p> </section> </section> <section id="CD015395-sec-0021"> <h4 class="title">Types of interventions</h4> <p>All doses and regimens of nirmatrelvir/ritonavir were eligible for this systematic review. Nirmatrelvir/ritonavir is authorized and approved by the US Food and Drug Administration (FDA) at a dose of 300 mg (as two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice‐daily for five days (<a href="./references#CD015395-bbs2-0090" title="US Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for Paxlovid. www.fda.gov/media/155050/download (accessed 14 February 2022).">EUA for Paxlovid</a>). </p> <p>We compared nirmatrelvir/ritonavir plus SoC to SoC with or without placebo, or to any other intervention for treating COVID‐19 and for preventing SARS‐CoV‐2 infection including traditional Chinese medicine (TCM). We planned to investigate different active comparators in separate comparisons. Co‐interventions (SoC) must have been comparable between the study arms. </p> </section> <section id="CD015395-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated core outcomes in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for people with COVID‐19 (<a href="./references#CD015395-bbs2-0083" title="Core Outcome Measures in Effectiveness Trials (COMET) Initiative. Core outcome set developers' response to COVID-19. comet-initiative.org/Studies/Details/1538 (accessed 13 June 2021).">COMET 2020</a>; <a href="./references#CD015395-bbs2-0115" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: 32539990]">Marshall 2020</a>), and additional outcomes that have been prioritized by consumer representatives and the German guideline panel for treatment of people with COVID‐19 (<a href="./references#CD015395-bbs2-0095" title="BlankenfeldH , KaduszkiewiczH , KochenMM , PömslJ . SARS-CoV-2/Covid-19 Informationen und Praxishilfen für niedergelassene Hausärztinnen und Hausärzte. awmf.org/leitlinien/detail/ll/053-054.html (accessed 14 February 2022).">German AWMF Guideline 2021</a>). </p> <p>We used different outcome sets for the use of nirmatrelvir/ritonavir for treating people with COVID‐19 in the out‐ and inpatient setting, and for preventing SARS‐CoV‐2 infection. If studies were eligible for inclusion regarding study design, population, intervention, and comparator, but no outcomes of interest were reported, they were not included for meta‐analysis. However, we summarized reported outcomes for all included studies in the <a href="./references#CD015395-sec-0143" title="">Characteristics of included studies</a> table. We did not exclude studies if they did not report outcomes of interest. </p> <section id="CD015395-sec-0023"> <h5 class="title">Primary outcomes</h5> <section id="CD015395-sec-0024"> <h6 class="title">Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings </h6> <p> <ul id="CD015395-list-0001"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and up to the longest follow‐up.</p> </li> <li> <p>Worsening of clinical status within 28 days.</p> <ul id="CD015395-list-0002"> <li> <p>Admission to hospital or death.</p> </li> <li> <p>Admission to ICU or death.</p> </li> </ul> </li> <li> <p>Improvement of clinical status.</p> <ul id="CD015395-list-0003"> <li> <p>All initial symptoms resolved (asymptomatic) at day 14, day 28, and up to the longest follow‐up. </p> </li> <li> <p>Time to symptom resolution.</p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardized scales (e.g. WHOQOL‐100) at up to 7 days, up to 28 days, and longest follow‐up available. </p> </li> <li> <p>Serious adverse events (SAEs) during the study period, defined as number of participants with any event. </p> </li> <li> <p>Adverse events (AEs) during the study period, defined as number of participants with any event. </p> <ul id="CD015395-list-0004"> <li> <p>Any grade treatment‐emergent adverse events (TEAEs; AEs temporally related to the study treatment). </p> </li> <li> <p>Any grade treatment‐related adverse events (TRAE; AEs assessed as causally related to the study treatment by the study investigator). </p> </li> <li> <p>Discontinuation of study drug due to AEs.</p> </li> </ul> </li> <li> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at baseline, and 3, 7, and 14 days. </p> </li> </ul> </p> </section> <section id="CD015395-sec-0025"> <h6 class="title">Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings </h6> <p>We used a similar outcome set for treating people with COVID‐19 in out‐ and inpatient settings, but with different definitions of the outcomes of 'Worsening of clinical status' and 'Improvement of clinical status'. For inpatient settings, we used the following definitions. </p> <p> <ul id="CD015395-list-0005"> <li> <p>Worsening of clinical status within 28 days.</p> <ul id="CD015395-list-0006"> <li> <p>Participants with new need for invasive mechanical ventilation or death.</p> </li> <li> <p>Participants with need for ICU admission or death.</p> </li> </ul> </li> <li> <p>Improvement of clinical status within 28 days.</p> <ul id="CD015395-list-0007"> <li> <p>Participants discharged alive. Participants should have been discharged without clinical deterioration or death. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD015395-sec-0026"> <h6 class="title">Nirmatrelvir/ritonavir for preventing SARS‐CoV‐2 infection (pre‐ and postexposure)</h6> <p>We used the same outcome set for PrEP and PEP scenarios, but with different time frames for the outcome assessment. For PEP studies, the relevant period is 14 to 28 days and for PrEP studies, a longer period of up to six months is relevant. </p> <p> <ul id="CD015395-list-0008"> <li> <p>SARS‐CoV‐2 infection (confirmed by RT‐PCR or antigen testing) at 14 days (PEP) and six months (PrEP). </p> </li> <li> <p>Development of clinical COVID‐19 symptoms up to 28 days (PEP) and six months (PrEP); for example, assessed in accordance with individual items of the WHO scale (<a href="./references#CD015395-bbs2-0115" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: 32539990]">Marshall 2020</a>), or any other standardized scale. If the study did not use the standardized WHO scale to assess the status of the participants, we would have categorized their status according to the WHO scale with the information provided by the study. </p> <ul id="CD015395-list-0009"> <li> <p>Uninfected (WHO scale 0).</p> </li> <li> <p>Ambulatory mild disease (WHO scale 1 to 3).</p> </li> <li> <p>Hospitalized with moderate disease (WHO scale 4 to 5).</p> </li> <li> <p>Hospitalized with severe disease (WHO scale 7 to 9).</p> </li> <li> <p>Mortality (WHO scale 10).</p> </li> </ul> </li> <li> <p>All‐cause mortality up to the longest follow‐up.</p> </li> <li> <p>Admission to hospital or death within 28 days (PEP) and six months (PrEP).</p> </li> <li> <p>Quality of life assessed with the standardized scale, WHOQOL‐100, up to 28 days (PEP) and six months (PrEP), and at longest follow‐up available. </p> </li> <li> <p>SAEs during the study period, defined as number of participants with any event.</p> </li> <li> <p>AEs during the study period, defined as number of participants with any event.</p> <ul id="CD015395-list-0010"> <li> <p>Any grade TEAE (AEs temporally related to the study treatment).</p> </li> <li> <p>Any grade TRAE (AEs assessed as causally related to the study treatment by the study investigator). </p> </li> <li> <p>Discontinuation of study drug due to AEs.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD015395-sec-0027"> <h6 class="title">Timing of outcome measurement</h6> <p>We collected information on outcomes from all time points reported in the publications and study reports. If only a few studies contributed data to an outcome, we planned to pool different time points, provided the studies produced valid data and pooling was clinically reasonable. The current review version included two studies. </p> <p>For time‐to‐event analysis (e.g. for time to death), we planned to use the longest follow‐up time measured from randomization. </p> <p>We reported time points of outcome measurement in the footnotes of the forest plots. We included SAEs and AEs occurring during the study period, including AEs during active treatment and long‐term AEs. If sufficient data had been available, we planned to group the measurement time points of eligible outcomes into those measured directly after treatment (up to seven days), medium‐term outcomes (up to 14 days), and longer‐term outcomes (28 days or more). </p> </section> </section> <section id="CD015395-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p>This review specifies no secondary outcomes. All outcomes were treated as a primary outcome set which informed the summary of findings tables. </p> </section> </section> </section> <section id="CD015395-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015395-sec-0030"> <h4 class="title">Electronic searches</h4> <p>Our Information Specialist (MIM) conducted systematic searches in the following sources from the inception of each database to 15 May 2023 and placed no restrictions on the language of publication. </p> <p> <ul id="CD015395-list-0011"> <li> <p>Cochrane COVID‐19 Study Register (CCSR) (<a href="https://www.covid-19.cochrane.org" target="_blank">www.covid-19.cochrane.org</a>), comprising: </p> <ul id="CD015395-list-0012"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), monthly updates;</p> </li> <li> <p>MEDLINE (PubMed), weekly updates;</p> </li> <li> <p>Embase, weekly updates;</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), daily updates; </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>), weekly updates; </p> </li> <li> <p>medRxiv (<a href="http://www.medrxiv.org" target="_blank">www.medrxiv.org</a>), weekly updates. </p> </li> </ul> </li> <li> <p>Scopus (Elsevier).</p> </li> <li> <p>WHO COVID‐19 Research Database (<a href="https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/" target="_blank">search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/</a>). </p> </li> </ul> </p> <p>For detailed search strategies, see <a href="./appendices#CD015395-sec-0131">Appendix 1</a>. As this review is a LSR, we conducted monthly update searches until December 2022 and changed to conduct search updates every two months thereafter (due to lack of publication of relevant studies) which are being made publicly available on OSF (<a href="https://osf.io/7g49c/" target="_blank">osf.io/7g49c/</a>; <a href="./references#CD015395-bbs2-0130" title='ReisS , MetzendorfM , KuehnR , PoppM , GagyorI , KrankeP , et al. Living evidence base for Cochrane Review "Nirmatrelvir combined with ritonavir for preventing and treating COVID-19". osf.io/7g49c/ (created 30 May 2022). [DOI: 10.17605/OSF.IO/7G49C]'>Reis 2022a</a>). See section 'Methods for future updates' on specific LSR methodology. </p> <p>We do not conduct separate searches of the databases required by the MECIR standards (<a href="./references#CD015395-bbs2-0100" title="HigginsJP , LassersonT , ChandlerJ , ToveyD , ThomasJ , FlemyngE , et al. Methodological Expectations of Cochrane Intervention Reviews (MECIR). community.cochrane.org/mecir-manual/ (accessed 12 December 2021).">Higgins 2021</a>), since these databases are being regularly searched for the production of the CCSR. </p> </section> <section id="CD015395-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We searched for other potentially eligible studies or ancillary publications by searching the reference lists of included studies, systematic reviews, and meta‐analyses. </p> </section> </section> <section id="CD015395-sec-0032"> <h3 class="title" id="CD015395-sec-0032">Data collection and analysis</h3> <section id="CD015395-sec-0033"> <h4 class="title">Selection of studies</h4> <section id="CD015395-sec-0034"> <h5 class="title">Inclusion criteria</h5> <p>We performed study selection in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015395-bbs2-0112" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Lefebvre 2022</a>). Three review authors (SR, RK, and SW) independently screened titles and abstracts of identified records. We retrieved full‐text articles and independently assessed eligibility of the remaining records against the predefined eligibility criteria. We resolved discrepancies through discussion between the review authors. We included studies irrespective of whether measured outcome data were reported in a 'usable' way. We collated multiple reports of the same study, so that the study, rather than the report, was the unit of interest in the review. </p> </section> <section id="CD015395-sec-0035"> <h5 class="title">Research integrity screening</h5> <p>Early in the COVID‐19 pandemic several studies were identified as unsuitable for public use due to research ethics and integrity concerns and were retracted, withdrawn, or noted with concern (<a href="./references#CD015395-bbs2-0078" title="BramstedtKA . The carnage of substandard research during the COVID-19 pandemic: a call for quality. Journal of Medical Ethics2020;46:803-7. [PMID: 33004545]">Bramstedt 2020</a>). Cochrane has published a policy on managing problematic studies and guidance to facilitate research integrity checks in the reviews it publishes, but these checks have not routinely formed part of evidence synthesis processes to date (<a href="./references#CD015395-bbs2-0082" title="Cochrane Database of Systematic Reviews: editorial policies. Cochrane policy on managing potentially problematic studies. cochranelibrary.com/cdsr/editorial-policies#problematic-studies (assessed 4 April 2022).">Cochrane policy – managing problematic studies</a>). Current standard tools for systematic reviews do not systematically consider issues of research integrity. However, there are useful tools available such as the 'REAPPRAISED' checklist for evaluation of publication integrity (<a href="./references#CD015395-bbs2-0098" title="GreyA , BollandMJ , AvenellA , KleinAA , GunsalusCK . Check for publication integrity before misconduct. Nature2020;577(7789):167-9. [PMID: 31911697]">Grey 2020</a>), or the data extraction sheet from the Cochrane Pregnancy and Childbirth Group that addresses scientific integrity and trustworthiness (<a href="./references#CD015395-bbs2-0085" title="Cochrane Pregnancy and Childbirth Group. pcg_data_extraction_form_v_2.2_-_13_july_2021_1.docx. pregnancy.cochrane.org/author-resources-new-reviews (website is no longer available) (accessed 9 December 2021).">Data extraction template 2021</a>). We modified these existing tools and developed a specific tool for studies in this pandemic that we used for updating the Cochrane Review on ivermectin (<a href="./references#CD015395-bbs2-0129" title="PoppM , ReisS , SchießerS , Hausinger R Ilona, StegemannM , et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews2022, Issue 6. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub3]">Popp 2022</a>; <a href="./references#CD015395-bbs2-0145" title="WeibelS , PoppM , ReisS , SkoetzN , GarnerP , SydenhamE . Identifying and managing problematic trials: a Research Integrity Assessment (RIA) tool for randomized controlled trials in evidence synthesis. www.medrxiv.org/content/10.1101/2022.05.31.22275756v1 (first received 5 June 2022). [DOI: 10.1101/2022.05.31.22275756]">Weibel 2022</a>). This tool, along with detailed methodological instructions and critical and important signalling questions to key aspects (domains), is described in <a href="./appendices#CD015395-sec-0132">Appendix 2</a>, and elsewhere (<a href="./references#CD015395-bbs2-0145" title="WeibelS , PoppM , ReisS , SkoetzN , GarnerP , SydenhamE . Identifying and managing problematic trials: a Research Integrity Assessment (RIA) tool for randomized controlled trials in evidence synthesis. www.medrxiv.org/content/10.1101/2022.05.31.22275756v1 (first received 5 June 2022). [DOI: 10.1101/2022.05.31.22275756]">Weibel 2022</a>). Briefly, all trials fulfilling the PIC (patient, intervention, and comparator) eligibility criteria were assessed for issues with research integrity, such as retraction notices, prospective trial registration, ethics approval, plausible study authorship, sufficient reporting of methods regarding relevant eligibility criteria (e.g. randomization), and plausibility of study results. Studies were only eligible for the review if they met critical aspects assuring research integrity. Studies were excluded if they were retracted or if they were not prospectively registered in a national or international studies' registry according to the WHO guidelines for clinical trial registration (<a href="./references#CD015395-bbs2-0147" title="World Health Organization (WHO). International standards for clinical trial registries – 2nd edition. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Available at www.who.int/publications/i/item/international-standards-for-clinical-trial-registers.">WHO 2018</a>). All potentially eligible studies with disparities in the reporting of the methods and results were held in 'awaiting classification' until the study authors clarified certain questions upon request. The process was documented and decisions were transparently reported. </p> <p>We documented the study selection process in a PRISMA flow diagram with the total number of studies included, excluded, awaiting classification, and ongoing. We listed the reasons for exclusion in the <a href="./references#CD015395-sec-0144" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD015395-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SR and SW) independently extracted data using a standardized data extraction form, including details of the study, participants, intervention, comparator, and outcomes. If necessary, we attempted to obtain missing data by contacting the authors of relevant articles. At each step of data extraction, we resolved any discrepancies through discussion between the review authors. In case of discrepancies between different documents of one study (e.g. preprint, journal publication, clinical study reports, registered trial protocol), we planned to contact the authors for clarification. </p> <p>We extracted the following information, if reported.</p> <p> <ul id="CD015395-list-0013"> <li> <p>General information: author, trial name, title, source, country, language, type of publication/report, and publication date. </p> </li> <li> <p>Study characteristics: setting and dates, inclusion/exclusion criteria, number of study arms, comparability of groups, length of follow‐up, and funding. </p> </li> <li> <p>Participant characteristics: number of participants randomized/received intervention/analyzed, COVID‐19 diagnostics, severity of disease, age, gender, race, ethnicity, comorbidities (e.g. diabetes, immunosuppression, obesity), concurrent medication, time since symptom onset, vaccination status (e.g. type of vaccine, number of doses), serology status, and history of SARS‐CoV‐2 infection. </p> </li> <li> <p>Intervention: dose, frequency, time from symptom onset to treatment initiation, and duration and route of administration. </p> </li> <li> <p>Control intervention: type of control, dose and frequency, and duration and route of administration. </p> </li> <li> <p>Outcomes: as specified under <a href="#CD015395-sec-0022">Types of outcome measures</a>. </p> </li> </ul> </p> <p>To address health equity, we considered the following population characteristics and report them per outcome at the study‐level in additional tables. </p> <p> <ul id="CD015395-list-0014"> <li> <p>Elderly people (older than 65 years). People of advanced age are at increased risk for severe disease. The intervention (nirmatrelvir/ritonavir) could potentially have greater impact on elderly people. </p> </li> <li> <p>People at social disadvantage due to the number of comorbid health conditions. The intervention (nirmatrelvir/ritonavir) is aimed at people with at least one risk factor for severe disease. Risk factors include individuals with a comorbid health condition, or multimorbidity, the presence of which is associated with social disadvantage (multimorbidity is associated with a reduction in quality of life, increased disability, and premature mortality). The intervention could potentially have greater impact on people with comorbid health conditions, promoting health equity. </p> </li> <li> <p>People from LICs, LMICs, UMICs, and HICs as defined by the <a href="./references#CD015395-bbs2-0157" title="World Bank. The world by income and region. datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html (accessed 15 February 2022).">World Bank 2022</a> (studies were categorized based on the date of first participant enrollment). Differences exist in access to care and the quality of care across LICs, LMICs, UMICs, and HICs. People from LICs and LMICs may not have access to the intervention within five days of onset of symptoms of COVID‐19. Use of diagnostic tools in LICs and LMICs is also limited. In this context, nirmatrelvir/ritonavir could then be seen to have a potentially greater effectiveness for people from UMICs and HICs. </p> </li> <li> <p>People from different ethnic and racial backgrounds, including minorities. Differences exist in access to care and the quality of care across different ethnic and racial minority groups who may not have access to the intervention within five days of onset of symptoms of a SARS‐CoV‐2 infection. Nirmatrelvir/ritonavir could therefore be seen as having a lower impact in these population groups. </p> </li> </ul> </p> </section> <section id="CD015395-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in the included studies using RoB 2 (<a href="./references#CD015395-bbs2-0101" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022a</a>; <a href="./references#CD015395-bbs2-0136" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>). The effect of interest is the effect of assignment at baseline, regardless of whether the interventions were received as intended (the 'intention‐to‐treat effect'). We assessed the risk of bias for all results (outcomes) reported in the included study that we specified as outcomes for the review and that contributed to the review's summary of findings tables. </p> <p>Two review authors (SR, SW) independently assessed the risk of bias of all results. We resolved any disagreements through discussion with a third review author. </p> <p>The RoB 2 tool considers the following domains:</p> <p> <ul id="CD015395-list-0015"> <li> <p>bias arising from the randomization process;</p> </li> <li> <p>bias due to deviations from the intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome; and</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>We assessed the RoB 2 domains using the recommended signalling questions and the following response options: </p> <p> <ul id="CD015395-list-0016"> <li> <p>yes;</p> </li> <li> <p>probably yes;</p> </li> <li> <p>probably no;</p> </li> <li> <p>no; or</p> </li> <li> <p>no information.</p> </li> </ul> </p> <p>RoB 2 algorithms map responses to signalling questions. We used the proposed algorithm after verification to reach a risk of bias judgement, and assigned one of three levels to each domain: </p> <p> <ul id="CD015395-list-0017"> <li> <p>low risk of bias;</p> </li> <li> <p>some concerns; or</p> </li> <li> <p>high risk of bias.</p> </li> </ul> </p> <p>Similarly, we reached an overall risk of bias judgement for a specific outcome by considering all domains resulting in one of the three judgement options described above. Overall low risk of bias of the trial result was assumed when all domains were at low risk; some concerns of bias was assumed when the trial results were judged to raise some concerns in at least one domain for this result, but not at high risk of bias for any domain; overall high risk of bias of the trial result was assumed when the trials were at high risk of bias in at least one domain for this result or when it was judged to have some concerns for multiple domains in a way that substantially lowered confidence in the result (<a href="./references#CD015395-bbs2-0101" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022a</a>). </p> <p>We used the RoB 2 Excel tool (version beta_v7) to implement RoB 2 (available at <a href="https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2" target="_blank">www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2</a>). We stored the full RoB 2 data (e.g. completed Excel tool) in an online repository. </p> </section> <section id="CD015395-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we recorded the number of events and the number of analyzed participants in the intervention and control groups. For any AEs, we counted the number of events as number of participants with (at least) one event. We used the risk ratio (RR) with 95% confidence interval (CI) as the effect measure. </p> <p>For continuous outcomes, we planned to record the mean, the standard deviation (SD), and the number of analyzed participants in the intervention and control groups. If the SD was not reported, we planned to use standard errors (SEs), CIs, or P values to calculate the SD with the formulas described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015395-bbs2-0102" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022b</a>). If studies in future review updates have reported data as median with interquartile range (IQR), we will assume that the median is similar to the mean when the distribution of the outcome is similar to the normal distribution (e.g. symmetric IQR). In these cases, the width of the IQR is approximately 1.35 SDs (<a href="./references#CD015395-bbs2-0102" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022b</a>). We planned to use the mean difference (MD) with 95% CI as the effect measure. For continuous outcomes measured on different scales (e.g. quality of life), we planned to perform analyses using the standardized mean difference (SMD). For interpreting SMDs, we would have re‐expressed SMDs in the original units of a particular scale with the most clinical relevance and impact. The current review version did not contain a continuous outcome. </p> <p>If available in future review updates, we will extract and report hazard ratios (HRs) for time‐to‐event outcomes (e.g. time to death). If HRs are not available, we make every effort to estimate the HR as accurately as possible from available data using the methods proposed by <a href="./references#CD015395-bbs2-0124" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34. [DOI: 10.1002/(sici)1097-0258(19981230)17:24&amp;lt;2815::aid-sim110&amp;gt;3.0.co;2-8]">Parmar 1998</a> and <a href="./references#CD015395-bbs2-0141" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [PMID: 17555582]">Tierney 2007</a>. If sufficient studies provide HRs, we plan to use HRs rather than RRs or MDs in a meta‐analysis, as they provide more information. The current review version did not contain a time‐to‐event outcome. </p> <p>We considered effect estimates of dichotomous outcomes with the range of the 95% CIs not crossing 1 (the line of null effect) and continuous outcomes with the range of the 95% CIs not crossing 0 as statistically significant effect estimates. A statistically significant effect does not necessarily mean that the estimated effect is clinically relevant. Clinical experts assessed the clinical relevance of the effects based on anticipated absolute effects separately, and we reported this transparently. </p> </section> <section id="CD015395-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis for this review was the randomized participant.</p> <p>In studies with multiple intervention groups, we planned to combine groups if reasonable (e.g. study arms with different doses of nirmatrelvir/ritonavir). If it was not reasonable to pool the groups, we planned to split the 'shared' comparator group to avoid double‐counting of participants. No study groups were pooled for the current review as neither of the included studies investigated multiple intervention groups. </p> </section> <section id="CD015395-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>There are many potential sources of missing data in a systematic review or meta‐analysis, which can affect the level of studies, outcomes, summary data, individuals, or study‐level characteristics (<a href="./references#CD015395-bbs2-0087" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). Incomplete data can introduce bias into the meta‐analysis, if they are not missing at random. We addressed all sources of missing data. Missing studies may be the result of reporting bias, and we addressed this as described in the <a href="#CD015395-sec-0042">Assessment of reporting biases</a> section. Missing outcomes and summary data may be the result of selective reporting bias; missing individuals may be the result of attrition from the study or lack of intention‐to‐treat analysis. We addressed these sources of missing data using the RoB 2 tool (<a href="#CD015395-sec-0037">Assessment of risk of bias in included studies</a>). If data were incompletely reported, we contacted the study authors to request additional information. </p> </section> <section id="CD015395-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to use the descriptive statistics reported in the <a href="./references#CD015395-sec-0143" title="">Characteristics of included studies</a> table to assess whether the studies within each pairwise comparison were homogeneous enough, with respect to study and intervention details and population baseline characteristics, that the assumption of homogeneity might be plausible. In case of excessive clinical heterogeneity, we planned not to pool the findings of included studies. </p> <p>We planned to measure statistical heterogeneity using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic (<a href="./references#CD015395-bbs2-0087" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>), and the 95% prediction interval (PI) for random‐effects meta‐analysis (<a href="./references#CD015395-bbs2-0105" title="IntHoutJ , IoannidisJP , RoversMM , GoemanJJ . Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open2016;12(6):e010247. [DOI: 10.1136/bmjopen-2015-010247] [PMID: 27406637]">IntHout 2016</a>). The PI helps in the clinical interpretation of heterogeneity by estimating what true treatment effects can be expected in future settings (<a href="./references#CD015395-bbs2-0105" title="IntHoutJ , IoannidisJP , RoversMM , GoemanJJ . Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open2016;12(6):e010247. [DOI: 10.1136/bmjopen-2015-010247] [PMID: 27406637]">IntHout 2016</a>). Calculation of a 95% PI is restricted to meta‐analyses with four or more studies (200 participants or more), since the interval is imprecise when a summary estimate is based on only a few small studies. The current review did not contain meta‐analyses with a sufficient number of studies to investigate heterogeneity. We plan to use the open‐source statistical software R package meta to calculate 95% PIs in review updates (<a href="./references#CD015395-bbs2-0116" title="Meta: General Package for Meta-Analysis. SchwarzerG , Version 5.2-0. The R Project, 2022. Available at cran.r-project.org/package=meta.">Meta 2022</a>). In future updates, we will declare statistical heterogeneity if the P value is less than 0.1 for the Chi<sup>2</sup> statistic, or the I<sup>2</sup> statistic is equal to or greater than 40% (40% to 60%: moderate heterogeneity; 50% to 90%: substantial heterogeneity; and 75% to 100%: considerable heterogeneity; <a href="./references#CD015395-bbs2-0087" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>), or the range of the 95% PI reveals a different clinical interpretation of the effect estimate compared to the 95% CI. </p> </section> <section id="CD015395-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to identify all research that met our predefined eligibility criteria. Missing studies can introduce bias to the analysis. We searched for completed non‐published trials in trial registers, and contacted authors to seek assurance that results will be made available. We classified these studies as 'awaiting classification' until the results were reported. We also planned to report the number of completed non‐published trials. The current review did not identify completed non‐published trials. </p> <p>If there were 10 or more relevant studies pooled in a meta‐analysis, we planned to investigate risk of reporting bias (publication bias) in pairwise meta‐analyses using contour‐enhanced funnel plots. If funnel plot asymmetry was suggested by a visual assessment, we planned to perform exploratory analyses (e.g. Rücker's arcsine test for dichotomous data and Egger's linear regression test for continuous data) to further investigate funnel plot asymmetry. A P value of less than 0.1 is considered as the level of statistical significance. We planned to analyze reporting bias using the open‐source statistical software R package meta (<a href="./references#CD015395-bbs2-0116" title="Meta: General Package for Meta-Analysis. SchwarzerG , Version 5.2-0. The R Project, 2022. Available at cran.r-project.org/package=meta.">Meta 2022</a>). The current review did not contain meta‐analyses with a sufficient number of studies to investigate reporting bias. </p> </section> <section id="CD015395-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We compared nirmatrelvir/ritonavir plus SoC with SoC with or without placebo, or to any active comparator with efficacy. Co‐interventions (SoC) must have been comparable between the study arms. </p> <p>We created the following comparisons.</p> <p> <ul id="CD015395-list-0018"> <li> <p>nirmatrelvir/ritonavir plus SoC versus SoC (with or without placebo); and</p> </li> <li> <p>nirmatrelvir/ritonavir versus active pharmacological intervention (separate comparisons for different active interventions; no studies available for the current review version). </p> </li> </ul> </p> <p>We planned to analyze trials with different objectives of nirmatrelvir/ritonavir use separately, as follows. </p> <p> <ul id="CD015395-list-0019"> <li> <p>Treatment of COVID‐19 in an outpatient setting: participants with confirmed SARS‐CoV‐2 infection. </p> </li> <li> <p>Treatment of COVID‐19 in an inpatient setting: participants with confirmed SARS‐CoV‐2 infection. </p> </li> <li> <p>Prevention of SARS‐CoV‐2 infection (PEP): RT‐PCR‐negative participants at baseline with a high risk of developing the infection following exposure to infected people or infectious viral particles (no studies available for the current review version). </p> </li> <li> <p>Prevention of SARS‐CoV‐2 infection (PrEP): RT‐PCR‐negative participants at baseline not yet exposed to infected people or infectious viral particles but at increased risk of contracting the disease (e.g. healthcare workers) (no studies available for the current review version). </p> </li> </ul> </p> <p>We performed meta‐analyses according to the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015395-bbs2-0087" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). We used forest plots to visualize meta‐analyses. </p> <p>If clinical and methodological characteristics of individual studies were sufficiently homogeneous, we planned to pool the data in meta‐analyses. When meta‐analyses were feasible, we planned to use the random‐effects model as we assume that the intervention effects were related but might not be the same in included studies. For dichotomous outcomes, we performed meta‐analyses using the Mantel‐Haenszel method using a random‐effects model to calculate the summary (combined) intervention effect estimate as a weighted mean of the intervention effects estimated in the individual studies. For continuous outcomes, we planned to use the inverse‐variance method. </p> <p>We planned to present descriptive statistics only if we deemed meta‐analysis inappropriate for a certain outcome because of heterogeneity, or because of serious study limitations leading to considerably high risk of bias (e.g. competing risk of death not taken into account in outcome measurement). </p> <p>We used RevMan Web for meta‐analysis and to calculate the effect estimate of the included studies (<a href="./references#CD015395-bbs2-0132" title="Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). </p> </section> <section id="CD015395-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We reported details of the intervention and population at baseline for the included studies in the footnotes of the forest plot. </p> <p>The current review version included one study for inpatients and one study for outpatients, therefore investigation of heterogeneity between studies was not applicable. For future updates, we plan to investigate heterogeneity by visual inspection of the forest plot. </p> <p>If statistical heterogeneity is present, we plan to investigate heterogeneity by subgroup analysis to calculate RR or MD in conjunction with the corresponding CIs for each subgroup, if sufficient studies are available. </p> <p>The following characteristics will be used for subgroup analyses to explore statistical heterogeneity, if reported. </p> <p> <ul id="CD015395-list-0020"> <li> <p>Nirmatrelvir/ritonavir used as treatment (in‐ and outpatients):</p> <ul id="CD015395-list-0021"> <li> <p>studies including participants with different severities of condition at baseline (symptomatic versus asymptomatic); </p> </li> <li> <p>studies including participants with a history of SARS‐CoV‐2 infection/vaccination versus participants with no history of infection/vaccination; </p> </li> <li> <p>studies with different recruitment periods examining different dominant virus variants circulating at the time of the study (e.g. Alpha versus Beta versus Gamma versus Delta versus Omicron, etc.); </p> </li> <li> <p>studies that started nirmatrelvir/ritonavir treatment early (five days or fewer) versus late (more than five days after symptom onset); </p> </li> <li> <p>studies investigating different doses of nirmatrelvir/ritonavir (low versus recommended versus high). If necessary in future review updates, we will consider and categorize dosing schemes into recommended (nirmatrelvir 300 mg/ritonavir 100 mg, twice‐daily for five days), low (less than recommended dose), and high doses (greater than recommended dose). We planned to analyze different doses in subgroup analysis, if sufficient studies are available. The one study considering treatment in the current review did not investigate different doses. </p> </li> </ul> </li> <li> <p>Nirmatrelvir/ritonavir used for prevention:</p> <ul id="CD015395-list-0022"> <li> <p>studies including participants with a history of SARS‐CoV‐2 infection/vaccination versus participants with no history of infection/vaccination; </p> </li> <li> <p>studies investigating different modes of exposure (e.g. working place, nursing home) and burden of exposure (e.g. living in a high‐risk area, high‐risk medical contact) in prevention studies; </p> </li> <li> <p>studies with different recruitment periods examining different dominant virus variants circulating at the time of the study (e.g. Alpha versus Beta versus Gamma versus Delta versus Omicron, etc.); </p> </li> <li> <p>studies investigating different doses of nirmatrelvir/ritonavir (low versus recommended versus high). </p> </li> </ul> </li> </ul> </p> <p>We investigated health equity considering elderly people, socially disadvantaged people with comorbidities, populations from LICs/LMICs, and people from different ethnic and racial backgrounds using subgroup analysis independent of statistical heterogeneity. We planned to perform the following subgroup analyses for treatment and prevention settings: </p> <p> <ul id="CD015395-list-0023"> <li> <p>studies including different populations regarding age of the population (children versus adults versus older adults (greater than 65 years)); </p> </li> <li> <p>studies including participants with different levels of comorbidity (high‐risk versus low‐risk population); </p> </li> <li> <p>studies including participants from HICs, middle‐income country, or LIC settings and populations according to the World Bank classification (<a href="./references#CD015395-bbs2-0157" title="World Bank. The world by income and region. datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html (accessed 15 February 2022).">World Bank 2022</a>) (LICs/LMICs versus UMICs/HICs); </p> </li> <li> <p>studies including different racial and ethnic groups (Asian, Black, White, Hispanic, and minority ethnic groups); </p> </li> </ul> </p> </section> <section id="CD015395-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to test the robustness of the meta‐analyses excluding: </p> <p> <ul id="CD015395-list-0024"> <li> <p>studies with overall high risk of bias;</p> </li> <li> <p>non‐peer reviewed studies (including preprint articles);</p> </li> <li> <p>studies reporting data as median instead of mean for continuous outcomes;</p> </li> <li> <p>studies using no treatment in the comparator arm for participant‐reported outcomes such as symptom resolution. </p> </li> </ul> </p> </section> <section id="CD015395-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in summary of findings tables, including a rating of the certainty of evidence based on the GRADE approach. We followed current GRADE guidance as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015395-bbs2-0134" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Schünemann 2022</a>). </p> <p>Two review authors (SR, SW) assessed the certainty of evidence, considering risk of bias, inconsistency, imprecision, indirectness, and publication bias. We used the overall RoB 2 assessment and RoB sensitivity analysis to inform the risk of bias judgement underlying the assessment of the certainty of evidence. </p> <p>We planned to create separate summary of findings tables for the use of nirmatrelvir/ritonavir with different intentions (e.g. treatment of people with COVID‐19 in out‐ and inpatient settings, prevention of SARS‐CoV‐2 infection as PEP, and prevention as PrEP), and for different comparisons with regard to the intervention and comparator. The summary of findings tables included the following outcomes. </p> <p><b>Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings.</b> </p> <p> <ul id="CD015395-list-0025"> <li> <p>All‐cause mortality; at longest follow‐up and greater than 60 days most favourable; if not reported all‐cause mortality day 60, followed by day 28, or time‐to‐event estimate, are reported in the summary of findings table. </p> </li> <li> <p>Admission to hospital or death within 28 days.</p> </li> <li> <p>Improvement of clinical status.</p> <ul id="CD015395-list-0026"> <li> <p>All initial symptoms resolved (asymptomatic) at day 14.</p> </li> <li> <p>Time to symptom resolution.</p> </li> </ul> </li> <li> <p>Quality of life at longest follow‐up available.</p> </li> <li> <p>SAEs during the study period.</p> </li> <li> <p>AEs during the study period.</p> <ul id="CD015395-list-0027"> <li> <p>Any grade TEAE.</p> </li> <li> <p>Any grade TRAE.</p> </li> </ul> </li> <li> <p>Viral clearance at seven days.</p> </li> </ul> </p> <p><b>Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings.</b> </p> <p> <ul id="CD015395-list-0028"> <li> <p>All‐cause mortality at longest follow‐up and greater than 60 days most favourable; if not reported all‐cause mortality day 60, followed by day 28, or time‐to‐event estimate, are reported in the summary of findings table. </p> </li> <li> <p>Worsening of clinical status within 28 days.</p> <ul id="CD015395-list-0029"> <li> <p>Participants with new need for invasive mechanical ventilation or death.</p> </li> </ul> </li> <li> <p>Improvement of clinical status within 28 days.</p> <ul id="CD015395-list-0030"> <li> <p>Participants discharged alive. Participants should be discharged without clinical deterioration or death. </p> </li> </ul> </li> <li> <p>Quality of life at longest follow‐up available.</p> </li> <li> <p>SAEs during the study period.</p> </li> <li> <p>AEs during the study period.</p> <ul id="CD015395-list-0031"> <li> <p>Any grade TEAE.</p> </li> <li> <p>Any grade TRAE.</p> </li> </ul> </li> <li> <p>Viral clearance at seven days.</p> </li> </ul> </p> <p><b>Nirmatrelvir/ritonavir for preventing SARS‐CoV‐2 infection (PEP).</b> </p> <p> <ul id="CD015395-list-0032"> <li> <p>SARS‐CoV‐2 infection at 14 days.</p> </li> <li> <p>Development of clinical COVID‐19 symptoms up to 28 days.</p> </li> <li> <p>All‐cause mortality up to the longest follow‐up.</p> </li> <li> <p>Admission to hospital or death within 28 days.</p> </li> <li> <p>Quality of life at longest follow‐up available.</p> </li> <li> <p>SAEs during the study period.</p> </li> <li> <p>AEs during the study period.</p> <ul id="CD015395-list-0033"> <li> <p>Any grade TEAE.</p> </li> <li> <p>Any grade TRAE.</p> </li> </ul> </li> </ul> </p> <p><b>Nirmatrelvir/ritonavir for preventing SARS‐CoV‐2 infection (PrEP).</b> </p> <p> <ul id="CD015395-list-0034"> <li> <p>SARS‐CoV‐2 infection at six months.</p> </li> <li> <p>Development of clinical COVID‐19 symptoms up to six months.</p> </li> <li> <p>All‐cause mortality up to the longest follow‐up.</p> </li> <li> <p>Admission to hospital or death within six months.</p> </li> <li> <p>Quality of life at longest follow‐up available.</p> </li> <li> <p>SAEs during the study period.</p> </li> <li> <p>AEs during the study period.</p> <ul id="CD015395-list-0035"> <li> <p>Any grade TEAE.</p> </li> <li> <p>Any grade TRAE.</p> </li> </ul> </li> </ul> </p> <p>The GRADE assessment result in one of four levels of certainty and these express our confidence in the estimate of effect (<a href="./references#CD015395-bbs2-0076" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines – 3: rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6. [PMID: 21208779]">Balshem 2011</a>). </p> <p> <ul id="CD015395-list-0036"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We addressed equity for all outcomes presented in summary of findings tables. Interpretation of evidence occurred for the specific populations which are defined as important recipients of the intervention (see <a href="#CD015395-sec-0036">Data extraction and management</a>). </p> <p> <ul id="CD015395-list-0037"> <li> <p>Elderly people.</p> </li> <li> <p>People at social disadvantage due to the number of comorbid health conditions.</p> </li> <li> <p>People from LICs/LMICs.</p> </li> <li> <p>People from different ethnic and racial backgrounds, including minorities.</p> </li> </ul> </p> <p>Interpretation considers the questions, whether findings are likely to be applicable in those populations, even if they did not make up a large proportion of the participant populations in included studies. We reported inequities in the footnotes of the summary of findings tables. </p> <p>We used the MAGICapp to create summary of findings tables (<a href="https://app.magicapp.org/" target="_blank">MAGICapp</a>), and incorporate the results into RevMan Web manually (<a href="./references#CD015395-bbs2-0132" title="Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). </p> <section id="CD015395-sec-0047"> <h5 class="title">Methods for future updates – living systematic review considerations</h5> <p>Our Information Specialist (MIM) provides us with new search records each month, which two review authors screen, extract, evaluate, and integrate following the guidance for Cochrane LSRs. We maintain an Excel spreadsheet every second month, which lists the search results and new studies potentially to be included in this review. It is publicly available on the open science framework (OSF) platform (<a href="https://osf.io/7g49c/" target="_blank">osf.io/7g49c/</a>; <a href="./references#CD015395-bbs2-0130" title='ReisS , MetzendorfM , KuehnR , PoppM , GagyorI , KrankeP , et al. Living evidence base for Cochrane Review "Nirmatrelvir combined with ritonavir for preventing and treating COVID-19". osf.io/7g49c/ (created 30 May 2022). [DOI: 10.17605/OSF.IO/7G49C]'>Reis 2022a</a>). Details on this 'living method' are available in <a href="./references#CD015395-bbs2-0117" title="MetzendorfMI , WeibelS , ReisS , McDonaldS . Pragmatic and open science-based solution to a current problem in the reporting of living systematic reviews. BMJ Evidence-Based Medicine2023;28(4):267-72. [DOI: 10.1136/bmjebm-2022-112019] [PMID: 36351782]">Metzendorf 2022</a>. </p> <p>We manually check platform trials for new treatment arms investigating nirmatrelvir/ritonavir.</p> <p>We wait until the accumulating evidence changes our conclusions of the implications of research and practice before republishing the review. We consider one or more of the following components to inform this decision. </p> <p> <ul id="CD015395-list-0038"> <li> <p>The findings of one or more prioritized outcomes.</p> </li> <li> <p>The credibility (e.g. GRADE rating) of one or more prioritized outcomes.</p> </li> <li> <p>New settings, populations, interventions, comparisons (not TCM), or outcomes studied.</p> </li> </ul> </p> <p>In the case of emerging policy relevance due to global controversies regarding the intervention, we consider republishing an updated review even though our conclusions remain unchanged. We review the review scope and methods approximately monthly, or more frequently if appropriate, in light of potential changes in COVID‐19 research (e.g. when additional comparisons, interventions, subgroups, outcomes, or new review methods become available). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015395-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015395-sec-0048"></div> <section id="CD015395-sec-0049"> <h3 class="title">Description of studies</h3> <section id="CD015395-sec-0050"> <h4 class="title">Results of the search</h4> <p>The literature search up to 15 May 2023 resulted in 739 records identified in 12 search updates. After deduplication in Endnote (<a href="./references#CD015395-bbs2-0089" title="EndNote. Version EndNote 20. Philadelphia, PA: Clarivate, 2013.">EndNote 2013</a>), 593 records remained. During title and abstract screening, we judged 497 records as irrelevant as they did not meet the prespecified inclusion criteria. We proceeded to full‐text screening with 96 records. We considered published full‐texts in journals or on preprint servers or, if these were unavailable, trials' register entries. A total of 31 records met our eligibility criteria regarding patient population, intervention, and comparator of which 14 records belonged to 13 ongoing studies and three studies with eight records are currently awaiting classification. We excluded 61 records (53 studies) with reasons after full‐text assessment. Two studies with results were excluded due to concerns regarding research integrity. </p> <p>We included nine records (two studies) with results in this review.</p> <p>Finally, we included one study for outpatients and one study for inpatients in our qualitative synthesis. One study was in the original review (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>), and one study from this update (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). Due to the limited number of available studies, meta‐analysis was not possible. The search process is shown in <a href="#CD015395-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD015395-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram." data-id="CD015395-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> </div> <p>This is a LSR and we conduct update searches every two months which are being made publicly available on the OSF platform (<a href="https://osf.io/7g49c/" target="_blank">osf.io/7g49c/</a>; <a href="./references#CD015395-bbs2-0130" title='ReisS , MetzendorfM , KuehnR , PoppM , GagyorI , KrankeP , et al. Living evidence base for Cochrane Review "Nirmatrelvir combined with ritonavir for preventing and treating COVID-19". osf.io/7g49c/ (created 30 May 2022). [DOI: 10.17605/OSF.IO/7G49C]'>Reis 2022a</a>). </p> </section> <section id="CD015395-sec-0051"> <h4 class="title">Eligibility screening for research integrity</h4> <p>We evaluated four studies for issues with research integrity.</p> <p> <ul id="CD015395-list-0039"> <li> <p>Two studies with results identified by the search in April 2022 (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>) and March 2023 (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>) passed research integrity assessment. There were no retraction notice or concerns expressed elsewhere, and the trials were prospectively registered with adequate ethics approval. The method of randomization was sufficiently reported, and study results were plausible. </p> </li> <li> <p>We excluded two trials with results identified by the search in December 2022 (<a href="./references#CD015395-bbs2-0006" title="BalykovaLA , SeleznevaNM , GorsheninaEI , ShepelevaOI , KirichenkoNV , SimakinaEN , et al. Modern directed antiviral COVID-19 therapy: results of multicenter clinical effectiveness and safety study of fixed nirmatrelvir+ritonavir combination. Pharmacy &amp; Pharmacology2022;10(4):371-86. [DOI: 10.19163/2307-9266-2022-10-4-371-386]NCT05601167. Open multicentre study of the safety and efficacy against COVID-19 of nirmatrelvir/ritonavir in the adult population. clinicaltrials.gov/ct2/show/NCT05601167 (first received 1 November 2022). ">Balykova 2022</a>) and March 2023 (<a href="./references#CD015395-bbs2-0010" title="CaoZ , GaoH , BaoH , FengH , MeiS , ChenP , et al. VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19. New England Journal of Medicine2023;388:406-17. [DOI: 10.1056/NEJMoa2208822]ChiCTR2200057856. A multicenter, single-blind, randomized, controlled clinical study evaluating the efficacy and safety of JT001 (VV116) compared to Paxlovid for the early treatment of coronavirus disease 2019 (COVID-19 in participants with mild to moderate COVID-19). chictr.org.cn/showprojen.aspx?proj=167904 (first received 19 March 2022). NCT05341609. Efficacy and safety of JT001 (VV116) compared with Paxlovid. clinicaltrials.gov/ct2/show/NCT05341609 (first received 22 April 2022). ">Cao 2023</a>). <a href="./references#CD015395-bbs2-0006" title="BalykovaLA , SeleznevaNM , GorsheninaEI , ShepelevaOI , KirichenkoNV , SimakinaEN , et al. Modern directed antiviral COVID-19 therapy: results of multicenter clinical effectiveness and safety study of fixed nirmatrelvir+ritonavir combination. Pharmacy &amp; Pharmacology2022;10(4):371-86. [DOI: 10.19163/2307-9266-2022-10-4-371-386]NCT05601167. Open multicentre study of the safety and efficacy against COVID-19 of nirmatrelvir/ritonavir in the adult population. clinicaltrials.gov/ct2/show/NCT05601167 (first received 1 November 2022). ">Balykova 2022</a> was a retrospective trial registration and there was no response from study authors regarding ethics approval. We excluded <a href="./references#CD015395-bbs2-0010" title="CaoZ , GaoH , BaoH , FengH , MeiS , ChenP , et al. VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19. New England Journal of Medicine2023;388:406-17. [DOI: 10.1056/NEJMoa2208822]ChiCTR2200057856. A multicenter, single-blind, randomized, controlled clinical study evaluating the efficacy and safety of JT001 (VV116) compared to Paxlovid for the early treatment of coronavirus disease 2019 (COVID-19 in participants with mild to moderate COVID-19). chictr.org.cn/showprojen.aspx?proj=167904 (first received 19 March 2022). NCT05341609. Efficacy and safety of JT001 (VV116) compared with Paxlovid. clinicaltrials.gov/ct2/show/NCT05341609 (first received 22 April 2022). ">Cao 2023</a> as recruitment of participants (4 April 2022) started before ethics approval was obtained (23 April 2022). </p> </li> </ul> </p> <p>The research integrity assessment is described in <a href="./appendices#CD015395-sec-0132">Appendix 2</a> and decisions regarding this review's study pool are transparently reported and publicly available (<a href="./references#CD015395-bbs2-0137" title="WeibelS , ReisS . Supplementary File_Nirmatrelvir_Research Integrity Assessment (Version 2). Zenodo2023. [DOI: 10.5281/zenodo.10117597]">Supplementary File_Nirmatrelvir_Research Integrity</a>). </p> </section> <section id="CD015395-sec-0052"> <h4 class="title">Included studies</h4> <p>Details of both included studies are reported in the <a href="./references#CD015395-sec-0143" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD015395-sec-0053"> <h4 class="title">Design and publication status</h4> <p>We included two multicentre RCTs with 2510 randomized adults comparing nirmatrelvir/ritonavir with control (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). Both trials were available as peer‐reviewed journal articles and comprised two trial arms. One trial had an open‐label design using SoC as comparator (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>), the other trial was double‐blinded and placebo‐controlled (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). One trial was conducted in China (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>), and the other at 343 sites worldwide (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> was funded by Pfizer, while <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> was funded by departmental resources and a Chinese government grant. </p> </section> <section id="CD015395-sec-0054"> <h4 class="title">Setting</h4> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> investigated outpatients in 343 sites worldwide. Of those, 27 sites (7.9%) were placed in LICs and LMICs. The other 319 sites (92.1%) were set in UMICs or HICs. There was no information regarding the actual number of included participants per site/country. Participants were recruited during the Delta wave between July and December 2021. <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> investigated inpatients at five sites in the UMIC in China. Participants were recruited during the Omicron wave between April and May 2022. </p> </section> <section id="CD015395-sec-0055"> <h4 class="title">Participants</h4> <p>The included studies investigated nirmatrelvir/ritonavir for treatment of non‐hospitalized people with COVID‐19 (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>) and hospitalized people with COVID‐19 (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). No study investigating nirmatrelvir/ritonavir for treating hospitalized people with COVID‐19 and preventing SARS‐CoV‐2 infection has been included in this review. </p> <section id="CD015395-sec-0056"> <h5 class="title">Outpatient setting</h5> <p>One trial compared nirmatrelvir/ritonavir to placebo in an outpatient setting (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). </p> <p>For the outpatient setting, we classified participants as 2 to 3 on the WHO clinical progression scale (<a href="./references#CD015395-bbs2-0115" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: 32539990]">Marshall 2020</a>). All participants had a confirmed SARS‐CoV‐2 infection with symptom onset of five days or less before randomization. Randomization coincided with the Delta wave. Mean time between symptom onset and start of treatment was 2.96 days with 66.3% of participants starting treatment within three days. As per the study exclusion criteria, all participants were unvaccinated against SARS‐CoV‐2. Further exclusion criteria were previous confirmed SARS‐CoV‐2 infection, hospitalization for COVID‐19, or therapy with convalescent COVID‐19 plasma. </p> <p>Median age was 46 years (IQR 18 to 88) and 51.1% of participants were men. The trial excluded pregnant or breastfeeding women. Age was reported for the modified intention‐to‐treat (mITT1) population (2085 participants) according to groups aged 65 years or greater and less than 65 years, with 87.1% of participants younger than 65 years. Regarding race and ethnicity, most participants identified as White (71.5%), 14% as Asian, and 4.9% as Black. </p> <p>Participants were eligible for inclusion into the trial if they were at high risk for progression to severe disease due to at least one coexisting condition or had other characteristics associated with an increased risk of developing severe illness from COVID‐19 (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). In the full analysis set (FAS), 61.0% of participants had two or more coexisting conditions or characteristics associated with an increased risk of developing severe COVID‐19 (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). The most common prespecified characteristics and comorbidities associated with an increased risk of developing severe disease were a body mass index (BMI) over 25 kg/m<sup>2</sup> in 1807 participants (80.5%), current smoking in 876 participants (39.0%), and hypertension in 739 participants (32.9%). Frequency of comorbidities were separately reported for the mITT1 population only (subgroup analyses); 79.7% had none or one comorbidity and 20.3% of the 2085 participants in the mITT1 population had two or more comorbidities, most commonly a BMI over 25 kg/m<sup>2</sup> (80.0%), hypertension (33.0%), and diabetes (12.1%). The study did not report the number of participants without any comorbidity. Few participants had other baseline comorbidities (e.g. chronic lung disease, cardiovascular disorder, chronic kidney disease, HIV infection, sickle cell disease, neurodevelopmental disorder, and cancer). </p> </section> <section id="CD015395-sec-0057"> <h5 class="title">Inpatient setting</h5> <p>One trial compared nirmatrelvir/ritonavir to placebo in an inpatient setting (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). </p> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> classified participants according to the Guidelines on the Diagnosis and Treatment of COVID‐19 (Ninth Trial Edition) which approximately translates to 2 to 4 on the WHO clinical progression scale (<a href="./references#CD015395-bbs2-0115" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: 32539990]">Marshall 2020</a>; <a href="./references#CD015395-bbs2-0159" title="XuY , ChenY , TangX . Guidelines on the diagnosis and treatment of COVID-19 ninth trial edition. www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf (accessed 15 March 2022).">Xu 2022</a>). All participants had confirmed SARS‐CoV‐2 infection with symptom onset of five days or less before randomization or a Ct value less than 25 by RT‐PCR. Randomization occurred during the Omicron wave in China. Median time between symptom onset and hospital admission was three days, with a range of two to six days in the intervention group, and one to five days in the control group. About 73.48% of participants were unvaccinated, 25% of participants had received two or more doses of vaccination against SARS‐CoV‐2, the rest had received one dose (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). Further exclusion criteria were previously confirmed SARS‐CoV‐2 infection, active liver disease, dialysis, HIV infection, and the expected use of amabacizumab/romlusevimab, intravenous COVID‐19 human immunoglobulin, and convalescent plasma and tocilizumab during the treatment period. </p> <p>Participants were older than those in <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>, with a mean age of 70.4 (SD 13.12) years. About 53.8% of participants were men. Pregnant or breastfeeding women were excluded from the trial. Age was reported according to groups: greater than 65 years and 65 years or less with 31.8% of participants aged 65 years or less. The study did not report race or ethnicity. <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> investigated participants at risk of severe COVID‐19. Participants were eligible for inclusion if they were hospitalized with mild to moderate COVID‐19 and either severe comorbidities, or a Sequential Organ Failure Assessment (SOFA)/Charlson score of 2 or greater. About 61.7% of participants had two or more coexisting conditions. The most common prespecified comorbidity being cardiovascular disease in 141 participants (53.4%). The number of participants with multiple comorbidities was higher in <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> with 61.7% of participants having two or more comorbidities as compared to 20.3% of the <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> mITT. Median Charlson score was 3 with a range of 2 to 4 across both study arms and median SOFA score was 1 with a range of 0 to 2 across both study arms (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). </p> </section> </section> <section id="CD015395-sec-0058"> <h4 class="title">Interventions and comparators</h4> <p>Both included studies administered nirmatrelvir/ritonavir orally at 300 mg/100 mg twice daily for five days and compared with either placebo plus SoC (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>), or SoC alone (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). SoC in the <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> trial varied throughout study centres. The studies prohibited any medications or substances known to be strong inducers of CYP3A4 within 28 days prior to dosing of study intervention. Medications highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations may be associated with serious or life‐threatening (or both) events were not permitted during the study period. Treatment with COVID‐19 monoclonal antibodies as part of SoC was allowed in US study centres only. SoC in <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> included antiviral and anticoagulant therapy, prone position ventilation, awake prone positioning, corticosteroid therapy, and nutrient support. While <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> allowed the concomitant use of monoclonal antibodies, <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> excluded people with expected use of amabacizumab/romlusevimab, intravenous COVID‐19 human immunoglobulin, and convalescent plasma and tocilizumab during the treatment period. </p> <p>No studies investigated other comparators.</p> </section> <section id="CD015395-sec-0059"> <h4 class="title">Outcome measures</h4> <p>The included studies contributed outcomes to different prespecified outcome sets, one for outpatients (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>) and one for inpatients (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). </p> <p>Primary outcomes of the included studies were 'COVID‐19‐related hospitalization or death from any cause through day 28', which we used for the analysis of (any) 'admission to hospital or death within 28 days' (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>) and '28‐days all‐cause mortality' (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). Subgroup analyses according to age for both these outcomes were available but with slightly different cut‐offs: less than 65 years versus 65 years or over (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>) and 65 years or less versus greater than 65 years of age (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> further included subgroup analyses for White, Asian, Black/African American and a mixed ethnic group termed "other" (mITT1 population; see <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>), while <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> reported subgroup analyses for the primary outcome in relation to vaccination status, COVID‐19 severity, and the number of comorbidities. </p> <p>For the outpatient setting, further outcomes eligible for this review included all‐cause mortality at 28 days, any grade TRAEs, any grade TEAEs, SAEs, and discontinuation of study drug (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). All safety outcomes were assessed within 34 days (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). </p> <p>For the inpatient setting, further outcomes eligible for this review included viral clearance at seven and 14 days. Regarding the safety of nirmatrelvir/ritonavir, the study reported on any grade TRAEs, TEAEs, SAEs, and discontinuation of study drug (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). However, due to insufficient and inconsistent information on the time of the outcome assessment, the handling of missing outcome data, and the outcome assessment itself, we have excluded all safety outcomes from the quantitative analysis in this review. Upon enquiry, the study authors provided no further information regarding the outcomes. </p> <p>The studies reported no subgroups for any outcome other than the primary outcome of the studies (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). The included studies did not report on worsening or improvement of clinical status, symptom resolution, time to symptom resolution, or quality of life at any of our prespecified time points. </p> </section> <section id="CD015395-sec-0060"> <h4 class="title">Equity‐related aspects</h4> <p>There were no study data for the following equity‐related element of World Bank country classification by income level and level of comorbidity. For inpatients, there were no data for the equity‐related element race/ethnicity (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). Both studies reported data regarding age (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> further reported on race/ethnicity. </p> </section> <section id="CD015395-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Details of excluded studies are reported in the <a href="./references#CD015395-sec-0144" title="">Characteristics of excluded studies</a> table. </p> <p>We excluded 53 studies that did not match our inclusion criteria. Two studies analysed an ineligible study population of healthy participants without exposure to SARS‐CoV‐2 (<a href="./references#CD015395-bbs2-0035" title="NCT05690646. Prophylactic effect of nirmatrelvir/ritonavir and ursodeoxycholic acid on reducing complications after cardiac surgery. classic.clinicaltrials.gov/ct2/show/NCT05690646 (first received 19 January 2023). ">NCT05690646</a>; <a href="./references#CD015395-bbs2-0046" title="SinghR , ToussiSS , HackmanF , ChanPL , RaoR , AllenR , et al. Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. medRxiv2022;2022.02.08:22270649. [DOI: 10.1101/2022.02.08.22270649]SinghRS , ToussiSS , HackmanF , ChanPL , RaoR , AllenR , et al. Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clinical Pharmacology &amp; Therapeutics2022;112(1):101-11. [DOI: 10.1002/cpt.2603]">Singh 2022</a>), seven studies focused on an intervention other than nirmatrelvir/ritonavir (<a href="./references#CD015395-bbs2-0004" title="2020-001860-27. AGILE: seamless Phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment. clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB (first received 17 April 2020). GriffithsG , FitzgeraldR , JakiT , CorkhillA , MarwoodE , ReynoldsH , et al. AGILE-ACCORD: a randomized, multicentre, seamless, adaptive Phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial. Trials2020;21(1):544. [DOI: 10.1186/s13063-020-04473-1]GriffithsGO , FitzGeraldR , JakiT , CorkhillA , ReynoldsH , EwingsS , et al. AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. Trials2022;22:487. [DOI: 10.1186/s13063-021-05458-4]NCT04746183. AGILE (Early Phase Platform Trial for COVID-19). beta.clinicaltrials.gov/study/NCT04746183?distance=50&amp;term=NCT04746183&amp;rank=1 (first received 8 February 2021). ">AGILE 2020</a>; <a href="./references#CD015395-bbs2-0024" title="JittamalaP , SchillingWH , WatsonJA , LuviraV , SiripoonT , NgamprasertchaiT , et al. Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants. medRxiv2022;10(17):22281161. [DOI: 10.1101/2022.10.17.22281161]">Jittamala 2022</a>; <a href="./references#CD015395-bbs2-0027" title="CTRI/2022/01/039426. A study in non-hospitalized COVID-19 patients to assess safety and effectiveness of study drug. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=64299 (first received 14 January 2022). NCT04518410. ACTIV-2: a study for outpatients with COVID-19. clinicaltrials.gov/ct2/show/NCT04518410 (first received 19 August 2020). ">NCT04518410</a>; <a href="./references#CD015395-bbs2-0029" title="NCT04864548. COV-CHIM01: SARS-CoV-2 (COVID-19) dose finding infection study. clinicaltrials.gov/ct2/show/NCT04864548 (first received 29 April 2021). ">NCT04864548</a>; <a href="./references#CD015395-bbs2-0030" title="NCT05305547. A study to compare S-217622 with placebo in non-hospitalized high-risk participants with COVID-19. clinicaltrials.gov/ct2/show/NCT05305547 (first received 31 March 2022). ">NCT05305547</a>; <a href="./references#CD015395-bbs2-0038" title="PER-084-20. Adaptive platform treatment trial for outpatients with COVID-19 (ADAPT OUT COVID). ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevo.asp?numEC=084-20&amp;val=&amp;NroPag=1&amp;flg=0 (first received 27 November 2020). ">PER‐084‐20</a>; <a href="./references#CD015395-bbs2-0040" title="RaziaD , SinduD , GriefK , CherrierL , OmarA , WaliaR , et al. Molnupiravir vs remdesivir for treatment of Covid-19 in lung transplant recipients. Journal of Heart &amp; Lung Transplantation2023;42(4):165-6. [DOI: 10.1016/j.healun.2023.02.1653]">Razia 2023</a>), one study investigated an ineligible comparator of nirmatrelvir/ritonavir plus remdesivir versus nirmatrelvir/ritonavir alone and of five days versus 10 days of nirmatrelvir plus ritonavir in immunocompromised participants (<a href="./references#CD015395-bbs2-0033" title="NCT05587894. Optimisation of antiviral therapy in immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial. clinicaltrials.gov/ct2/show/NCT05587894 (first received 20 October 2022). ">NCT05587894</a>), two studies focused on participants with long‐COVID or after COVID (<a href="./references#CD015395-bbs2-0032" title="NCT05576662. Paxlovid for treatment of long Covid. clinicaltrials.gov/ct2/show/NCT05576662 (first received 12 October 2022). ">NCT05576662</a>; <a href="./references#CD015395-bbs2-0034" title="NCT05668091. A decentralized Phase 2 efficacy and safety study of nirmatrelvir/ritonavir in adult participants with long COVID. clinicaltrials.gov/ct2/show/NCT05668091 (first received 29 December 2022). ">NCT05668091</a>), 23 studies had an ineligible study design (<a href="./references#CD015395-bbs2-0003" title="AggarwalNR , MolinaK , BeatyL , BennettTD , CarlsonN , GindeAA . Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during the emergence of Omicron variants BA.2/BA2.12.1. Medrxiv2022;9(12):22279866. [DOI: 10.1101/2022.09.12.22279866]">Aggarwal 2022</a>; <a href="./references#CD015395-bbs2-0011" title="ChiCTR2200059743. Study on the changed characteristics of glycolipid and immune metabolism in patients with coronavirus disease 2019 (COVID-19) treated by Paxlovid. chictr.org.cn/showprojEN.html?proj=169998 (first received 10 May 2022). ">ChiCTR2200059743</a>; <a href="./references#CD015395-bbs2-0012" title="ChiCTR2200060700. The therapeutic effect of paxlovid combined with conventional therapy in patients aged 60 and over with COVID-19. chictr.org.cn/showprojEN.html?proj=172057 (first received 8 June 2022). ">ChiCTR2200060700</a>; <a href="./references#CD015395-bbs2-0013" title="ChiCTR2200063778. Efficacy evaluation of nirmatrelvir/ritonavir tablets on SARSC-CoV-2 infection-induced myocardial injury. chictr.org.cn/showprojEN.html?proj=172892 (first received 16 September 2022). ">ChiCTR2200063778</a>; <a href="./references#CD015395-bbs2-0018" title="2022-000075-39. A phase 2/3 safety, pharmacokinetics, and efficacy study of nirmatrelvir/ritonavir in pediatric, nonhospitalized symptomatic participants with COVID-19 who are at risk of progression to severe disease. clinicaltrialsregister.eu/ctr-search/trial/2022-000075-39/HU (first received 5 April 2022). ">EPIC‐PEDS 2022</a>; <a href="./references#CD015395-bbs2-0020" title="ISRCTN12428408. Paxlovid in the treatment of COVID-19. isrctn.com/ISRCTN12428408 (first received 9 March 2023). [DOI: 10.1186/ISRCTN12428408]">ISRCTN12428408</a>; <a href="./references#CD015395-bbs2-0021" title="ITMCTR2200005942. A real world study comparing the efficacy and safety of Huashi Baidu granule and paxlovid in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. International Traditional Medicine Clinical Trial Registry (ccebtcm.org.cn) (first received 28 April 2022). ">ITMCTR2200005942</a>; <a href="./references#CD015395-bbs2-0022" title="ITMCTR2200005943. A real world study comparing the efficacy and safety of Jingyin granule and Paxlovid in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. International Traditional Medicine Clinical Trial Registry (ccebtcm.org.cn) (first received 28 April 2022). ">ITMCTR2200005943</a>; <a href="./references#CD015395-bbs2-0023" title="ITMCTR2200005944. A real world study comparing the efficacy and safety of Jingyin Qinghua granule and Paxlovid in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. itmctr.ccebtcm.org.cn/en-us/Home/ProjectView?pid=b54ce2cc-c2a5-4b61-8d6f-e464134d3a44 (first received 28 April 2022). ">ITMCTR2200005944</a>; <a href="./references#CD015395-bbs2-0025" title="KimH , YangJS , KoJH , LeeM , LeeJY , ParkS , et al. Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?Frontiers in Medicine2022;9:988559. [DOI: 10.3389/fmed.2022.988559]">Kim 2022</a>; <a href="./references#CD015395-bbs2-0026" title="LiH , GaoM , YouH , ZhangP , PanY , LiN , et al. Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19. Clinical Infectious Diseases2022;76(3):e148-54. [DOI: 10.1093/cid/ciac600]">Li 2022</a>; <a href="./references#CD015395-bbs2-0028" title="NCT04756531. Study of PF-07321332 in healthy participants. clinicaltrials.gov/ct2/show/NCT04756531 (first received 16 February 2021). ">NCT04756531</a>; <a href="./references#CD015395-bbs2-0031" title="NCT05487040. A study to measure the amount of study medicine in blood in adult participants with COVID-19 and severe kidney disease. clinicaltrials.gov/ct2/show/NCT05487040 (first received 4 August 2021). ">NCT05487040</a>; <a href="./references#CD015395-bbs2-0036" title="NCT05813600. Efficacy and safety of nirmatrelvir/ritonavir for treating Omicron variant of COVID-19. clinicaltrials.gov/ct2/show/NCT05813600 (first received 14 April 2023). ">NCT05813600</a>; <a href="./references#CD015395-bbs2-0037" title="ParkH , ParkYJ , LeeHY , YuM , SongYJ , LeeSE , et al. The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2. Osong Public Health and Research Perspectives2022;13(6):443-7. [DOI: 10.24171/j.phrp.2022.0262]">Park 2022</a>; <a href="./references#CD015395-bbs2-0044" title="RossSB , Bortolussi-Courval É, HanulaR , LeeTC , Goodwin WilsonM , McDonaldEG . Drug interactions with nirmatrelvir-ritonavir in older adults using multiple medications. JAMA Network Open2022;5(7):E2220184. [DOI: 10.1001/jamanetworkopen.2022.20184]">Ross 2022</a>; <a href="./references#CD015395-bbs2-0045" title="ShaoJ , FanR , HuJ , ZhangT , LeeC , HuangX , et al. Clinical progression and outcome of hospitalized patients infected with SARS-CoV-2 Omicron variant in Shanghai, China. Vaccines2022;10(9):1409. [DOI: 10.3390/vaccines10091409]">Shao 2022</a>; <a href="./references#CD015395-bbs2-0047" title="SpiliopoulouV , Ntanasis-StathopoulosI , MalandrakisP , GavriatopoulouM , TheodorakakouF , FotiouD , et al. Use of oral antivirals ritonavir-nirmatrelvir and molnupiravir in patients with multiple myeloma is associated with low rates of severe COVID-19: a single-center, prospective study. Viruses2023;15(3):704. [DOI: 10.3390/v15030704]">Spiliopoulou 2023</a>; <a href="./references#CD015395-bbs2-0050" title="WanEY , YanVK , MokAH , WangB , XuW , ChengFW , et al. Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19 a target trial emulation study. Annals of Internal Medicine2023;176(4):505-14. [DOI: 10.7326/M22-3057]">Wan 2023</a>; <a href="./references#CD015395-bbs2-0052" title="WengC , XieR , HanG , YuanY , LiS , WangC , et al. Safety and efficacy of Paxlovid against Omicron variants of coronavirus disease 2019 in elderly patients. Infectious Diseases and Therapy2023;12(2):649-62. [DOI: 10.1007/s40121-023-00760-x]">Weng 2023</a>; <a href="./references#CD015395-bbs2-0053" title="XieY , BoweB , Al-AlyZ . Nirmatrelvir and risk of hospital admission or death in adults with COVID-19: emulation of a randomized target trial using electronic health records. BMJ2023;381:e073312. [DOI: 10.1136/bmj-2022-073312]">Xie 2023</a>; <a href="./references#CD015395-bbs2-0054" title="YanG , ZhouJ , ZhuH , ChenY , LuY , ZhangT , et al. The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study. Annals of Translational Medicine2022;10(11):619. [DOI: 10.21037/atm-22-2791]">Yan 2022</a>; <a href="./references#CD015395-bbs2-0055" title="YanJ , CaiH , WangJ , ZhuM , LiP , LiP , et al. Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge. Frontiers in Pharmacology2023;14:1147980. [DOI: 10.3389/fphar.2023.1147980]">Yan 2023</a>), two studies failed the research integrity assessment (<a href="./references#CD015395-bbs2-0006" title="BalykovaLA , SeleznevaNM , GorsheninaEI , ShepelevaOI , KirichenkoNV , SimakinaEN , et al. Modern directed antiviral COVID-19 therapy: results of multicenter clinical effectiveness and safety study of fixed nirmatrelvir+ritonavir combination. Pharmacy &amp; Pharmacology2022;10(4):371-86. [DOI: 10.19163/2307-9266-2022-10-4-371-386]NCT05601167. Open multicentre study of the safety and efficacy against COVID-19 of nirmatrelvir/ritonavir in the adult population. clinicaltrials.gov/ct2/show/NCT05601167 (first received 1 November 2022). ">Balykova 2022</a>; <a href="./references#CD015395-bbs2-0010" title="CaoZ , GaoH , BaoH , FengH , MeiS , ChenP , et al. VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19. New England Journal of Medicine2023;388:406-17. [DOI: 10.1056/NEJMoa2208822]ChiCTR2200057856. A multicenter, single-blind, randomized, controlled clinical study evaluating the efficacy and safety of JT001 (VV116) compared to Paxlovid for the early treatment of coronavirus disease 2019 (COVID-19 in participants with mild to moderate COVID-19). chictr.org.cn/showprojen.aspx?proj=167904 (first received 19 March 2022). NCT05341609. Efficacy and safety of JT001 (VV116) compared with Paxlovid. clinicaltrials.gov/ct2/show/NCT05341609 (first received 22 April 2022). ">Cao 2023</a>), and 16 studies were classified as a commentary, letter, etc. (<a href="./references#CD015395-bbs2-0005" title="Nirmatrelvir and ritonavir. Australian Prescriber2022;45(2):61. [DOI: 10.18773/austprescr.2022.015]">Australian Prescriber 2022</a>; <a href="./references#CD015395-bbs2-0007" title="BeinfeldM , YeungK , WhittingtonMD , MohammedR , NhanE , PearsonSD . Oral treatments for outpatient COVID-19: effectiveness and value. Journal of Managed Care and Specialty Pharmacy2022;28(8):903-9. [DOI: 10.18553/jmcp.2022.28.8.903]">Beinfeld 2022</a>; <a href="./references#CD015395-bbs2-0008" title="BiehleL , VandiverJW . Oral antivirals for high-risk COVID-19 patients. US Pharmacist2022;47(7):34-40. ">Biehle 2022</a>; <a href="./references#CD015395-bbs2-0009" title="CaceresJ , MakiDG , HennekensCH . Cautious optimism and considerations for health providers and patients: oral antiviral for early treatment of high-risk patients and vaccines for prevention of COVID-19. American Journal of Medicine2022;135(7):808-9. [DOI: 10.1016/j.amjmed.2022.02.041]">Caceres 2022</a>; <a href="./references#CD015395-bbs2-0014" title="DoynoCR . Paxlovid: oral antiviral for the treatment of COVID-19. Drug Topics2022;166(2):27. ">Doyno 2022</a>; <a href="./references#CD015395-bbs2-0015" title="EbellMH . Nirmatrelvir/ritonavir reduces risk of hospitalization in at-risk outpatients. American Family Physician2022;105(5):552A-C. ">Ebell 2022</a>; <a href="./references#CD015395-bbs2-0016" title="ElliottW , ChanJ . Nirmatrelvir and ritonavir tablets (Paxlovid). Internal Medicine Alert2022;44(1):Issue date: 15 January 2022. ">Elliott 2022</a>; <a href="./references#CD015395-bbs2-0017" title="EnikeevaDA , BondarchukNG . Pharmacological agents with antiviral activity against coronavirus SARS-CoV-2. Eksperimental'naya i Klinicheskaya Farmakologiya2022;85(7):13-22. [DOI: 10.30906/0869-2092-2022-85-7-13-22]">Enikeeva 2022</a>; <a href="./references#CD015395-bbs2-0019" title="GottliebRL , RazonableRR . Stewardship of COVID-19 volunteers by nested trial design. Lancet Infectious Diseases2022;22(10):1400-1. [DOI: 10.1016/S1473-3099(22)00429-7]">Gottlieb 2022</a>; <a href="./references#CD015395-bbs2-0039" title="Pupo CorreiaM , FernandesS , FilipeP . Cutaneous adverse reactions to the new oral antiviral drugs against SARS-CoV-2. Clinical and Experimental Dermatology2022;47(9):1738-40. [DOI: 10.1111/ced.15281]">Pupo Correia 2022</a>; <a href="./references#CD015395-bbs2-0041" title="RobinsonJ . Oral antiviral may cut risk of COVID-19 hospitalisation by nearly 90%, manufacturer claims. Pharmaceutical Journal2021;307(7955):[3 p.]. [DOI: 10.1211/PJ.2021.1.114284]">Robinson 2021</a>; <a href="./references#CD015395-bbs2-0042" title="RobinsonJ . Pfizer COVID-19 antiviral paxlovid authorised by MHRA. Pharmaceutical Journal2022;308(7957):[3 p.]. [DOI: 10.1211/PJ.2022.1.122332]">Robinson 2022</a>; <a href="./references#CD015395-bbs2-0043" title="RosenbergK . New data on Paxlovid reported. American Journal of Nursing2022;122(10):59. [DOI: 10.1097/01.NAJ.0000890244.62778.a4]">Rosenberg 2022</a>; <a href="./references#CD015395-bbs2-0048" title="TrøseidM , HentzienM , AderF , CardosoSW , ArribasJR , MolinaJM , et al. Immunocompromised patients have been neglected in COVID-19 trials: a call for action. Clinical Microbiology and Infection2022;28(9):1182-3. [DOI: 10.1016/j.cmi.2022.05.005]">Trøseid 2022</a>; <a href="./references#CD015395-bbs2-0049" title="VassilopoulosA , MylonakisE . In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death. Annals of Internal Medicine2022;175(6):JC63. [DOI: 10.7326/J22-0038]">Vassilopoulos 2022</a>; <a href="./references#CD015395-bbs2-0051" title="WangZ , YangL . In the age of omicron variant: Paxlovid raises new hopes of COVID-19 recovery. Journal of Medical Virology2022;94(5):1766-7. [DOI: 10.1002/jmv.27540]">Wang 2022</a>). </p> </section> <section id="CD015395-sec-0062"> <h4 class="title">Studies awaiting classification</h4> <p>Details are available in the <a href="./references#CD015395-sec-0145" title="">Characteristics of studies awaiting classification</a> table. </p> <p>Three studies are currently awaiting classification (<a href="./references#CD015395-bbs2-0056" title="2022-002447-22. A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/BG (first received 23 September 2022). NCT05545319. A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19 (EPIC-HOS). clinicaltrials.gov/ct2/show/NCT05545319 (first received 16 September 2022). ">EPIC‐HOS</a>; <a href="./references#CD015395-bbs2-0057" title="2021-002894-24-ES. A phase 2/3 postexposure prophylaxis study of PF-07321332/ritonavir in household contacts of a patient with COVID-19. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002894-24 (first received 20 July 2021). NCT05047601. A post-exposure prophylaxis study of PF-07321332/ritonavir in adult household contacts of an individual with symptomatic COVID-19. clinicaltrials.gov/ct2/show/NCT05047601 (first received 17 September 2021). jRCT2031210349. A study of a potential oral treatment to prevent COVID-19 in adults who are exposed to household member(s) with a confirmed symptomatic COVID-19 infection. jrct.niph.go.jp/en-latest-detail/jRCT2031210349 (first received 28 September 2021). ">EPIC‐PEP 2021</a>; <a href="./references#CD015395-bbs2-0058" title="2021-002857-28-HU. A phase 2/3 efficacy and safety study of PF-07321332/ritonavir in nonhospitalized low-risk adult participants with COVID-19. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002857-28 (first received 23 August 2021). NCT05011513. A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. clinicaltrials.gov/ct2/show/NCT05011513 (first received 18 August 2021). jRCT2031210274. A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. jrct.niph.go.jp/en-latest-detail/jRCT2031210274 (first received 26 August 2021). ">EPIC‐SR 2021</a>). One is investigating nirmatrelvir/ritonavir as PEP (<a href="./references#CD015395-bbs2-0057" title="2021-002894-24-ES. A phase 2/3 postexposure prophylaxis study of PF-07321332/ritonavir in household contacts of a patient with COVID-19. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002894-24 (first received 20 July 2021). NCT05047601. A post-exposure prophylaxis study of PF-07321332/ritonavir in adult household contacts of an individual with symptomatic COVID-19. clinicaltrials.gov/ct2/show/NCT05047601 (first received 17 September 2021). jRCT2031210349. A study of a potential oral treatment to prevent COVID-19 in adults who are exposed to household member(s) with a confirmed symptomatic COVID-19 infection. jrct.niph.go.jp/en-latest-detail/jRCT2031210349 (first received 28 September 2021). ">EPIC‐PEP 2021</a>), while the other two are investigating nirmatrelvir/ritonavir as treatment for people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID‐19 (<a href="./references#CD015395-bbs2-0056" title="2022-002447-22. A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/BG (first received 23 September 2022). NCT05545319. A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19 (EPIC-HOS). clinicaltrials.gov/ct2/show/NCT05545319 (first received 16 September 2022). ">EPIC‐HOS</a>) and for people at standard risk (<a href="./references#CD015395-bbs2-0058" title="2021-002857-28-HU. A phase 2/3 efficacy and safety study of PF-07321332/ritonavir in nonhospitalized low-risk adult participants with COVID-19. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002857-28 (first received 23 August 2021). NCT05011513. A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. clinicaltrials.gov/ct2/show/NCT05011513 (first received 18 August 2021). jRCT2031210274. A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. jrct.niph.go.jp/en-latest-detail/jRCT2031210274 (first received 26 August 2021). ">EPIC‐SR 2021</a>). All three studies were initiated and funded by Pfizer. One study has been completed without publication of results (<a href="./references#CD015395-bbs2-0057" title="2021-002894-24-ES. A phase 2/3 postexposure prophylaxis study of PF-07321332/ritonavir in household contacts of a patient with COVID-19. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002894-24 (first received 20 July 2021). NCT05047601. A post-exposure prophylaxis study of PF-07321332/ritonavir in adult household contacts of an individual with symptomatic COVID-19. clinicaltrials.gov/ct2/show/NCT05047601 (first received 17 September 2021). jRCT2031210349. A study of a potential oral treatment to prevent COVID-19 in adults who are exposed to household member(s) with a confirmed symptomatic COVID-19 infection. jrct.niph.go.jp/en-latest-detail/jRCT2031210349 (first received 28 September 2021). ">EPIC‐PEP 2021</a>), while the other two have been terminated either due to challenges related to the operational feasibility of the study, taking into account the current epidemiology and declining hospitalization rates for severe COVID‐19 (<a href="./references#CD015395-bbs2-0056" title="2022-002447-22. A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/BG (first received 23 September 2022). NCT05545319. A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19 (EPIC-HOS). clinicaltrials.gov/ct2/show/NCT05545319 (first received 16 September 2022). ">EPIC‐HOS</a>), or due to a very low rate of hospitalization or death observed in the standard‐risk patient population (<a href="./references#CD015395-bbs2-0058" title="2021-002857-28-HU. A phase 2/3 efficacy and safety study of PF-07321332/ritonavir in nonhospitalized low-risk adult participants with COVID-19. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002857-28 (first received 23 August 2021). NCT05011513. A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. clinicaltrials.gov/ct2/show/NCT05011513 (first received 18 August 2021). jRCT2031210274. A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. jrct.niph.go.jp/en-latest-detail/jRCT2031210274 (first received 26 August 2021). ">EPIC‐SR 2021</a>). Results have not been posted for any of the studies. </p> </section> <section id="CD015395-sec-0063"> <h4 class="title">Ongoing studies</h4> <p>Details of ongoing studies are reported in the <a href="./references#CD015395-sec-0146" title="">Characteristics of ongoing studies</a> table. </p> <p>We classified 13 studies as ongoing. All studies investigate nirmatrelvir/ritonavir for treatment of COVID‐19 (<a href="./references#CD015395-bbs2-0059" title="2022-001362-35. A study to learn about the study medicines called nirmatrelvir/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised. clinicaltrialsregister.eu/ctr-search/trial/2022-001362-35/BG (first received 18 January 2022). ">2022‐001362‐35</a>; <a href="./references#CD015395-bbs2-0060" title="ChiCTR2200059390. A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. chictr.org.cn/showproj.aspx?proj=169088 (first received 28 April 2022). ">ChiCTR2200059390</a>; <a href="./references#CD015395-bbs2-0061" title="ChiCTR2200059726. Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059726 (first received 10 May 2022). ">ChiCTR2200059726</a>; <a href="./references#CD015395-bbs2-0062" title="ChiCTR2200059739. A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059739 (first received 10 May 2022). ">ChiCTR2200059739</a>; <a href="./references#CD015395-bbs2-0063" title="ChiCTR2200060010. Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200060010 (first received 14 May 2022). ">ChiCTR2200060010</a>; <a href="./references#CD015395-bbs2-0064" title="NCT05041907. Finding treatments for COVID-19: a trial of antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV). clinicaltrials.gov/ct2/show/NCT05041907 (first received 13 September 2021). ">NCT05041907</a>; <a href="./references#CD015395-bbs2-0065" title="NCT05321394. Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19. clinicaltrials.gov/ct2/show/NCT05321394?term=NCT05321394&amp;draw=2&amp;rank=1 (first received 11 April 2022). ">NCT05321394</a>; <a href="./references#CD015395-bbs2-0066" title="NCT05386433. Paxlovid in the treatment of COVID-19 patients with uremia. clinicaltrials.gov/ct2/show/NCT05386433 (first received 23 May 2022). ">NCT05386433</a>; <a href="./references#CD015395-bbs2-0067" title="2022-002827-36. A study to learn about a repeat 5-day treatment with nirmatrelvir/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK (first received 3 October 2022). NCT05567952. A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrials.gov/ct2/show/NCT05567952 (first received 11 April 2022). ">NCT05567952</a>; <a href="./references#CD015395-bbs2-0068" title="NCT05614349. Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID). clinicaltrials.gov/ct2/show/NCT05614349 (first received 14 November 2022). ">NCT05614349</a>; <a href="./references#CD015395-bbs2-0069" title="NCT05642910. The efficacy of azvudine and Paxlovid in high-risk patients with COVID-19: a prospective randomized controlled trial. clinicaltrials.gov/ct2/show/NCT05642910 (first received 8 December 2022). ">NCT05642910</a>; <a href="./references#CD015395-bbs2-0070" title="ISRCTN30448031. A clinical trial investigating novel treatments for COVID-19 in the community. isrctn.com/ISRCTN30448031 (first received 28 October 2021). ">PANORAMIC 2021</a>; <a href="./references#CD015395-bbs2-0071" title="NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). ">RECOVERY 2020</a>). No study investigating nirmatrelvir/ritonavir as PEP or PrEP is currently ongoing. Of the 13 studies investigating nirmatrelvir/ritonavir for treatment of COVID‐19, two studies are focusing on an inpatient setting (<a href="./references#CD015395-bbs2-0069" title="NCT05642910. The efficacy of azvudine and Paxlovid in high-risk patients with COVID-19: a prospective randomized controlled trial. clinicaltrials.gov/ct2/show/NCT05642910 (first received 8 December 2022). ">NCT05642910</a>; <a href="./references#CD015395-bbs2-0071" title="NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). ">RECOVERY 2020</a>), while four others are investigating nirmatrelvir/ritonavir in outpatient settings (<a href="./references#CD015395-bbs2-0059" title="2022-001362-35. A study to learn about the study medicines called nirmatrelvir/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised. clinicaltrialsregister.eu/ctr-search/trial/2022-001362-35/BG (first received 18 January 2022). ">2022‐001362‐35</a>; <a href="./references#CD015395-bbs2-0065" title="NCT05321394. Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19. clinicaltrials.gov/ct2/show/NCT05321394?term=NCT05321394&amp;draw=2&amp;rank=1 (first received 11 April 2022). ">NCT05321394</a>; <a href="./references#CD015395-bbs2-0068" title="NCT05614349. Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID). clinicaltrials.gov/ct2/show/NCT05614349 (first received 14 November 2022). ">NCT05614349</a>; <a href="./references#CD015395-bbs2-0070" title="ISRCTN30448031. A clinical trial investigating novel treatments for COVID-19 in the community. isrctn.com/ISRCTN30448031 (first received 28 October 2021). ">PANORAMIC 2021</a>). Seven studies did not include information about the study setting in the trial registration (<a href="./references#CD015395-bbs2-0060" title="ChiCTR2200059390. A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. chictr.org.cn/showproj.aspx?proj=169088 (first received 28 April 2022). ">ChiCTR2200059390</a>; <a href="./references#CD015395-bbs2-0061" title="ChiCTR2200059726. Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059726 (first received 10 May 2022). ">ChiCTR2200059726</a>; <a href="./references#CD015395-bbs2-0062" title="ChiCTR2200059739. A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059739 (first received 10 May 2022). ">ChiCTR2200059739</a>; <a href="./references#CD015395-bbs2-0063" title="ChiCTR2200060010. Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200060010 (first received 14 May 2022). ">ChiCTR2200060010</a>; <a href="./references#CD015395-bbs2-0064" title="NCT05041907. Finding treatments for COVID-19: a trial of antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV). clinicaltrials.gov/ct2/show/NCT05041907 (first received 13 September 2021). ">NCT05041907</a>; <a href="./references#CD015395-bbs2-0066" title="NCT05386433. Paxlovid in the treatment of COVID-19 patients with uremia. clinicaltrials.gov/ct2/show/NCT05386433 (first received 23 May 2022). ">NCT05386433</a>; <a href="./references#CD015395-bbs2-0067" title="2022-002827-36. A study to learn about a repeat 5-day treatment with nirmatrelvir/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK (first received 3 October 2022). NCT05567952. A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrials.gov/ct2/show/NCT05567952 (first received 11 April 2022). ">NCT05567952</a>). </p> <p>Four studies are investigating nirmatrelvir/ritonavir plus SoC versus SoC for treatment of COVID‐19 (<a href="./references#CD015395-bbs2-0068" title="NCT05614349. Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID). clinicaltrials.gov/ct2/show/NCT05614349 (first received 14 November 2022). ">NCT05614349</a>; <a href="./references#CD015395-bbs2-0066" title="NCT05386433. Paxlovid in the treatment of COVID-19 patients with uremia. clinicaltrials.gov/ct2/show/NCT05386433 (first received 23 May 2022). ">NCT05386433</a>; <a href="./references#CD015395-bbs2-0070" title="ISRCTN30448031. A clinical trial investigating novel treatments for COVID-19 in the community. isrctn.com/ISRCTN30448031 (first received 28 October 2021). ">PANORAMIC 2021</a>; <a href="./references#CD015395-bbs2-0071" title="NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). ">RECOVERY 2020</a>), one uses an additional placebo in the comparator group (<a href="./references#CD015395-bbs2-0059" title="2022-001362-35. A study to learn about the study medicines called nirmatrelvir/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised. clinicaltrialsregister.eu/ctr-search/trial/2022-001362-35/BG (first received 18 January 2022). ">2022‐001362‐35</a>), and one compares nirmatrelvir/ritonavir to placebo plus ritonavir (<a href="./references#CD015395-bbs2-0067" title="2022-002827-36. A study to learn about a repeat 5-day treatment with nirmatrelvir/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK (first received 3 October 2022). NCT05567952. A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrials.gov/ct2/show/NCT05567952 (first received 11 April 2022). ">NCT05567952</a>). Seven studies are comparing nirmatrelvir/ritonavir with active comparators (<a href="./references#CD015395-bbs2-0063" title="ChiCTR2200060010. Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200060010 (first received 14 May 2022). ">ChiCTR2200060010</a>; <a href="./references#CD015395-bbs2-0060" title="ChiCTR2200059390. A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. chictr.org.cn/showproj.aspx?proj=169088 (first received 28 April 2022). ">ChiCTR2200059390</a>; <a href="./references#CD015395-bbs2-0061" title="ChiCTR2200059726. Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059726 (first received 10 May 2022). ">ChiCTR2200059726</a>; <a href="./references#CD015395-bbs2-0062" title="ChiCTR2200059739. A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059739 (first received 10 May 2022). ">ChiCTR2200059739</a>; <a href="./references#CD015395-bbs2-0064" title="NCT05041907. Finding treatments for COVID-19: a trial of antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV). clinicaltrials.gov/ct2/show/NCT05041907 (first received 13 September 2021). ">NCT05041907</a>; <a href="./references#CD015395-bbs2-0065" title="NCT05321394. Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19. clinicaltrials.gov/ct2/show/NCT05321394?term=NCT05321394&amp;draw=2&amp;rank=1 (first received 11 April 2022). ">NCT05321394</a>; <a href="./references#CD015395-bbs2-0069" title="NCT05642910. The efficacy of azvudine and Paxlovid in high-risk patients with COVID-19: a prospective randomized controlled trial. clinicaltrials.gov/ct2/show/NCT05642910 (first received 8 December 2022). ">NCT05642910</a>). Four are platform trials with estimated enrollment numbers between 1500 and 50,000 participants (<a href="./references#CD015395-bbs2-0064" title="NCT05041907. Finding treatments for COVID-19: a trial of antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV). clinicaltrials.gov/ct2/show/NCT05041907 (first received 13 September 2021). ">NCT05041907</a>; <a href="./references#CD015395-bbs2-0068" title="NCT05614349. Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID). clinicaltrials.gov/ct2/show/NCT05614349 (first received 14 November 2022). ">NCT05614349</a>; <a href="./references#CD015395-bbs2-0070" title="ISRCTN30448031. A clinical trial investigating novel treatments for COVID-19 in the community. isrctn.com/ISRCTN30448031 (first received 28 October 2021). ">PANORAMIC 2021</a>; <a href="./references#CD015395-bbs2-0071" title="NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). ">RECOVERY 2020</a>). For all other trials, estimated enrollment numbers range from 40 participants to about 1000 participants (<a href="./references#CD015395-bbs2-0059" title="2022-001362-35. A study to learn about the study medicines called nirmatrelvir/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised. clinicaltrialsregister.eu/ctr-search/trial/2022-001362-35/BG (first received 18 January 2022). ">2022‐001362‐35</a>; <a href="./references#CD015395-bbs2-0060" title="ChiCTR2200059390. A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. chictr.org.cn/showproj.aspx?proj=169088 (first received 28 April 2022). ">ChiCTR2200059390</a>; <a href="./references#CD015395-bbs2-0061" title="ChiCTR2200059726. Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059726 (first received 10 May 2022). ">ChiCTR2200059726</a>; <a href="./references#CD015395-bbs2-0062" title="ChiCTR2200059739. A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059739 (first received 10 May 2022). ">ChiCTR2200059739</a>; <a href="./references#CD015395-bbs2-0063" title="ChiCTR2200060010. Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200060010 (first received 14 May 2022). ">ChiCTR2200060010</a>; <a href="./references#CD015395-bbs2-0065" title="NCT05321394. Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19. clinicaltrials.gov/ct2/show/NCT05321394?term=NCT05321394&amp;draw=2&amp;rank=1 (first received 11 April 2022). ">NCT05321394</a>; <a href="./references#CD015395-bbs2-0066" title="NCT05386433. Paxlovid in the treatment of COVID-19 patients with uremia. clinicaltrials.gov/ct2/show/NCT05386433 (first received 23 May 2022). ">NCT05386433</a>; <a href="./references#CD015395-bbs2-0067" title="2022-002827-36. A study to learn about a repeat 5-day treatment with nirmatrelvir/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK (first received 3 October 2022). NCT05567952. A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrials.gov/ct2/show/NCT05567952 (first received 11 April 2022). ">NCT05567952</a>; <a href="./references#CD015395-bbs2-0069" title="NCT05642910. The efficacy of azvudine and Paxlovid in high-risk patients with COVID-19: a prospective randomized controlled trial. clinicaltrials.gov/ct2/show/NCT05642910 (first received 8 December 2022). ">NCT05642910</a>). </p> <p>One ongoing trial is conducted in the UK (<a href="./references#CD015395-bbs2-0070" title="ISRCTN30448031. A clinical trial investigating novel treatments for COVID-19 in the community. isrctn.com/ISRCTN30448031 (first received 28 October 2021). ">PANORAMIC 2021</a>), one in Italy (<a href="./references#CD015395-bbs2-0065" title="NCT05321394. Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19. clinicaltrials.gov/ct2/show/NCT05321394?term=NCT05321394&amp;draw=2&amp;rank=1 (first received 11 April 2022). ">NCT05321394</a>), six in China (<a href="./references#CD015395-bbs2-0063" title="ChiCTR2200060010. Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200060010 (first received 14 May 2022). ">ChiCTR2200060010</a>; <a href="./references#CD015395-bbs2-0060" title="ChiCTR2200059390. A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. chictr.org.cn/showproj.aspx?proj=169088 (first received 28 April 2022). ">ChiCTR2200059390</a>; <a href="./references#CD015395-bbs2-0061" title="ChiCTR2200059726. Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059726 (first received 10 May 2022). ">ChiCTR2200059726</a>; <a href="./references#CD015395-bbs2-0062" title="ChiCTR2200059739. A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059739 (first received 10 May 2022). ">ChiCTR2200059739</a>; <a href="./references#CD015395-bbs2-0066" title="NCT05386433. Paxlovid in the treatment of COVID-19 patients with uremia. clinicaltrials.gov/ct2/show/NCT05386433 (first received 23 May 2022). ">NCT05386433</a>; <a href="./references#CD015395-bbs2-0069" title="NCT05642910. The efficacy of azvudine and Paxlovid in high-risk patients with COVID-19: a prospective randomized controlled trial. clinicaltrials.gov/ct2/show/NCT05642910 (first received 8 December 2022). ">NCT05642910</a>), and one in Canada (<a href="./references#CD015395-bbs2-0068" title="NCT05614349. Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID). clinicaltrials.gov/ct2/show/NCT05614349 (first received 14 November 2022). ">NCT05614349</a>). Four trials are conducted in two to nine different countries including LICs, LMICs, UMICs, and HICs (<a href="./references#CD015395-bbs2-0059" title="2022-001362-35. A study to learn about the study medicines called nirmatrelvir/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised. clinicaltrialsregister.eu/ctr-search/trial/2022-001362-35/BG (first received 18 January 2022). ">2022‐001362‐35</a>; <a href="./references#CD015395-bbs2-0064" title="NCT05041907. Finding treatments for COVID-19: a trial of antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV). clinicaltrials.gov/ct2/show/NCT05041907 (first received 13 September 2021). ">NCT05041907</a>; <a href="./references#CD015395-bbs2-0067" title="2022-002827-36. A study to learn about a repeat 5-day treatment with nirmatrelvir/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK (first received 3 October 2022). NCT05567952. A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrials.gov/ct2/show/NCT05567952 (first received 11 April 2022). ">NCT05567952</a>; <a href="./references#CD015395-bbs2-0071" title="NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). ">RECOVERY 2020</a>). </p> <p>Two ongoing trials are funded by pharmaceutical companies (<a href="./references#CD015395-bbs2-0059" title="2022-001362-35. A study to learn about the study medicines called nirmatrelvir/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised. clinicaltrialsregister.eu/ctr-search/trial/2022-001362-35/BG (first received 18 January 2022). ">2022‐001362‐35</a>; <a href="./references#CD015395-bbs2-0067" title="2022-002827-36. A study to learn about a repeat 5-day treatment with nirmatrelvir/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK (first received 3 October 2022). NCT05567952. A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrials.gov/ct2/show/NCT05567952 (first received 11 April 2022). ">NCT05567952</a>). </p> <p>Eight studies are currently recruiting (<a href="./references#CD015395-bbs2-0061" title="ChiCTR2200059726. Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059726 (first received 10 May 2022). ">ChiCTR2200059726</a>; <a href="./references#CD015395-bbs2-0060" title="ChiCTR2200059390. A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. chictr.org.cn/showproj.aspx?proj=169088 (first received 28 April 2022). ">ChiCTR2200059390</a>; <a href="./references#CD015395-bbs2-0064" title="NCT05041907. Finding treatments for COVID-19: a trial of antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV). clinicaltrials.gov/ct2/show/NCT05041907 (first received 13 September 2021). ">NCT05041907</a>; <a href="./references#CD015395-bbs2-0065" title="NCT05321394. Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19. clinicaltrials.gov/ct2/show/NCT05321394?term=NCT05321394&amp;draw=2&amp;rank=1 (first received 11 April 2022). ">NCT05321394</a>; <a href="./references#CD015395-bbs2-0067" title="2022-002827-36. A study to learn about a repeat 5-day treatment with nirmatrelvir/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK (first received 3 October 2022). NCT05567952. A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrials.gov/ct2/show/NCT05567952 (first received 11 April 2022). ">NCT05567952</a>; <a href="./references#CD015395-bbs2-0068" title="NCT05614349. Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID). clinicaltrials.gov/ct2/show/NCT05614349 (first received 14 November 2022). ">NCT05614349</a>; <a href="./references#CD015395-bbs2-0069" title="NCT05642910. The efficacy of azvudine and Paxlovid in high-risk patients with COVID-19: a prospective randomized controlled trial. clinicaltrials.gov/ct2/show/NCT05642910 (first received 8 December 2022). ">NCT05642910</a>; <a href="./references#CD015395-bbs2-0071" title="NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). ">RECOVERY 2020</a>), three are not yet recruiting (<a href="./references#CD015395-bbs2-0062" title="ChiCTR2200059739. A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059739 (first received 10 May 2022). ">ChiCTR2200059739</a>; <a href="./references#CD015395-bbs2-0063" title="ChiCTR2200060010. Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200060010 (first received 14 May 2022). ">ChiCTR2200060010</a>; <a href="./references#CD015395-bbs2-0066" title="NCT05386433. Paxlovid in the treatment of COVID-19 patients with uremia. clinicaltrials.gov/ct2/show/NCT05386433 (first received 23 May 2022). ">NCT05386433</a>), and two give no further information about the current status of the trial (<a href="./references#CD015395-bbs2-0059" title="2022-001362-35. A study to learn about the study medicines called nirmatrelvir/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised. clinicaltrialsregister.eu/ctr-search/trial/2022-001362-35/BG (first received 18 January 2022). ">2022‐001362‐35</a>; <a href="./references#CD015395-bbs2-0070" title="ISRCTN30448031. A clinical trial investigating novel treatments for COVID-19 in the community. isrctn.com/ISRCTN30448031 (first received 28 October 2021). ">PANORAMIC 2021</a>). Three trials were expected to be completed in 2022 (<a href="./references#CD015395-bbs2-0060" title="ChiCTR2200059390. A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors. chictr.org.cn/showproj.aspx?proj=169088 (first received 28 April 2022). ">ChiCTR2200059390</a>; <a href="./references#CD015395-bbs2-0065" title="NCT05321394. Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19. clinicaltrials.gov/ct2/show/NCT05321394?term=NCT05321394&amp;draw=2&amp;rank=1 (first received 11 April 2022). ">NCT05321394</a>; <a href="./references#CD015395-bbs2-0066" title="NCT05386433. Paxlovid in the treatment of COVID-19 patients with uremia. clinicaltrials.gov/ct2/show/NCT05386433 (first received 23 May 2022). ">NCT05386433</a>), four are estimated to be completed in 2023 (<a href="./references#CD015395-bbs2-0068" title="NCT05614349. Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID). clinicaltrials.gov/ct2/show/NCT05614349 (first received 14 November 2022). ">NCT05614349</a>; <a href="./references#CD015395-bbs2-0067" title="2022-002827-36. A study to learn about a repeat 5-day treatment with nirmatrelvir/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK (first received 3 October 2022). NCT05567952. A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir/ritonavir. clinicaltrials.gov/ct2/show/NCT05567952 (first received 11 April 2022). ">NCT05567952</a>; <a href="./references#CD015395-bbs2-0069" title="NCT05642910. The efficacy of azvudine and Paxlovid in high-risk patients with COVID-19: a prospective randomized controlled trial. clinicaltrials.gov/ct2/show/NCT05642910 (first received 8 December 2022). ">NCT05642910</a>; <a href="./references#CD015395-bbs2-0070" title="ISRCTN30448031. A clinical trial investigating novel treatments for COVID-19 in the community. isrctn.com/ISRCTN30448031 (first received 28 October 2021). ">PANORAMIC 2021</a>), one in 2024 (<a href="./references#CD015395-bbs2-0064" title="NCT05041907. Finding treatments for COVID-19: a trial of antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV). clinicaltrials.gov/ct2/show/NCT05041907 (first received 13 September 2021). ">NCT05041907</a>), and one in 2032 (<a href="./references#CD015395-bbs2-0071" title="NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). ">RECOVERY 2020</a>). Four trials did not include information about the estimated completion date in the trial registration (<a href="./references#CD015395-bbs2-0059" title="2022-001362-35. A study to learn about the study medicines called nirmatrelvir/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised. clinicaltrialsregister.eu/ctr-search/trial/2022-001362-35/BG (first received 18 January 2022). ">2022‐001362‐35</a>; <a href="./references#CD015395-bbs2-0062" title="ChiCTR2200059739. A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059739 (first received 10 May 2022). ">ChiCTR2200059739</a>; <a href="./references#CD015395-bbs2-0061" title="ChiCTR2200059726. Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200059726 (first received 10 May 2022). ">ChiCTR2200059726</a>; <a href="./references#CD015395-bbs2-0063" title="ChiCTR2200060010. Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200060010 (first received 14 May 2022). ">ChiCTR2200060010</a>). </p> </section> </section> <section id="CD015395-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed methodological quality and risk of bias using the RoB 2 tool recommended in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015395-bbs2-0101" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022a</a>). The two included trials contributed 17 study results to nine outcomes (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). Six outcomes for an outpatient population and three outcomes for an inpatient population. Regarding the outpatient population, six study results (whole study population) contributed to all six outcomes and six additional study results (two subgroups for age and four for ethnicity) contributed to one of the six outcomes (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). To account for different analysis sets used for subgroup analyses in the trial, the outcome 'hospitalization or death' has been assessed for the whole population as well as the individual subgroups using RoB 2. Regarding the inpatient population, three study results (whole study population) contributed to all three outcomes and two additional study results (subgroups for age) contributed to one of the three outcomes. The RoB 2 judgements for all study results per outcome and for all domains are available in an interactive risk of bias table (<a href="./references#CD015395-bbs2-0138" title="WeibelS , ReisS . Supplementary File_Nirmatrelvir_Risk of Bias Excel Tool (Version 2). Zenodo2023. [DOI: 10.5281/zenodo.10102195]">Supplementary File_Nirmatrelvir_Risk of Bias</a>) and are briefly summarized below. The completed RoB 2 tool with responses to all assessed signalling questions is available online at: <a href="./references#CD015395-bbs2-0138" title="WeibelS , ReisS . Supplementary File_Nirmatrelvir_Risk of Bias Excel Tool (Version 2). Zenodo2023. [DOI: 10.5281/zenodo.10102195]">Supplementary File_Nirmatrelvir_Risk of Bias</a>. </p> <section id="CD015395-sec-0065"> <h4 class="title">Overall risk of bias by study</h4> <p>From 17 outcomes, we rated five (29.41%) at low risk of bias and noted some concerns in 12 (70.59%) study results. Regarding the respective studies, we included the following: </p> <p> <ul id="CD015395-list-0040"> <li> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>: 12 study results with some concerns for the overall risk of bias; </p> </li> <li> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>: five study results with low risk of bias. </p> </li> </ul> </p> </section> <section id="CD015395-sec-0066"> <h4 class="title">Overall risk of bias by outcome</h4> <section id="CD015395-sec-0067"> <h5 class="title">Nirmatrelvir/ritonavir versus placebo in outpatient settings</h5> <p>We have some concern regarding risk of bias for all outcomes included in the <a href="./full#CD015395-tbl-0001">summary of findings Table 1</a>. For the outcomes 'all‐cause mortality at 28 days', 'worsening of clinical status: admission to hospital or death at 28 days', 'SAEs during the study period', and 'any grade TEAEs during the study period', the included study was at overall some concern of bias due to use of an inappropriate per‐protocol analysis (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-tblf-0022" title="">Risk of bias table for Analysis 1.1</a>; <a href="./references#CD015395-tblf-0023" title="">Risk of bias table for Analysis 1.2</a>; <a href="./references#CD015395-tblf-0026" title="">Risk of bias table for Analysis 1.5</a>; <a href="./references#CD015395-tblf-0027" title="">Risk of bias table for Analysis 1.6</a>). For the outcome 'admission to hospital or death at 28 days', we applied the respective risk of bias assessments to the subgroup analyses, as well (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-tblf-0024" title="">Risk of bias table for Analysis 1.3</a>; <a href="./references#CD015395-tblf-0025" title="">Risk of bias table for Analysis 1.4</a>). For the outcomes 'TRAEs during the study period' and 'discontinuation of study medication due to adverse events' the study has been assessed as overall some concern of bias due to use of an inappropriate per‐protocol analysis and lack of prospective outcome registration (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-tblf-0028" title="">Risk of bias table for Analysis 1.7</a>; <a href="./references#CD015395-tblf-0029" title="">Risk of bias table for Analysis 1.8</a>). </p> </section> <section id="CD015395-sec-0068"> <h5 class="title">Nirmatrelvir/ritonavir versus standard of care in inpatient settings</h5> <p>We have no concern of bias regarding the outcomes included in the <a href="./full#CD015395-tbl-0002">summary of findings Table 2</a>. For the outcomes 'all‐cause mortality at 28 days', 'viral clearance at seven days', and 'viral clearance at 14 days', the included study was assessed at no concerns for bias (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>; <a href="./references#CD015395-tblf-0030" title="">Risk of bias table for Analysis 2.1</a>; <a href="./references#CD015395-tblf-0032" title="">Risk of bias table for Analysis 2.3</a>; <a href="./references#CD015395-tblf-0033" title="">Risk of bias table for Analysis 2.4</a>). We also applied the respective risk of bias assessments to the subgroup analysis for age (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>; <a href="./references#CD015395-tblf-0031" title="">Risk of bias table for Analysis 2.2</a>). </p> </section> </section> </section> <section id="CD015395-sec-0069"> <h3 class="title" id="CD015395-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD015395-tbl-0001"><b>Summary of findings 1</b> Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings</a>; <a href="./full#CD015395-tbl-0002"><b>Summary of findings 2</b> Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings</a> </p> <p>One study investigating nirmatrelvir/ritonavir for treatment of non‐hospitalized people with COVID‐19 (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>), and one study investigating nirmatrelvir/ritonavir for treatment of hospitalized people with COVID‐19 (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>) were included in the qualitative synthesis of this review. </p> <p>Subgroup analyses between studies to explore heterogeneity and sensitivity analysis to test robustness of the results could not be performed due to an insufficient number of studies. </p> <p>We looked at subgroups to address health equity. Both included studies reported subgroups for their primary outcome only. <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> reported subgroups for age and ethnicity for the outcome 'admission to hospital or death at 28 days'. <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> reported subgroups for age for the outcome 'all‐cause mortality at 28 days'. The studies reported no further results for relevant subgroups (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). </p> <p>The main findings are summarized in <a href="./full#CD015395-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD015395-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD015395-sec-0070"> <h4 class="title">Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings </h4> <p>See <a href="./full#CD015395-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD015395-sec-0071"> <h5 class="title">All‐cause mortality at day 28</h5> <p>One study reported data on all‐cause mortality at day 28 (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). At 28 days, none of the participants in the nirmatrelvir/ritonavir group and 12 participants in the comparator group had died. Nirmatrelvir/ritonavir plus SoC may reduce all‐cause mortality at 28 days compared to SoC plus placebo (RR 0.04, 95% CI 0.00 to 0.68; 1 study, 2224 participants; low‐certainty evidence; <a href="./references#CD015395-fig-0002" title="">Analysis 1.1</a>). We downgraded the certainty of evidence one level for serious risk of bias due to inappropriate analysis and one level for serious imprecision due to few events. </p> <section id="CD015395-sec-0072"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analyses for age, ethnicity, comorbidity, and World Bank country classification by income level due to missing data (<a href="#CD015395-tbl-0003">Table 1</a>). </p> <div class="table" id="CD015395-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Equity assessment – outpatients</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comorbidities, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Race/ethnicity, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>World Bank country classification by income level, n (%)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worsening of clinical status: admission to hospital or death at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children: NR</p> <p>Adults &lt; 65 years: 1817 (87%)<sup>a</sup> </p> <p>Adults ≥ 65 years: 268 (13%)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian: 296 (14%)<sup>a</sup> </p> <p>Black: 94 (4.5%)<sup>a</sup> </p> <p>Hispanics: NR</p> <p>White: 1486 (71.3%)<sup>a</sup> </p> <p>Minorities: NR</p> <p>Other: 209 (10%)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events during the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade treatment‐emergent adverse events during the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade treatment‐related adverse events during the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation of study drug due to adverse events during the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Modified intention to treat (mITT1), 2085 participants.<br/>n: number of participants; NR: not reported. </p> </div> </div> </section> </section> <section id="CD015395-sec-0073"> <h5 class="title">Worsening of clinical status within 28 days</h5> <section id="CD015395-sec-0074"> <h6 class="title">Admission to hospital or death</h6> <p>One study reported data on worsening of clinical status assessed as admission to hospital or death within 28 days (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). The study defined the outcome was defined as "COVID‐19 related hospital admission or death". At 28 days, nine participants in the nirmatrelvir/ritonavir group and 68 participants in the comparator group had been admitted to hospital or were dead. Nirmatrelvir/ritonavir plus SoC may reduce admission to hospital or death within 28 days compared to SoC plus placebo (RR 0.13, 95% CI 0.07 to 0.27; 1 study, 2224 participants; low‐certainty evidence; <a href="./references#CD015395-fig-0003" title="">Analysis 1.2</a>). We downgraded the certainty of evidence one level for serious risk of bias due to inappropriate analysis and one level for serious indirectness as the study only assessed COVID‐19‐related hospitalizations. </p> <section id="CD015395-sec-0075"> <p><b>Subgroup analysis</b></p> <p>Subgroup analyses were available regarding age and ethnicity for the mITT1 population (<a href="#CD015395-tbl-0003">Table 1</a>). We could not perform subgroup analyses for World Bank country classification by income level due to missing data. No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated people with COVID‐19 at high risk for disease progression that was either due to coexisting conditions (e.g. current smoking) or comorbidities. </p> <p><b>Participants under 65 years versus 65 years and older</b> </p> <p>Of 1817 adults younger than 65 years of age, seven in the nirmatrelvir/ritonavir group and 46 in the comparator group were admitted to hospital or died (RR 0.15, 95% CI 0.07 to 0.34; <a href="./references#CD015395-fig-0004" title="">Analysis 1.3</a>). Of 268 participants aged 65 years or older, one in the nirmatrelvir/ritonavir group and 20 in the comparator group were admitted to hospital or died (RR 0.05, 95% CI 0.01 to 0.38; <a href="./references#CD015395-fig-0004" title="">Analysis 1.3</a>). The test for subgroup differences indicated no difference between both groups (P = 0.33) and no heterogeneity (I<sup>2</sup> = 0%). In both groups, the RR favoured treatment with nirmatrelvir/ritonavir, but the number of the included participants 65 years or older was low. </p> <p><b>Participants from different ethnic groups</b> </p> <p>Of 1486 participants identifying as White, eight in the nirmatrelvir/ritonavir group and 52 in the comparator group were admitted to hospital or died (RR 0.16, 95% CI 0.07 to 0.33; <a href="./references#CD015395-fig-0005" title="">Analysis 1.4</a>). Of 94 participants identifying as Black or African American, none in the nirmatrelvir/ritonavir group and one in the comparator group were admitted to hospital or died (RR 0.29, 95% CI 0.01 to 7.04; <a href="./references#CD015395-fig-0005" title="">Analysis 1.4</a>). Of 296 participants identifying as Asian, none in the nirmatrelvir/ritonavir and seven in the comparator group were admitted to hospital or died (RR 0.07, 95% CI 0.00 to 1.19; <a href="./references#CD015395-fig-0005" title="">Analysis 1.4</a>). Of 209 participants categorized as "other" ethnicity, none in the nirmatrelvir/ritonavir and six in the comparator group were admitted to hospital or died (RR 0.08, 95% CI 0.00 to 1.34; <a href="./references#CD015395-fig-0005" title="">Analysis 1.4</a>). The test for subgroup differences indicated no difference between all pairwise groups (P = 0.88) and no heterogeneity (I<sup>2</sup> = 0%). The estimated effect favoured treatment with nirmatrelvir/ritonavir for the White ethnic group, and all estimated effects of the other ethnic groups included the line of no effect (RR = 1). The numbers of participants in the other ethnic groups were low. </p> </section> </section> <section id="CD015395-sec-0076"> <h6 class="title">Admission to intensive care unit or death</h6> <p>No study reported data for worsening of clinical status assessed as admission to ICU or death within 28 days. </p> </section> </section> <section id="CD015395-sec-0077"> <h5 class="title">Improvement of clinical status</h5> <section id="CD015395-sec-0078"> <h6 class="title">All initial symptoms resolved at 28 days and up to the longest follow‐up</h6> <p>No study reported data for improvement of clinical status assessed as all initial symptoms resolved at 28 days and up to the longest follow‐up. </p> </section> <section id="CD015395-sec-0079"> <h6 class="title">Time to symptom resolution</h6> <p>No study reported data for improvement of clinical status assessed as time to symptom resolution. </p> </section> </section> <section id="CD015395-sec-0080"> <h5 class="title">Quality of life up to 28 days and longest follow‐up available</h5> <p>No study reported data for quality of life at any time point.</p> </section> <section id="CD015395-sec-0081"> <h5 class="title">Serious adverse events during the study period</h5> <p>One study reported data on SAEs during the study period (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). Eighteen participants in the nirmatrelvir/ritonavir group and 74 participants in the comparator group experienced SAEs during the 34‐day observation period. Nirmatrelvir/ritonavir plus SoC may reduce SAEs during the study period compared to SoC plus placebo (RR 0.24, 95% CI 0.15 to 0.41; 1 study, 2224 participants; low‐certainty evidence; <a href="./references#CD015395-fig-0006" title="">Analysis 1.5</a>). We downgraded the certainty of evidence one level for serious risk of bias due to inappropriate analysis and one level for serious imprecision as there were few SAEs other than hospitalization or death. </p> <section id="CD015395-sec-0082"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analyses for age, ethnicity, comorbidity, and World Bank country classification by income level due to missing data (<a href="#CD015395-tbl-0003">Table 1</a>). </p> </section> </section> <section id="CD015395-sec-0083"> <h5 class="title">Adverse events during the study period</h5> <section id="CD015395-sec-0084"> <h6 class="title">Any grade treatment‐emergent adverse events</h6> <p>One study reported data on any grade TEAEs during the study period (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). In total, 251 participants in the nirmatrelvir/ritonavir group and 266 participants in the placebo comparator group experienced TEAEs during the 34‐day observation period (<a href="./references#CD015395-fig-0007" title="">Analysis 1.6</a>). Nirmatrelvir/ritonavir plus SoC probably has little or no effect on TEAEs during the study period compared to SoC plus placebo (RR 0.95, 95% CI 0.82 to 1.10; 1 study, 2224 participants; moderate‐certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias due to inappropriate analysis. </p> <section id="CD015395-sec-0085"> <p><b>Subgroup analysis</b></p> <p>We could not perform subgroup analyses for age, ethnicity, comorbidity, and World Bank country classification by income level due to missing data (<a href="#CD015395-tbl-0003">Table 1</a>). </p> </section> </section> <section id="CD015395-sec-0086"> <h6 class="title">Any grade treatment‐related adverse events</h6> <p>One study reported data on any grade TRAEs during the study period (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). In total, 86 participants in the nirmatrelvir/ritonavir group and 42 participants in the comparator group experienced TRAEs during the 34‐day observation period. Nirmatrelvir/ritonavir plus SoC probably increases TRAEs during the study period compared to SoC plus placebo (RR 2.06, 95% CI 1.44 to 2.95; 1 study, 2224 participants; moderate‐certainty evidence; <a href="./references#CD015395-fig-0008" title="">Analysis 1.7</a>). TRAEs were mostly attributed to dysgeusia and diarrhoea. We downgraded the certainty of evidence one level for serious risk of bias due to inappropriate analysis. </p> <section id="CD015395-sec-0087"> <p><b>Subgroup analysis</b></p> <p>We could not perform subgroup analyses for age, ethnicity, comorbidity, and World Bank country classification by income level due to missing data (<a href="#CD015395-tbl-0003">Table 1</a>). </p> </section> </section> <section id="CD015395-sec-0088"> <h6 class="title">Discontinuation of study drug due to adverse events</h6> <p>One study reported data on discontinuation of study drug due to AEs (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). In total, 23 participants in the nirmatrelvir/ritonavir group and 47 participants in the comparator group discontinued the study drug due to AEs. Nirmatrelvir/ritonavir plus SoC probably decreases discontinuation of study drug due to AEs compared to SoC plus placebo (RR 0.49, 95% CI 0.30 to 0.80; 1 study, 2224 participants; moderate‐certainty evidence; <a href="./references#CD015395-fig-0009" title="">Analysis 1.8</a>). TRAEs were mostly attributed to dysgeusia and diarrhoea. We downgraded the certainty of evidence one level for serious risk of bias due to inappropriate analysis. </p> <section id="CD015395-sec-0089"> <p><b>Subgroup analysis</b></p> <p>We could not perform subgroup analyses for age, ethnicity, comorbidity, and World Bank country classification by income level due to missing data (<a href="#CD015395-tbl-0003">Table 1</a>). </p> </section> </section> </section> <section id="CD015395-sec-0090"> <h5 class="title">Viral clearance at 14 days</h5> <p>No study reported data on viral clearance at 14 days.</p> </section> </section> <section id="CD015395-sec-0091"> <h4 class="title">Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings </h4> <section id="CD015395-sec-0092"> <h5 class="title">All‐cause mortality at day 28</h5> <p>One study reported data on all‐cause mortality at day 28 (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). At 28 days, five participants in the nirmatrelvir/ritonavir group and eight participants in the comparator group had died. We are uncertain whether nirmatrelvir/ritonavir plus SoC reduces all‐cause mortality at 28 days compared to SoC alone (RR 0.63, 95% CI 0.21 to 1.86; 1 study, 264 participants; very low‐certainty evidence; <a href="./references#CD015395-fig-0010" title="">Analysis 2.1</a>). We downgraded the certainty of evidence two levels for imprecision and one level for indirectness. </p> <section id="CD015395-sec-0093"> <h6 class="title">Subgroup analysis</h6> <p>We performed subgroup analyses for age. We did not perform subgroup analyses for ethnicity and World Bank country classification by income level due to missing data. No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated people with COVID‐19 at high risk for disease progression defined as participants with severe comorbidities or a SOFA/Charlson score of 2 or greater (<a href="#CD015395-tbl-0004">Table 2</a>). </p> <div class="table" id="CD015395-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Equity assessment – inpatients</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comorbidities, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Race/ethnicity, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>World Bank country classification by income level, n (%)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children: NR</p> <p>Adult ≤ 65 years: 84 (32%)</p> <p>Adult &gt; 65 years: 180 (68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2: 101 (38%)</p> <p>≥ 2: 163 (62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events during the treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade treatment‐emergent adverse events during the treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade treatment‐related adverse events during the treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation of study drug due to adverse events during the treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n: number of participants; NR: not reported; RT‐PCR: reverse transcription polymerase chain reaction. </p> </div> </div> <p><b>Participants 65 years and under versus over 65 years</b> </p> <p>Of 84 adults aged 65 years and under, one in the nirmatrelvir/ritonavir group and two in the comparator group had died at day 28 (RR 0.61, 95% CI 0.06 to 6.42; <a href="./references#CD015395-fig-0011" title="">Analysis 2.2</a>). Of 180 participants older than 65 years, four in the nirmatrelvir/ritonavir group and six in the comparator group had died at day 28 (RR 0.61, 95% CI 0.18 to 2.09; <a href="./references#CD015395-fig-0011" title="">Analysis 2.2</a>). The test for subgroup differences indicated no difference between both groups (P = 1.0) and no heterogeneity (I<sup>2</sup> = 0%). Estimated effects for both groups included the line of no effect (RR = 1). The number of included participants 65 years or younger was low. </p> </section> </section> <section id="CD015395-sec-0094"> <h5 class="title">Worsening of clinical status within 28 days</h5> <section id="CD015395-sec-0095"> <h6 class="title">Participants with new need for invasive mechanical ventilation or death</h6> <p>No study reported data for worsening of clinical status assessed as new need for invasive mechanical ventilation or death. </p> </section> <section id="CD015395-sec-0096"> <h6 class="title">Participants with need for intensive care unit admission or death</h6> <p>No study reported data for worsening of clinical status assessed as admission to ICU or death within 28 days. </p> </section> </section> <section id="CD015395-sec-0097"> <h5 class="title">Improvement of clinical status within 28 days</h5> <section id="CD015395-sec-0098"> <h6 class="title">Participants discharged alive</h6> <p>No study reported data for participants discharged alive</p> </section> <section id="CD015395-sec-0099"> <h6 class="title">Participants discharged without clinical deterioration or death</h6> <p>No study reported data for participants discharged without clinical deterioration or death. </p> </section> </section> <section id="CD015395-sec-0100"> <h5 class="title">Quality of life up to 28 days and longest follow‐up available</h5> <p>No study reported data for quality of life at any time point.</p> </section> <section id="CD015395-sec-0101"> <h5 class="title">Serious adverse events during the study period</h5> <p>We did not include data for the outcome SAEs during the study period in the quantitative analysis due to insufficient and inconsistent information on the time of the outcome assessment, the handling of missing outcome data, and the outcome assessment itself. </p> </section> <section id="CD015395-sec-0102"> <h5 class="title">Adverse events during the study period</h5> <section id="CD015395-sec-0103"> <h6 class="title">Any grade treatment‐emergent adverse events</h6> <p>We did not include data for the outcome any grade TEAEs during the study period in the quantitative analysis due to insufficient and inconsistent information on the time of the outcome assessment, the handling of missing outcome data, and the outcome assessment itself. </p> </section> <section id="CD015395-sec-0104"> <h6 class="title">Any grade treatment‐related adverse events</h6> <p>We did not include data for the outcome any grade TRAEs during the study period in the quantitative analysis due to insufficient and inconsistent information on the time of the outcome assessment, the handling of missing outcome data, and the outcome assessment itself. </p> </section> <section id="CD015395-sec-0105"> <h6 class="title">Discontinuation of study drug due to adverse events</h6> <p>We did not include data for the outcome discontinuation of study drug due to AEs in the quantitative analysis due to insufficient and inconsistent information on the time of the outcome assessment, the handling of missing outcome data, and the outcome assessment itself. </p> </section> </section> <section id="CD015395-sec-0106"> <h5 class="title">Viral clearance at seven days</h5> <p>One study reported data on viral clearance at seven days (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). Thirty‐six participants in the nirmatrelvir/ritonavir group and 34 participants in the comparator group reached viral clearance during the seven‐day observation period. We are uncertain whether nirmatrelvir/ritonavir plus SoC increases viral clearance at seven days compared to SoC (RR 1.06, 95% CI 0.71 to 1.58; 1 study, 264 participants; very low‐certainty evidence; <a href="./references#CD015395-fig-0012" title="">Analysis 2.3</a>). We downgraded the certainty of evidence two levels for imprecision and one level for indirectness. </p> <section id="CD015395-sec-0107"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analyses for age, ethnicity, comorbidity, and World Bank country classification by income level due to missing data. No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated people with COVID‐19 at high risk for disease progression that was either due to severe comorbidities or a SOFA/Charlson score of 2 or greater (<a href="#CD015395-tbl-0004">Table 2</a>). </p> </section> </section> <section id="CD015395-sec-0108"> <h5 class="title">Viral clearance at 14 days</h5> <p>One study reported data on viral clearance at 14 days (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). One hundred and three participants in the nirmatrelvir/ritonavir group and 98 participants in the comparator group reached viral clearance during the 14‐day observation period. We are uncertain whether nirmatrelvir/ritonavir plus SoC increases viral clearance at 14 days compared to SoC (RR 1.05, 95% CI 0.92 to 1.20; 1 study, 264 participants; very low‐certainty evidence; <a href="./references#CD015395-fig-0013" title="">Analysis 2.4</a>). We downgraded the certainty of evidence two levels for imprecision and one level for indirectness. </p> <section id="CD015395-sec-0109"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analyses for age, ethnicity, comorbidity, and World Bank country classification by income level due to missing data. No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated people with COVID‐19 at high risk for disease progression which is either due to severe comorbidities or a SOFA/Charlson score of 2 or greater. (<a href="#CD015395-tbl-0004">Table 2</a>). </p> </section> </section> </section> <section id="CD015395-sec-0110"> <h4 class="title">Nirmatrelvir/ritonavir for preventing SARS‐CoV‐2 infection (pre‐ and postexposure)</h4> <p>No study with published results investigating nirmatrelvir/ritonavir for preventing SARS‐CoV‐2 infection has been included in this review. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015395-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015395-sec-0111"></div> <section id="CD015395-sec-0112"> <h3 class="title" id="CD015395-sec-0112">Summary of main results</h3> <p>This Cochrane Review aimed to assess the efficacy and safety of nirmatrelvir/ritonavir for treating and preventing COVID‐19. </p> <section id="CD015395-sec-0113"> <h4 class="title">Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings </h4> <p>For people with a confirmed diagnosis of COVID‐19, we identified one RCT with 2246 randomized participants with mild symptomatic COVID‐19 (WHO 2 to 3) conducted during the Delta wave in the outpatient setting comparing nirmatrelvir/ritonavir plus SoC to SoC plus placebo. Trial participants were unvaccinated, without previous confirmed SARS‐CoV‐2 infection, had a symptom onset of five days or less before randomization, and were at high risk for progression to severe disease. </p> <p>The study was assessed without concerns for research integrity.</p> <p>The main findings of this review are summarized in <a href="./full#CD015395-tbl-0001">summary of findings Table 1</a>. </p> <p> <ul id="CD015395-list-0041"> <li> <p>Nirmatrelvir/ritonavir may reduce all‐cause mortality at 28 days and clinical worsening assessed as admission to hospital or death within 28 days (low‐certainty evidence). </p> </li> <li> <p>Nirmatrelvir/ritonavir may reduce SAEs during the study period (low‐certainty evidence); there were few SAEs other than hospitalization or death. </p> </li> <li> <p>Nirmatrelvir/ritonavir probably has little or no effect on any TEAEs during the study period (moderate‐certainty evidence) </p> </li> <li> <p>Nirmatrelvir/ritonavir probably increases any TRAEs during the study period (moderate‐certainty evidence); TRAEs were mostly attributed to dysgeusia and diarrhoea. </p> </li> <li> <p>Nirmatrelvir/ritonavir probably decreases discontinuation of study drug due to AEs (moderate‐certainty evidence). </p> </li> </ul> </p> <p>We identified no study results reporting on improvement of clinical status, quality of life, and viral clearance. We identified four ongoing trials investigating nirmatrelvir/ritonavir for treatment of people with mild COVID‐19 in outpatient settings. </p> <section id="CD015395-sec-0114"> <h5 class="title">Equity</h5> <p>No subgroups were reported for World Bank country classification by income level.</p> <p>No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated people with COVID‐19 at high risk for disease progression that was either due to coexisting conditions (e.g. current smoking) or comorbidities. Reported only for the mITT1 patient population, 79.7% of participants had none or one comorbidity and 20.3% of the participants had two or more comorbidities, most commonly a BMI over 25 kg/m<sup>2</sup> (80.0%), hypertension (33.0%), and diabetes (12.1%). The study did not report the number of participants without any comorbidity. Few participants had other baseline comorbidities (e.g. chronic lung disease, cardiovascular disorder, chronic kidney disease, HIV infection, sickle cell disease, neurodevelopmental disorder, and cancer). For the FAS, the study reported only the combination of coexisting conditions or characteristics associated with an increased risk of developing severe COVID‐19, with 61.0% of participants having two or more such characteristics or comorbidities. The most common prespecified characteristic associated with an increased risk of developing severe disease was current smoking in 876 participants (39.0%). </p> <p>Despite the study being conducted in 343 sites worldwide, only 27 sites were in LICs and LMICs, and the remaining 316 sites (92.1%) were in UMICs or HICs. There were no separate data available for participants from LICs, LMICs, UMICs, or HICs. </p> <p>Regarding equity, we highlight that most participants in the included study were younger than 65 years and 71.3% identified as White. </p> <p>For the outcome 'admission to hospital or death', we investigated the following subgroups for equity: age (less than 65 years versus 65 years and greater) and ethnicity (Asian versus Black versus White versus other). For age, the effects favoured treatment with nirmatrelvir/ritonavir in both groups, but the number of included participants in the subgroup of 65 years or older was low. For ethnicity, the effects favoured treatment with nirmatrelvir/ritonavir for the White ethnic group. Estimated effects of the other ethnic groups included the line of no effect (RR = 1). The test for subgroup differences indicated no difference between all pairwise groups as numbers of participants in the other ethnic groups were low. </p> <p>For all other outcomes included in this review, no subgroups were reported. As most participants were younger than 65 years and of White ethnicity, we are uncertain whether results are applicable to the other prespecified subgroups. </p> </section> </section> <section id="CD015395-sec-0115"> <h4 class="title">Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings </h4> <p>For people with a confirmed diagnosis of COVID‐19, we identified one RCT with 264 participants with mild to moderate symptomatic COVID‐19 (WHO 2 to 4) conducted during the Omicron wave in the inpatient setting comparing nirmatrelvir/ritonavir plus SoC to SoC alone. Trial participants were hospitalized with mild to moderate COVID‐19 and either severe comorbidities, or SOFA/Charlson score of 2 or greater. Duration from symptom onset to hospital admission was less than five days or Ct value less than 25 by RT‐PCR. </p> <p>The study was assessed without concerns for research integrity.</p> <p>The main findings of this review are summarized in <a href="./full#CD015395-tbl-0002">summary of findings Table 2</a>. </p> <p> <ul id="CD015395-list-0042"> <li> <p>We are uncertain whether nirmatrelvir/ritonavir plus SoC reduces all‐cause mortality at 28 days compared to SoC (very low‐certainty evidence). </p> </li> <li> <p>We are uncertain whether nirmatrelvir/ritonavir plus SoC increases viral clearance at seven days compared to SoC (very low‐certainty evidence). </p> </li> <li> <p>We are uncertain whether nirmatrelvir/ritonavir plus SoC increases viral clearance at 14 days compared to SoC (very low certainty evidence). </p> </li> </ul> </p> <p>We did not include any safety‐related outcomes in the quantitative analysis due to insufficient and inconsistent information on the time of the outcome assessment, the handling of missing outcome data, and the outcome assessment itself. We identified no study results reporting on improvement or worsening of clinical status and quality of life. We identified two ongoing trials investigating nirmatrelvir/ritonavir for treatment of COVID‐19 in inpatient settings. </p> <section id="CD015395-sec-0116"> <h5 class="title">Equity</h5> <p>The study was conducted in China which classifies as UMIC. Unfortunately, no subgroups were reported for World Bank country classification by income level or different racial and ethnic groups. </p> <p>No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated people with COVID‐19 at high risk for disease progression that was either due to comorbidities or a SOFA/Charlson score of 2 or greater. </p> <p>Regarding equity, we highlight that most study participants in the included study were aged over 65 years. For the outcome 'all‐cause mortality at 28 days', there was no difference between participants aged 65 years or less and participants greater than 65 years as well as for participants with two or fewer comorbidities versus two or greater comorbidities. All estimated effects included the line of no effect (RR = 1). </p> </section> </section> <section id="CD015395-sec-0117"> <h4 class="title">Nirmatrelvir/ritonavir for preventing SARS‐CoV‐2 infection (pre‐ or postexposure)</h4> <p>We did not identify any completed trials investigating nirmatrelvir/ritonavir for prevention of COVID‐19 but one ongoing trial investigating nirmatrelvir/ritonavir as PEP after exposure to SARS‐CoV‐2. </p> </section> </section> <section id="CD015395-sec-0118"> <h3 class="title" id="CD015395-sec-0118">Overall completeness and applicability of evidence</h3> <p>Originating from only one RCT with 2246 participants, the certainty of evidence for the efficacy of nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings was low and for safety aspects low to moderate. </p> <p>For hospitalized participants, data from one RCT with 264 participants was available. Certainty of evidence for the efficacy of nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings was very low. Safety aspects of nirmatrelvir/ritonavir could not be assessed for this setting. </p> <p>Both included studies investigated participants with mild and mild to moderate symptomatic COVID‐19, corresponding to WHO clinical progression scale 2 to 3 and 2 to 4, respectively. In the outpatient setting, only unvaccinated participants with high risk for disease progression due to coexisting conditions or characteristics were included in the trial, limiting external validity of the results as results may not be transferable to a broader population of vaccinated participants or those with standard risk for disease progression. As of 23 June 2023, there have been more than 760 million confirmed SARS‐CoV‐2 cases reported to the WHO and more than 13 billion vaccine doses have been administered (<a href="./references#CD015395-bbs2-0150" title="World Health Organization (WHO). WHO coronavirus disease (COVID-19) dashboard. covid19.who.int/table (accessed 23 May 2022).">WHO 2021a</a>). The influence of the vaccination status as well as previous SARS‐CoV‐2 infections could not be assessed for outpatients in this review. </p> <p>While the study on inpatients included about 73% unvaccinated as well as 25% vaccinated (at least two doses) participants, it also investigated participants with a high risk for severe COVID‐19 either due to severe comorbidities or a SOFA/Charlson score 2 or greater and without previous SARS‐CoV‐2 infection. Characteristics of the included participants suggest that the study population does not necessarily resemble typical COVID‐19 inpatients and a considerable proportion of participants would probably be managed ambulatory in many places. Whether this was due to political decisions and treatment guidelines was unclear. Again, this might limit external validity of the results as they may not be transferable to a broader population of moderately to severely affected participants with standard risk for disease progression and previous SARS‐CoV‐2 infection. </p> <p>With ritonavir being a CYP3A4 inhibitor, nirmatrelvir/ritonavir bears the potential for significant drug–drug interactions with many medications commonly used, especially in people with comorbidities. The exclusion criteria of <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> prohibited prior or concomitant therapies including medications highly dependent on CYP3A4 for clearance. Pfizer published an extensive list of potentially significant drug interactions, including contraindicated drugs such as HMG‐CoA reductase inhibitors and antiarrhythmics (<a href="./references#CD015395-bbs2-0127" title="Pfizer. Potentially significant drug interactions, including contraindicated drugs PAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets). pfizermedical.pfizerpro.com/api/vc/en/medical/assets/5773bb0d-ab2b-40bb-8988-be557bd70923/Potentially%20Significant%20Drug%20Interactions.pdf (accessed 20 May 2022).">Pfizer 2022</a>). If known problematic concomitant medications cannot be discontinued or reduced, Pfizer advises against the use of nirmatrelvir/ritonavir, thereby further limiting the transferability of results to a broader high‐risk population. </p> <p>Surprisingly, only 6% of participants in <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> received or were expected to receive COVID‐19 monoclonal antibody treatment, despite the sixth version of the WHO living guideline published 24 September 2021 suggesting "treatment with casirivimab and imdevimab for those at highest risk of hospital admission" (<a href="./references#CD015395-bbs2-0152" title="World Health Organization (WHO). Therapeutics and COVID-19: living guideline. app.magicapp.org/#/guideline/nBkO1E/rec/E850m0 24 September 2021 (accessed 23 May 2022);version 6:15-23.">WHO 2021c</a>). Since the emergence of the Omicron BA.1 variant, however, casirivimab and imdevimab have lost their efficacy (<a href="./references#CD015395-bbs2-0139" title="TakashitaE , KinoshitaN , YamayoshiS , Sakai-TagawaY , FujisakiS , ItoM , et al. Efficacy of antibodies and antiviral drugs against COVID-19 Omicron variant. New England Journal of Medicine2022;386(10):995-8. [DOI: 10.1056/NEJMc2119407]">Takashita 2022</a>). Concomitant treatment with monoclonal antibodies (ambacizumab/romlusevimab and tocilizumab) were prohibited in <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>, as was treatment with COVID‐19 immunoglobulins and convalescent plasma, again limiting external validity of the results. </p> <p>All outpatient participants included in this review were enrolled until December 2021, which coincided with the Delta wave before the start of the Omicron wave; therefore, the findings for outpatients of this review might not be directly applicable to the treatment situation of outpatients which are infected with later (sub‐)variants of SARS‐CoV‐2. The recruitment period for the included inpatient study co‐occurred with the Omicron wave. </p> <p>According to Pfizer, nirmatrelvir/ritonavir is to be administered within five days of symptom onset. In the included inpatient study, median time between symptom onset and start of treatment was three days (<a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a>). In the included outpatient study, mean time between symptom onset and start of treatment was 2.96 days with 66.3% of participants starting treatment within three days, which might have increased the effectiveness of treatment (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>). At the same time, this limits applicability outside idealized study conditions where time between symptom onset, confirmation of SARS‐CoV‐2 infection, and treatment start may well exceed three days due to limited healthcare access or testing capacities in LICs and LMICs but also disadvantaged groups other than ethnic and racial minorities, for example, refugees, people with mental or physical disabilities, and women in HICs. </p> <p>In both included studies, reported data were incomplete and inconsistent. For <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>, outcome data on the overall population of 2246 randomized participants were missing and the FAS was not reported. Instead, multiple versions of mITT analyses (mITT, mITT1, and mITT2; Table S2; <a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>) are presented. The primary analysis of the original study protocol from 18 June 2021 was defined as the mITT1 population including participants who were treated five days or less after COVID‐19 symptom onset. The mITT analysis set that is the main analysis set of the publication was added in amendment 2 (2 August 2021) to include only those participants who were treated within three days after COVID‐19 symptom onset. Any clear explanation why the authors did not report the FAS but provide the mITT as main analyses is missing in the publication. We would have expected the FAS to be presented as the primary analysis set and the mITTs as additional sensitivity analyses. The presented mITT analyses focus on smaller populations. In the abstract, the interim and final analysis of the mITT population with 1379/2246 randomized participants was presented, with 13 deaths reported. However, according to the results section and Figure 2, only nine participants died in this mITT population, which is inconsistent and confusing. Finally, there is no detailed information on the clinical characteristics of included participants for the FAS, particularly with regard to the comorbidities as risk factors for disease progression. The distribution of comorbidities can only be extrapolated for the mITT population using the subgroup analyses presented in Figure S2c. The information for all participants (FAS) is absent. </p> <p>For <a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> the assessment of safety outcomes is poorly reported and not prespecified in the registered protocol. The exact assessment period, mode of outcome assessment, and handling of missing outcome data remain unclear. It is to be assumed that missing outcome data have been imputed; however, no information is given about the extent thereof. </p> <p>To date, there are no completed studies that investigate nirmatrelvir/ritonavir for the prevention of COVID‐19. We found 13 ongoing studies of which seven planned to be completed in either 2022 or 2023. No study investigating nirmatrelvir/ritonavir as PrEP or PEP is currently ongoing. </p> </section> <section id="CD015395-sec-0119"> <h3 class="title" id="CD015395-sec-0119">Certainty of the evidence</h3> <p>The certainty of evidence for prioritized outcomes presented in the summary of findings tables ranged from low to moderate for outpatients (<a href="./full#CD015395-tbl-0001">summary of findings Table 1</a>), and was very low for inpatients (<a href="./full#CD015395-tbl-0002">summary of findings Table 2</a>). </p> <p>For outpatients, we downgraded the certainty of evidence for all outcomes included in our summary of findings table due to risk of bias arising from use of an inappropriate per‐protocol analysis only including participants randomly assigned to study intervention who received one or greater more doses of study intervention and had one or more postbaseline visits by day 28. Additionally, the outcomes 'treatment‐related adverse events during the study period; and 'discontinuation of study medication due to adverse events' were not prospectively registered. All‐cause mortality at 28 days and SAEs during the study period were further downgraded for serious imprecision due to low number of events. The outcome 'admission to hospital or death within 28 days' was additionally downgraded for serious indirectness as the study only assessed COVID‐19‐related hospitalizations. </p> <p>For inpatients, we downgraded the certainty of evidence for all outcomes included in our summary of findings table for indirectness due to an atypical hospital population of mildly to moderately affected patients and twice for imprecision using the minimally contextualized approach. </p> <p>We did not consider downgrading for publication bias because the intervention is new and most of the studies are still ongoing. </p> <p>We identified no study results reporting on improvement of clinical status, quality of life, and viral clearance. </p> </section> <section id="CD015395-sec-0120"> <h3 class="title" id="CD015395-sec-0120">Potential biases in the review process</h3> <p>We are confident that we identified all relevant studies using a broad search and will monitor ongoing studies after the publication of this review. This review is a LSR, and we maintain an Excel list of new studies potentially to be included in the next review update. This list is publicly available (<a href="https://osf.io/7g49c/" target="_blank">osf.io/7g49c/</a>; <a href="./references#CD015395-bbs2-0130" title='ReisS , MetzendorfM , KuehnR , PoppM , GagyorI , KrankeP , et al. Living evidence base for Cochrane Review "Nirmatrelvir combined with ritonavir for preventing and treating COVID-19". osf.io/7g49c/ (created 30 May 2022). [DOI: 10.17605/OSF.IO/7G49C]'>Reis 2022a</a>). </p> <p>We have changed the definition of our active comparator. In the protocol, we planned to compare nirmatrelvir/ritonavir with active comparisons with confirmed efficacy only. We decided to extend our definition of an eligible active comparator to any active comparator, including new interventions that will be investigated in future trials that may use nirmatrelvir/ritonavir as a comparator. We also included TCMs as an active comparator in this update since we identified several ongoing trials. TCMs are widely used in China and other countries to treat COVID‐19 and living guidelines integrating Chinese and western medicine for COVID‐19 are already available (<a href="./references#CD015395-bbs2-0094" title="GeL , ZhuH , WangQ , LiM , CaiJ , ChenY . Integrating Chinese and Western medicine for COVID-19: a living evidence-based guideline (version 1). Journal of Evidence Based Medicine2021;14:313-32. [DOI: 10.1111/jebm.12444]">Ge 2021</a>). </p> <p>None of the members of the review author team has any affiliation with any stakeholder group who favours or disapproves of nirmatrelvir/ritonavir or the comparators used in relevant studies. </p> </section> <section id="CD015395-sec-0121"> <h3 class="title" id="CD015395-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>One meta‐analysis, published as letter to the editor and including 12 studies (one published RCT, one unpublished RCT, and 10 observational studies) found that nirmatrelvir/ritonavir is likely effective in reducing mortality and probably decreases the risk of hospitalization. However, both outcomes had high levels of heterogeneity across studies. Moreover, due to lack of RCTs, most of the evidence came from observational studies and hence, is susceptible to confounding bias (<a href="./references#CD015395-bbs2-0080" title="CheemaHA , JafarU , SohailA , ShahidA , SahraS , EhsanM , et al. Nirmatrelvir–ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis. Journal of Medical Virology2023;95(2):e28471. [DOI: 10.1002/jmv.28471]">Cheema 2023</a>). </p> <p>Another systematic review with meta‐analysis published in April 2023 compared nirmatrelvir/ritonavir to other antiviral drugs for the treatment of people with COVID‐19. The meta‐analysis results showed that nirmatrelvir/ritonavir decreased the risk of long‐term mortality, hospitalization, and disease progression while showing little difference in safety compared to other antivirals (<a href="./references#CD015395-bbs2-0140" title="TianF , ChenZ , FengQ . Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis. Journal of Medical Virology2023;95(4):e28732. [DOI: 10.1002/jmv.28732]">Tian 2023</a>). </p> <p>The WHO living guideline strongly recommends treatment with nirmatrelvir/ritonavir for people with non‐severe COVID‐19 at highest risk of hospitalization (including pregnant and breastfeeding women) and advises against treatment in people with non‐severe COVID‐19 at low risk of hospitalization (<a href="./references#CD015395-bbs2-0111" title="LamontagneF , AgarwalA , RochwergB , SiemieniukRA , AgoritsasT , AskieL , et al. A living WHO guideline on drugs for COVID-19. BMJ2020;370:m3379. [DOI: 10.1136/bmj.m3379]">Lamontagne 2020</a>). The evidence summary was last updated on 13 January 2023 and informed by two trials (<a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a>; <a href="./references#CD015395-bbs2-0058" title="2021-002857-28-HU. A phase 2/3 efficacy and safety study of PF-07321332/ritonavir in nonhospitalized low-risk adult participants with COVID-19. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002857-28 (first received 23 August 2021). NCT05011513. A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. clinicaltrials.gov/ct2/show/NCT05011513 (first received 18 August 2021). jRCT2031210274. A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. jrct.niph.go.jp/en-latest-detail/jRCT2031210274 (first received 26 August 2021). ">EPIC‐SR 2021</a>), of which the second one is to date only published as a press release with results from an interim analysis. Press releases are not eligible for the current review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015395-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram." data-id="CD015395-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 1: All‐cause mortality at day 28" data-id="CD015395-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 1: All‐cause mortality at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 2: Worsening of clinical status at day 28: admission to hospital or death" data-id="CD015395-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 2: Worsening of clinical status at day 28: admission to hospital or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 3: Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on age)" data-id="CD015395-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 3: Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 4: Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on ethnicity)" data-id="CD015395-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 4: Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on ethnicity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 5: Serious adverse events during the study period" data-id="CD015395-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 5: Serious adverse events during the study period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 6: Any grade treatment‐emergent adverse events during the study period" data-id="CD015395-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 6: Any grade treatment‐emergent adverse events during the study period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 7: Any grade treatment‐related adverse events during the study period" data-id="CD015395-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 7: Any grade treatment‐related adverse events during the study period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 8: Discontinuation of study drug due to adverse events during the study period" data-id="CD015395-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings, Outcome 8: Discontinuation of study drug due to adverse events during the study period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings, Outcome 1: All‐cause mortality at day 28" data-id="CD015395-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings, Outcome 1: All‐cause mortality at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings, Outcome 2: All‐cause mortality at day 28 (subgroup analysis based on age)" data-id="CD015395-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings, Outcome 2: All‐cause mortality at day 28 (subgroup analysis based on age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings, Outcome 3: Viral clearance at day 7" data-id="CD015395-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings, Outcome 3: Viral clearance at day 7 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015395-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/urn:x-wiley:14651858:media:CD015395:CD015395-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings, Outcome 4: Viral clearance at day 14" data-id="CD015395-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_t/tCD015395-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings, Outcome 4: Viral clearance at day 14 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/media/CDSR/CD015395/image_n/nCD015395-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015395-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> nirmatrelvir/ritonavir (plus standard of care) </p> <p><b>Comparison:</b> placebo (plus standard of care) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with nirmatrelvir/ritonavir</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality at day 28</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.04</b> (0.00 to 0.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir may reduce all‐cause mortality<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>11 fewer per 1000</b> </p> <p>(11 fewer to 4 fewer)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Worsening of clinical status within 28 days</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Admission to hospital or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.13</b> (0.07 to 0.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir may reduce (COVID‐19‐related) hospitalization or death<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>53 fewer per 1000</b> </p> <p>(57 fewer to 45 fewer)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admission to ICU or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported admission to ICU or death</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Improvement of clinical status</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All initial symptoms resolved at 28 days, and up to the longest follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported all initial symptoms resolved</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to symptom resolution</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported time to symptom resolution</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life up to 28 days and longest follow‐up available</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>SAEs during the study period</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.24</b> (0.15 to 0.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir may reduce SAEs<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>50 fewer per 1000</b> </p> <p>(56 fewer to 39 fewer)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adverse events during the study period</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any grade TEAE</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.95</b> (0.82 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir probably has little or no effect on any TEAE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>12 fewer per 1000</b> </p> <p>(43 fewer to 24 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any grade TRAE</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.06</b> (1.44 to 2.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir probably increases any TRAE (mostly attributed to dysgeusia and diarrhoea)<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>40 more per 1000</b> </p> <p>(17 more to 74 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Discontinuation of study drug due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.49</b> (0.30 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2224 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nirmatrelvir/ritonavir probably decreases discontinuation of study drug due to adverse events<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>21 fewer per 1000</b> </p> <p>(29 fewer to 8 fewer)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral clearance at 14 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported viral clearance</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event; <b>TEAE:</b> treatment‐emergent adverse event; <b>TRAE:</b> treatment‐related adverse event; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations on certainty in the evidence (GRADE)</b> </p> <p><sup>a</sup>Downgraded one level for serious risk of bias (inappropriate analysis) and one level for serious imprecision (few events).<br/><sup>b</sup>Downgraded one level for serious risk of bias (inappropriate analysis) and one level for serious indirectness (COVID‐19‐related hospitalization).<br/><sup>c</sup>Downgraded one level for serious risk of bias (inappropriate analysis) and one level for serious imprecision (due to few SAEs other than hospitalization or death).<br/><sup>d</sup>Downgraded one level for serious risk of bias (inappropriate analysis). </p> <p><b>Explanations on 'equity considerations'</b> </p> <p>Most study participants were younger than 65 years, of white ethnicity, and from upper middle‐ or high‐income countries. No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated a high‐risk population.<br/><sup>1</sup>No subgroup analyses were reported for age, ethnicity, and World Bank country classification by income level. We are uncertain whether results are applicable to all prespecified subgroups.<br/><sup>2</sup>Subgroup analyses were reported for age and ethnicity only. There was no difference between subgroups of age. The effects favoured a treatment with nirmatrelvir/ritonavir for the white ethnic group. Estimated effects of the other ethnic groups included the line of no effect (RR = 1). Numbers of participants in the other ethnic groups were low. No subgroups were reported for World Bank country classification by income level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015395-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> nirmatrelvir/ritonavir (plus standard of care) </p> <p><b>Comparison:</b> standard of care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard of care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with nirmatrelvir/ritonavir</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality at day 28</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.63</b> (0.21 to 1.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>264 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain whether nirmatrelvir/ritonavir reduces all‐cause mortality<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>23 fewer per 1000</b> </p> <p>(48 fewer to 52 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Worsening of clinical status within 28 days</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with new need for invasive mechanical ventilation or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>—</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported worsening of clinical status</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Improvement of clinical status within 28 days</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants discharged alive. Participants should be discharged without clinical deterioration or death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported improvement of clinical status</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life up to 28 days and longest follow‐up available</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs during the study period</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed due to insufficient and inconsistent information</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adverse events during the study period</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade TEAE</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed due to insufficient and inconsistent information</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade TRAE</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed due to insufficient and inconsistent information</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation of study drug due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed due to insufficient and inconsistent information</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Viral clearance</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Viral clearance at 7 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>258</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.06</b> (0.71 to 1.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>264 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain whether nirmatrelvir/ritonavir increases viral clearance at 7 days<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: <b>15 more per 1000</b> </p> <p>(75 fewer to 150 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Viral clearance at 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>742</b> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>779</b> per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> (0.92 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>264 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain whether nirmatrelvir/ritonavir increases viral clearance at 7 days<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Difference <b>37 more per 1000</b><br/>(59 fewer to 148 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event; <b>TEAE:</b> treatment‐emergent adverse event; <b>TRAE:</b> treatment‐related adverse event; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations on certainty in the evidence (GRADE)</b> </p> <p><sup>a</sup>Downgraded two levels for imprecision (minimally contextualized approach), and one level for indirectness (atypical hospital population: WHO 2 to 4). </p> <p><b>Explanations on 'equity considerations'</b> </p> <p>Most study participants were older than 65 years. The study was conducted in China, which in general classifies as upper middle‐income country; however, no further information was given about World Bank country classification by income level and race/ethnicity of study participants. No subgroup analysis was possible for comorbidity (high‐risk versus low‐risk population) as the included study only investigated a high‐risk population.<br/><sup>1</sup>Subgroup analyses were reported for age only. There was no difference between subgroups of age. Estimated effects included the line of no effect (RR = 1).<br/><sup>2</sup>No subgroup analyses were reported for age, comorbidity, ethnicity, and World Bank country classification by income level. We are uncertain whether results are applicable to all prespecified subgroups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015395-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Equity assessment – outpatients</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comorbidities, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Race/ethnicity, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>World Bank country classification by income level, n (%)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worsening of clinical status: admission to hospital or death at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children: NR</p> <p>Adults &lt; 65 years: 1817 (87%)<sup>a</sup> </p> <p>Adults ≥ 65 years: 268 (13%)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian: 296 (14%)<sup>a</sup> </p> <p>Black: 94 (4.5%)<sup>a</sup> </p> <p>Hispanics: NR</p> <p>White: 1486 (71.3%)<sup>a</sup> </p> <p>Minorities: NR</p> <p>Other: 209 (10%)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events during the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade treatment‐emergent adverse events during the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade treatment‐related adverse events during the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation of study drug due to adverse events during the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0001" title="2021-002895-38. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 (first received 16 July 2021). HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Open Forum Infectious Diseases2022;9(2):ofac492.047. [DOI: 10.1093/ofid/ofac492.047]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open Forum Infectious Diseases2022;9(2):ofac492.994. [DOI: 10.1093/ofid/ofac492.994]HammondJ , Leister-TebbeH , GardnerA , AbreuP , BaoW , WisemandleW , et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine2022;386(15):1397-408. [DOI: 10.1056/NEJMoa2118542]NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. clinicaltrials.gov/ct2/show/NCT04960202 (first received 13 July 2021). SoaresH , BanieckiML , CardinR , Leister-TebbeH , ZhuY , GuanS , et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square 21 June 2022. [DOI: 10.21203/rs.3.rs-1720472/v2]jRCT2031210267. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 [An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness]. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 (first received 21 August 2021). ">EPIC‐HR 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Modified intention to treat (mITT1), 2085 participants.<br/>n: number of participants; NR: not reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Equity assessment – outpatients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015395-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Equity assessment – inpatients</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comorbidities, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Race/ethnicity, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>World Bank country classification by income level, n (%)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children: NR</p> <p>Adult ≤ 65 years: 84 (32%)</p> <p>Adult &gt; 65 years: 180 (68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2: 101 (38%)</p> <p>≥ 2: 163 (62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events during the treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade treatment‐emergent adverse events during the treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any grade treatment‐related adverse events during the treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation of study drug due to adverse events during the treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015395-bbs2-0002" title="ChiCTR2200058477. Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study. chictr.org.cn/showproj.html?proj=167163 (first received 9 April 2022). LiuJ , PanX , ZhangS , LiM , MaK , FanC , et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Regional Health. Western Pacific2023;33:100694. [DOI: 10.1016/j.lanwpc.2023.100694]">Liu 2023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>n: number of participants; NR: not reported; RT‐PCR: reverse transcription polymerase chain reaction. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Equity assessment – inpatients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/full#CD015395-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015395-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Worsening of clinical status at day 28: admission to hospital or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.07, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.06, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Aged &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.07, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Age ≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on ethnicity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.07, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.07, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Black/African American</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 7.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Asian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Serious adverse events during the study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.15, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Any grade treatment‐emergent adverse events during the study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Any grade treatment‐related adverse events during the study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.44, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Discontinuation of study drug due to adverse events during the study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.30, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with asymptomatic or mild COVID‐19 in outpatient settings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015395-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.21, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause mortality at day 28 (subgroup analysis based on age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.20, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Aged ≤ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.06, 6.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Aged &gt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.18, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Viral clearance at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.71, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Viral clearance at day 14 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.92, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Nirmatrelvir/ritonavir for treating people with moderate to severe COVID‐19 in inpatient settings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#CD015395-tbl-0006">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the mITT2 population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (mITT2).</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Worsening of clinical status at day 28: admission to hospital or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the mITT2 population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (mITT2).</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Worsening of clinical status at day 28: admission to hospital or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on age)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.1 Children</b> </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.2 Aged &lt; 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the mITT1 population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (mITT1).</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.3 Age ≥ 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the mITT1 population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (mITT1).</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on age)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on ethnicity)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.4.1 White</b> </p> </td> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the mITT1 population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (mITT1).</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.4.2 Black/African American</b> </p> </td> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the mITT1 population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (mITT1).</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.4.3 Asian</b> </p> </td> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the mITT1 population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (mITT1).</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.4.4 Other</b> </p> </td> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the mITT1 population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (mITT1).</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on ethnicity)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Serious adverse events during the study period</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the SAS population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (SAS).</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Serious adverse events during the study period</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Any grade treatment‐emergent adverse events during the study period</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the SAS population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (SAS).</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Any grade treatment‐emergent adverse events during the study period</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Any grade treatment‐related adverse events during the study period</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the SAS population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was not registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (SAS) and lack of prospective outcome registration.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Any grade treatment‐related adverse events during the study period</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Discontinuation of study drug due to adverse events during the study period</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>EPIC‐HR 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per‐protocol analysis was used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the SAS population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was not registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to per‐protocol analysis (SAS) and lack of prospective outcome registration.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Discontinuation of study drug due to adverse events during the study period</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Liu 2023</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of intervention received; those delivering the intervention were not. The analysis was appropriate (all participants were analyzed as randomized). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the study population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial; unclear whether the outcome assessor was blinded. However, outcome assessment does not involve judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 All‐cause mortality at day 28 (subgroup analysis based on age)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.2.1 Aged ≤ 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Liu 2023</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of intervention received; those delivering the intervention were not. The analysis was appropriate (all participants were analyzed as randomized). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the study population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial; unclear whether the outcome assessor was blinded. However, outcome assessment does not involve judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.2.2 Aged &gt; 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Liu 2023</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of intervention received; those delivering the intervention were not. The analysis was appropriate (all participants were analyzed as randomized). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the study population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial; unclear whether the outcome assessor was blinded. However, outcome assessment does not involve judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 All‐cause mortality at day 28 (subgroup analysis based on age)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Viral clearance at day 7</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Liu 2023</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of intervention received; those delivering the intervention were not. The analysis was appropriate (all participants were analyzed as randomized). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the study population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial; unclear whether the outcome assessor was blinded. Viral clearance is an observer‐decision outcome involving some judgement. However, a standardized approach was assumed. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Viral clearance at day 7</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Viral clearance at day 14</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Liu 2023</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized web‐based randomization. There are no baseline differences that would suggest a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were aware of intervention received; those delivering the intervention were not. The analysis was appropriate (all participants were analyzed as randomized). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported for all participants of the study population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial; unclear whether the outcome assessor was blinded. Viral clearance is an observer‐decision outcome involving some judgement. However, a standardized approach was assumed. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome was reported as registered.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Viral clearance at day 14</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015395.pub3/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015395.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015395-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015395-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015395-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015395-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD015395-note-0016">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD015395-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD015395-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD015395-note-0014">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015395-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015395\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015395\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015395\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015395\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015395\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015395.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015395.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015395.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015395.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015395.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716574596"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015395.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716574600"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015395.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da2d61ef99379',t:'MTc0MDcxNjU3NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 